[
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Normal follow up",
        "entry_id": 1,
        "id": 1,
        "lang": "en",
        "recommendation": "A repeat would be indicated on\nclinical grounds if there was a\nsignificant change in the patient’s\ncondition that indicated that an\nacute renal (or other electrolyte-\nrelated problem) was developing",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Inpatient monitoring of\na stable patient not on\nIV fluids",
        "entry_id": 2,
        "id": 2,
        "lang": "en",
        "recommendation": "An inpatient with an admission\nsodium within the reference range\nshould not have a repeat sodium\nwithin the average length of stay of\nfour days",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Inpatient monitoring of\na stable patient on IV\nfluids (adults as well as\nchildren)",
        "entry_id": 3,
        "id": 3,
        "lang": "en",
        "recommendation": "Daily monitoring of U&E and\nglucose",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R3",
        "source": "GAIN, <a href=\"/references#ref-6\" target=\"_blank\" class=\"reference-link\">2010.6<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "In symptomatic patients\nor following\nadministering of\nhypertonic saline",
        "entry_id": 4,
        "id": 4,
        "lang": "en",
        "recommendation": "Monitoring should be more\nfrequent, i.e. every two to four\nhours",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R4",
        "source": "GAIN, <a href=\"/references#ref-6\" target=\"_blank\" class=\"reference-link\">2010.6<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Patient diagnosed with\nAKI",
        "entry_id": 5,
        "id": 5,
        "lang": "en",
        "recommendation": "U&E checked on admission and\nwithin 24 hours",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R5",
        "source": "The Renal Association, <a href=\"/references#ref-7\" target=\"_blank\" class=\"reference-link\">2011.7<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Monitoring of ACE\ninhibitors",
        "entry_id": 6,
        "id": 6,
        "lang": "en",
        "recommendation": "Within one week of starting and\none week after each dose titration,\nthen annually (unless required\nmore frequently because of\nimpaired renal function)\nDrugs containing trimethoprim can\nalso result in a marked increase in\nserum creatinine without directly\naffecting kidney function. The\nserum creatinine should be\nrepeated to obtain a more accurate\nserum creatinine (and eGFR) 48\nhours after trimethoprim containing\nmedications are stopped",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R6",
        "source": "NICE Clinical Knowledge Summary, 2019.8 GAIN, <a href=\"/references#ref-9\" target=\"_blank\" class=\"reference-link\">2015.9<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Diuretic therapy",
        "entry_id": 7,
        "id": 7,
        "lang": "en",
        "recommendation": "Before the initiation of therapy and\nafter four weeks, and then six\nmonthly/yearly or more frequently\nin the elderly or in patients with\nrenal disease, disorders affecting\nelectrolyte status or patients taking\nother drugs (e.g. corticosteroids,\ndigoxin)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R7",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-8\" target=\"_blank\" class=\"reference-link\">2019.8<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Monitoring of\npotassium\nconcentrations in\npatients receiving\ndigoxin",
        "entry_id": 8,
        "id": 8,
        "lang": "en",
        "recommendation": "Eight days after initiation or change\nin digoxin therapy and/or\naddition/subtraction of interacting\ndrug, then annually if no change",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R8",
        "source": "NICE Clinical Knowledge Summary, 2019.10 NICE Clinical Knowledge Summary, <a href=\"/references#ref-10\" target=\"_blank\" class=\"reference-link\">2019.11<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Monitoring of\npotassium\nconcentrations in\npatients receiving\ndigoxin and diuretics",
        "entry_id": 9,
        "id": 9,
        "lang": "en",
        "recommendation": "Regular monitoring",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R9",
        "source": "National Public Health Service for Wales, <a href=\"/references#ref-12\" target=\"_blank\" class=\"reference-link\">2008.12<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Aminosalicylates",
        "entry_id": 10,
        "id": 10,
        "lang": "en",
        "recommendation": "In the elderly, every three months\nin first year, then every six months\nfor the next four years, then\nannually after that based on\npersonal risk factors",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R10",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-13\" target=\"_blank\" class=\"reference-link\">2019.13<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Carbamazepine",
        "entry_id": 11,
        "id": 11,
        "lang": "en",
        "recommendation": "Six months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R11",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-13\" target=\"_blank\" class=\"reference-link\">2019.13<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Antipsychotics",
        "entry_id": 12,
        "id": 12,
        "lang": "en",
        "recommendation": "12 months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R12",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-14\" target=\"_blank\" class=\"reference-link\">2019.14<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "eGFR-EPI: CKD",
        "entry_id": 13,
        "id": 13,
        "lang": "en",
        "recommendation": "Repeat in 14 days if new finding of\nreduced GFR and/or confirmation\nof eGFR <60 mL/min/1.73 m2\n*eGFR by MDRD not valid in AKI",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "eGFR-EPI:\nRadiological\nprocedures/contrast\nadministration",
        "entry_id": 14,
        "id": 14,
        "lang": "en",
        "recommendation": "eGFR or creatinine within previous\nseven days in patients with acute\nillness or renal disease\neGFR for angiography: <60\nmL/min/1.73 m2 should trigger local\nguidelines for contrast dosage\neGFR for gadolinium: <30\nmL/min/1.73 m2 high-risk agents\ncontraindicated\neGFR: 30–59 mL/min/1.73 m2\nlowest dose possible can be used\nand not repeated within seven days",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "eGFR: Cockcroft-Gault",
        "entry_id": 15,
        "id": 15,
        "lang": "en",
        "recommendation": "For estimating chemotherapy and\ndrug dosages. Within 24 hours\nunless rapidly changing creatinine\nconcentrations or fluid balance",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-R13c",
        "source": "None (inferred from British National Formulary)",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.1 Renal (refers to the measurement of U&E, unless otherwise stated)",
        "clinical_situation": "Iohexol GFR",
        "entry_id": 16,
        "id": 16,
        "lang": "en",
        "recommendation": "72 hours to avoid contamination\n(based on half-life of iohexol of two\nhours)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Non-acute setting\nunless there are other\nclinical indications",
        "entry_id": 17,
        "id": 17,
        "lang": "en",
        "recommendation": "Testing at three-monthly intervals",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Acute settings",
        "entry_id": 18,
        "id": 18,
        "lang": "en",
        "recommendation": "Testing at 48-hour intervals",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Acute hypo/\nhypercalcaemia, TPN\nand ITU patients",
        "entry_id": 19,
        "id": 19,
        "lang": "en",
        "recommendation": "May require more frequent\nmonitoring",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B3",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "ALP and total protein in\nacute setting",
        "entry_id": 20,
        "id": 20,
        "lang": "en",
        "recommendation": "Testing at weekly intervals. ALP\nmay need checking more often, but\nprobably only in the context of\nacute cholestatic changes. See\nLiver recommendations (section\n2.3)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Vitamin D request: no\nclinical signs and\nsymptoms",
        "entry_id": 21,
        "id": 21,
        "lang": "en",
        "recommendation": "Do not retest (whatever the result\nas there may be no indication to\ntest in the first place)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Vitamin D request:\ncholecalciferol or\nergocalciferol therapy\nfor whatever clinical\nindication, where\nbaseline vitamin D\nconcentration was\nadequate",
        "entry_id": 22,
        "id": 22,
        "lang": "en",
        "recommendation": "Do not retest, unless otherwise\nclinically indicated, e.g. sick coeliac\nor Crohn's patient",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B6",
        "source": "Sattar N et al. Lancet 2012;379:95–96.18 Sattar N et al. Lancet 2012;379: 1700–1701.19",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Vitamin D request:\ncholecalciferol or\nergocalciferol therapy\nfor whatever clinical\nindication, where\nbaseline vitamin D\nconcentration was low\nand where there is\nunderlying disease that\nmight impact negatively\non absorption",
        "entry_id": 23,
        "id": 23,
        "lang": "en",
        "recommendation": "Repeat after three to six months on\nrecommended replacement dose",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B7",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Vitamin D request:\ncalcitriol or\nalphacalcidol therapy",
        "entry_id": 24,
        "id": 24,
        "lang": "en",
        "recommendation": "Do not measure vitamin D",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B8",
        "source": "Consensus opinion of the relevant expert working group (GPP)",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Bone (refers to the measurement of the bone profile, unless otherwise stated)",
        "clinical_situation": "Biochemical testing in\nCKD-MBD: CKD stages\n3–5",
        "entry_id": 25,
        "id": 25,
        "lang": "en",
        "recommendation": "For stage 3b progressive, test bone\nprofile every six months, PTH at\nbaseline and 25OHVitD at baseline\nFor stage 4, test bone profile every\nthree months, PTH every six\nmonths and 25OHVitD at baseline\nFor stage 5, test bone profile every\nmonth, PTH every three months\nand 25OHVitD at baseline\nFor stage 5D, test bone profile\nevery month, PTH every three\nmonths and 25OHVitD at baseline",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-B9",
        "source": "The Renal Association, <a href=\"/references#ref-20\" target=\"_blank\" class=\"reference-link\">2015.20<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Liver (refers to the measurement of LFTs, unless otherwise stated)",
        "clinical_situation": "Non-acute setting",
        "entry_id": 26,
        "id": 26,
        "lang": "en",
        "recommendation": "Testing at one- to three-month\nintervals",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-L1",
        "source": "Smellie S et al. ACB Venture Publications, <a href=\"/references#ref-21\" target=\"_blank\" class=\"reference-link\">2011.21<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.3 Liver (refers to the measurement of LFTs, unless otherwise stated)",
        "clinical_situation": "Acute inpatient setting",
        "entry_id": 27,
        "id": 27,
        "lang": "en",
        "recommendation": "Testing at 72-hour intervals in\nacute setting (apart from those in\nL4)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-L2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Liver (refers to the measurement of LFTs, unless otherwise stated)",
        "clinical_situation": "GGT and conjugated\nbilirubin in acute setting",
        "entry_id": 28,
        "id": 28,
        "lang": "en",
        "recommendation": "Testing at weekly intervals",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-L3",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Liver (refers to the measurement of LFTs, unless otherwise stated)",
        "clinical_situation": "Acute poisoning (e.g.\nparacetamol), TPN,\nliver unit, acute liver\ninjury and ITU patients",
        "entry_id": 29,
        "id": 29,
        "lang": "en",
        "recommendation": "May require more frequent\nmonitoring",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-L4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Liver (refers to the measurement of LFTs, unless otherwise stated)",
        "clinical_situation": "Neonatal jaundice",
        "entry_id": 30,
        "id": 30,
        "lang": "en",
        "recommendation": "These recommendations must not\nbe used in the management of\nneonatal jaundice",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-L5",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.3 Liver (refers to the measurement of LFTs, unless otherwise stated)",
        "clinical_situation": "Initiating or changing\ntherapies for primary or\nsecondary\ncardiovascular disease\nprevention (LFTs)",
        "entry_id": 31,
        "id": 31,
        "lang": "en",
        "recommendation": "Three months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-L6",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-22\" target=\"_blank\" class=\"reference-link\">2019.22<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.4 Lipids (refers to the measurement of lipid profile [non-fasting], unless otherwise stated)",
        "clinical_situation": "Low-risk cases for IHD\nassessment",
        "entry_id": 32,
        "id": 32,
        "lang": "en",
        "recommendation": "Three years",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-LP1",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.4 Lipids (refers to the measurement of lipid profile [non-fasting], unless otherwise stated)",
        "clinical_situation": "Higher risk cases for\nIHD assessment and\nthose on stable\ntreatment",
        "entry_id": 33,
        "id": 33,
        "lang": "en",
        "recommendation": "One year",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-LP2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.4 Lipids (refers to the measurement of lipid profile [non-fasting], unless otherwise stated)",
        "clinical_situation": "Initiating or changing\ntherapies for primary or\nsecondary prevention\n(include non-HDL\ncholesterol)",
        "entry_id": 34,
        "id": 34,
        "lang": "en",
        "recommendation": "Three months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-LP3",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-22\" target=\"_blank\" class=\"reference-link\">2019.22<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.4 Lipids (refers to the measurement of lipid profile [non-fasting], unless otherwise stated)",
        "clinical_situation": "When assessing\ntriglyceridaemia to see\neffects of changing diet\nand alcohol",
        "entry_id": 35,
        "id": 35,
        "lang": "en",
        "recommendation": "One week",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-LP4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.4 Lipids (refers to the measurement of lipid profile [non-fasting], unless otherwise stated)",
        "clinical_situation": "In patients on TPN or\nwho have\nhypertriglyceridaemia-\ninduced pancreatitis",
        "entry_id": 36,
        "id": 36,
        "lang": "en",
        "recommendation": "One day",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-LP5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Thyroid function testing\nin a healthy person in\nthe absence of any\nclinical symptoms",
        "entry_id": 37,
        "id": 37,
        "lang": "en",
        "recommendation": "Three years",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Hyperthyroid:\nmonitoring of treatment\nin Graves’ disease",
        "entry_id": 38,
        "id": 38,
        "lang": "en",
        "recommendation": "Follow up in first one to two months\nafter radioactive iodine treatment\nfor Graves’. Measure fT4 and total\nT3. If patient remains thyrotoxic,\nbiochemical monitoring should\ncontinue at four- to six-week\nintervals\nFollowing thyroidectomy for\nGraves’ disease (and\ncommencement of levothyroxine),\nserum TSH should be measured\nsix to eight weeks post-op",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E2",
        "source": "Bahn Chair RS et al. Thyroid 2011;21:593–646.24",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Hyperthyroid:\nmonitoring of treatment\nin toxic multinodular\ngoitre and toxic\nadenoma",
        "entry_id": 39,
        "id": 39,
        "lang": "en",
        "recommendation": "Follow up in first one to two months\nafter radioactive iodine treatment\nfor toxic multinodular goitre and\ntoxic adenoma. Measure fT4 and\ntotal T3 and TSH. Should be\nrepeated at one- to two-month\nintervals until stable results, and\nthen annually thereafter\nFollowing surgery for toxic\nmultinodular goitre and start of\nthyroxine therapy, TSH should be\nmeasured one to two monthly until\nstable and annually thereafter\nFollowing surgery for toxic\nadenoma, TSH and fT4\nconcentrations should be\nmeasured four to six weeks\npost-op",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E3",
        "source": "Bahn Chair RS et al. Thyroid 2011;21:593–646.24",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "UK Thyroid guidelines",
        "entry_id": 40,
        "id": 40,
        "lang": "en",
        "recommendation": "TFTs should be performed every\nfour to six weeks for at least six\nmonths following radioiodine\ntreatment. Once fT4 remains in\nreference range then frequency of\ntesting should be reduced to\nannually. Lifelong annual follow up\nis required\nIndefinite surveillance required\nfollowing radioiodine or\nthyroidectomy for the development\nof hypothyroidism or recurrence of\nhyperthyroidism. TFTs should be\nassessed four to eight weeks post-\ntreatment, then three monthly for\nup to one year, then annually\nthereafter. TFTs should be\nperformed every four to six weeks\nafter commencing thionamides.\nTesting at three-monthly intervals\nis recommended once\nmaintenance dose achieved\nIn patients treated with 'block and\nreplace', assess TSH and T4 at\nfour- to six-weekly intervals, then\nafter a further three months once\nmaintenance dose achieved, then\nsix monthly thereafter",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E4",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Hypothyroidism:\nmonitoring treatment",
        "entry_id": 41,
        "id": 41,
        "lang": "en",
        "recommendation": "The minimum period to achieve\nstable concentrations after a\nchange of dose of thyroxine is two\nmonths and TFTs should not\nnormally be assessed before this\nperiod has elapsed\nPatients stabilised on long-term\nthyroxine therapy should have\nserum TSH checked annually\nAn annual fT4 should be performed\nin all patients with secondary\nhypothyroidism stabilised on\nthyroxine therapy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E5",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Monitoring adult\nsubclinical\nhyperthyroidism",
        "entry_id": 42,
        "id": 42,
        "lang": "en",
        "recommendation": "If a serum TSH below reference\nrange but >0.1 mU/L is found, then\nthe measurement should be\nrepeated one to two months later\nalong with T4 and T3 after\nexcluding non-thyroidal illness and\ndrug interferences. This is\ncontradicted later in the guidelines\nwhen the authors state that a\nthree- to six-month repeat interval\nis appropriate unless the patient is\nelderly or has underlying vascular\ndisease\nIf treatment is not undertaken, then\nserum TSH should be measured in\nthe long term every six to 12\nmonths, with follow up with fT4 and\nfT3 if serum TSH result is low",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E6",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Monitoring adult\nsubclinical\nhypothyroidism",
        "entry_id": 43,
        "id": 43,
        "lang": "en",
        "recommendation": "Patients with subclinical\nhypothyroidism should have the\npattern confirmed within three to\nsix months to exclude transient\ncauses of elevated TSH\nSubjects with subclinical\nhypothyroidism who are ATPOab\npositive should have TSH and fT4\nchecked annually\nSubjects with subclinical\nhypothyroidism who are ATPOab\nneg should have TSH and fT4\nchecked every three years",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E7",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Follow up of patients\nwho have had\ndifferentiated (papillary\nand follicular) thyroid\ncarcinoma and a total\nthyroidectomy and 131I\nablation",
        "entry_id": 44,
        "id": 44,
        "lang": "en",
        "recommendation": "TSH and fT4 should be measured\nas dose of levothyroxine increases\n(every six weeks) until the serum\nTSH is <0.1 mIU/L. Thereafter,\nthey should be measured annually\nunless clinically indicated/pregnant\nSamples for Tg should not be\ncollected sooner than six weeks\npost-thyroidectomy or 131I\nablation/therapy. TSH, fT4/fT3\n(whichever is being supplemented)\nand TgAb should be requested\nwhen Tg is measured. If TgAb are\ndetectable, measurement should\nbe repeated every six months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E8",
        "source": "British Thyroid Association, Royal College of Physicians, <a href=\"/references#ref-26\" target=\"_blank\" class=\"reference-link\">2014.26<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Follow up of patients\nwho have had\nmedullary thyroid\ncancer and surgical\nresection",
        "entry_id": 45,
        "id": 45,
        "lang": "en",
        "recommendation": "A baseline CEA and fasting\ncalcitonin should be taken prior to\noperation. Postoperative samples\nshould be measured no earlier than\n15 days after thyroidectomy and\nplasma calcitonin concentrations\nare most informative six months\nafter surgery\nAt least four measurements of\ncalcitonin over a two- to three-year\nperiod can be taken to provide an\naccurate estimate of the calcitonin\ndoubling time. CEA is elevated in\napproximately 30% of MTC\npatients and in those patients, CEA\ndoubling time is comparably\ninformative to calcitonin doubling\ntime\nCalcitonin monitoring should\ncontinue lifelong\nTFTs should be measured as per\nguidance for hypothyroidism",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E9",
        "source": "British Thyroid Association, Royal College of Physicians, 2014.26 Laure Giraudet A et al. Eur J Endocrinol 2008;158: 239– 246.27",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Anaplastic thyroid\ncancer",
        "entry_id": 46,
        "id": 46,
        "lang": "en",
        "recommendation": "There is no need for any\nmonitoring of thyroid function\nunless patient is on thyroid\nreplacement, then as per\nhypothyroidism",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E10",
        "source": "British Thyroid Association, Royal College of Physicians, <a href=\"/references#ref-26\" target=\"_blank\" class=\"reference-link\">2014.26<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Patients on amiodarone",
        "entry_id": 47,
        "id": 47,
        "lang": "en",
        "recommendation": "Should have thyroid function tested\nbefore commencing treatment and\nthen should be routinely monitored\nevery six months thereafter while\non treatment and up to 12 months\nafter cessation of therapy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E11",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Patients on lithium",
        "entry_id": 48,
        "id": 48,
        "lang": "en",
        "recommendation": "Thyroid function tested before\ncommencing treatment and then\nshould be routinely monitored\nevery six to 12 months while on\ntreatment",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E12",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Progesterone testing in\nwomen with prolonged\nirregular menstrual\ncycles",
        "entry_id": 49,
        "id": 49,
        "lang": "en",
        "recommendation": "Testing weekly in patients with\nirregular cycle from day 21 until\nnext menstrual period",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E13",
        "source": "NICE. CG156, <a href=\"/references#ref-28\" target=\"_blank\" class=\"reference-link\">2013.28<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Diagnosing premature\novarian insufficiency in\nwomen aged under 40\nyears with possible\nmenopausal symptoms",
        "entry_id": 50,
        "id": 50,
        "lang": "en",
        "recommendation": "Two tests four to six weeks apart in\nwomen with possible early or\npremature menopause",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E14",
        "source": "NICE NG23 <a href=\"/references#ref-29\" target=\"_blank\" class=\"reference-link\">2019.29<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Patients with suspected\ndrug-induced\nhyperprolactinaemia",
        "entry_id": 51,
        "id": 51,
        "lang": "en",
        "recommendation": "Discontinue medication for three\ndays and re-measure prolactin",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E15",
        "source": "Casanueva FFet al. Clin Endocrinol (Oxf) 2006;65:265–273.30 Melmed S et al. J Clin Endocrinol Metab 2011;96:273– 288.31",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Patients with\nhyperprolactinaemia\ncommencing dopamine\nagonist therapy",
        "entry_id": 52,
        "id": 52,
        "lang": "en",
        "recommendation": "Repeat prolactin measurement\nafter one month to guide therapy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E16",
        "source": "Melmed S et al. J Clin Endocrinol Metab 2011;96:273– 288.31",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Screening for diabetes\nin asymptomatic\npatients",
        "entry_id": 53,
        "id": 53,
        "lang": "en",
        "recommendation": "Adults <45 years old with normal\nweight and no risk factor: screening\nnot recommended\nAdults >45 years old with normal\nweight (BMI <25 kg/m2) and no risk\nfactor*: three years\nAdults >18 years old with BMI ≥25\nkg/m2 and 1 risk factor*: three\nyears, if result is normal\n*Risk(s) factors listed in Table 4 of\nDiabetes Care 2012;35(S1):S11–\nS63.32",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E17",
        "source": "Diabetes Care 2012;35(S1):S11– S63.32",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Diagnosing diabetes\nusing HbA1c in an\nasymptomatic patient\n(not to be used in\nchildren or young\nadults)",
        "entry_id": 54,
        "id": 54,
        "lang": "en",
        "recommendation": "Diagnosis should not be made on\nthe basis of a single abnormal\nplasma glucose or HbA1c value. At\nleast one additional HbA1c or\nplasma glucose test result with a\nvalue in the diabetic range is\nrequired within two weeks of the\ninitial measurement, either fasting,\nfrom a random (casual) sample, or\nfrom the OGTT",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E18",
        "source": "WHO, <a href=\"/references#ref-33\" target=\"_blank\" class=\"reference-link\">2011.33<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "HbA1c monitoring of\npatients with type 2\ndiabetes",
        "entry_id": 55,
        "id": 55,
        "lang": "en",
        "recommendation": "Two to six-monthly intervals\n(tailored to individual needs) until\nthe blood glucose concentration is\nstable on unchanging therapy; use\na measurement made at an interval\nof less than three months as an\nindicator of direction of change,\nrather than as a new steady state\nSix-monthly intervals once the\nblood glucose concentration and\nblood glucose lowering therapy are\nstable",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E19",
        "source": "NICE. NG28, <a href=\"/references#ref-34\" target=\"_blank\" class=\"reference-link\">2015.34<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Diagnosis of male\nandrogen deficiency",
        "entry_id": 56,
        "id": 56,
        "lang": "en",
        "recommendation": "Repeat testosterone measurement\nto confirm diagnosis recommended",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E20",
        "source": "Bhasin S et al. J Clin Endocrinol Metab 2010;95:2536– <a href=\"/references#ref-35\" target=\"_blank\" class=\"reference-link\">2559.35<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Monitoring of male\npatient with androgen\ndeficiency on\nreplacement therapy",
        "entry_id": 57,
        "id": 57,
        "lang": "en",
        "recommendation": "Measure testosterone value three\nto six months after initiation of\ntestosterone therapy\nMeasure testosterone every three\nto four months for first year\nMeasurement of PSA. Please refer\nto B-TM7",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E21",
        "source": "Bhasin S et al. J Clin Endocrinol Metab 2010;95:2536– 2559.35 Petak SM et al. Endocr Pract 2002;8:440–456.36",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Female androgen\nexcess",
        "entry_id": 58,
        "id": 58,
        "lang": "en",
        "recommendation": "If testosterone measurement found\nto be raised by an immunoassay\nmethod, confirm measurement with\na LCMS method\nThereafter, measurement should\nbe repeated yearly",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E22",
        "source": "Martin KA et al. J Clin Endocrinol Metab 2008;93:1105– 1120.37 Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Oestradiol",
        "entry_id": 59,
        "id": 59,
        "lang": "en",
        "recommendation": "No evidence, guideline or\nconsensus exists for repeat\nfrequency\nFor patients undergoing IVF\nsamples may be taken daily\nFor patients receiving implant\ntreatment (HRT) a pre-implant\nvalue is checked to avoid\ntachyphylaxis. Frequency depends\non frequency of implant\nFor patients receiving implant\ntreatment a pre-implant value is\nchecked to avoid tachyphylaxis",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E23",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Growth hormone\ndeficiency",
        "entry_id": 60,
        "id": 60,
        "lang": "en",
        "recommendation": "IGF-1 is the most useful marker for\nmonitoring and should be\nmeasured at least yearly.\nAssessment should be performed\nno earlier than six weeks following\na dose change",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E24",
        "source": "Ho KK et al. Eur J Endocrinol 2007;157:695– 700.38",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endocrine related (for pregnancy-related endocrinology, see 2.12)",
        "clinical_situation": "Acromegaly: post-\nsurgery\nAcromegaly: medical\ntherapy\nAcromegaly: medical\ntherapy using GH\nreceptor antagonists\nAcromegaly: post-\nradiotherapy",
        "entry_id": 61,
        "id": 61,
        "lang": "en",
        "recommendation": "Measure both GH and IGF-1 at\nthree months. If normal, then at\nannual follow up\nMeasure both GH and IGF-1 at\nthree months. If normal, then at\nannual follow up\nMeasure only IGF-1 at six-monthly\nintervals after dose titration.\nMonthly monitoring of LFTs for first\nsix months\nMeasurement of GH and IGF-1\nannually",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-E25",
        "source": "Growth Hormone Research Society, Pituitary Society. J Clin Endocrinol Metab 2004;89:3099– <a href=\"/references#ref-39\" target=\"_blank\" class=\"reference-link\">3102.39<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.6 Cardiac",
        "clinical_situation": "Using troponin: general\nUsing troponin: ACS\nUsing troponin: cardiac\nsurgery\nUsing troponin: renal\nfailure",
        "entry_id": 62,
        "id": 62,
        "lang": "en",
        "recommendation": "MRI largely dependent on the\nmanufacturers’ assay being used\nand the clinical scenario. MRI\nshould be implemented according\nto the local protocol used\nAlgorithms that have been\ndeveloped using high-sensitivity\ntroponin assays will usually require\nseveral samples. A second sample\nis required one to two hours after\npresentation. The sensitivity for\nmyocardial infarction is almost\n100%\nFor standard troponin assays: if the\nfirst blood sample for troponin is\nnot elevated, a second sample\nshould be obtained after six to nine\nhours. Sometimes a third sample\nafter 12–24 hours is required\nSingle measurement at 24 hours\npost-surgery gives best correlation\nwith outcome. Serial samples\njustified if clinical condition worsens\nand/or new ECG changes to\nassess ACS\nConcentrations of troponin are\nusually increased in CKD patients\n(especially using high sensitivity\nassays). Serial samples will be\nrequired if suspected ACS as\nabove",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-C1",
        "source": "Wu AHB et al. Clin Chem 2018;64:645– 655.40 Boeddinghaus J et al. Clin Chem 2018;64:1347– 1360.41 Hamm CW et al. Eur Heart J 2011;32:2999– 3054.42 Thygesen K et al. Eur Heart J 2010;31:2197– 2204.43 Croal BL et al. Circulation 2006;114:1468– 1475.44 Khan NA et al. Circulation 2005;112:3088– 3096.45 Consensus opinion of the relevant expert working group",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.6 Cardiac",
        "clinical_situation": "Using BNP (NT-\nProBNP):\nPrimary care\n(heart failure triage)\nSecondary care\n(acute failure)\nTherapeutic guidance\nin heart failure",
        "entry_id": 63,
        "id": 63,
        "lang": "en",
        "recommendation": "Should only be measured once\nunless there is a repeat episode of\nsuspected heart failure with a\nchange in clinical presentation and\nthe diagnosis of heart failure has\npreviously been excluded. Single\ntime point use adequate for NICE\nguidance purposes\nIn people presenting with new\nsuspected acute heart failure, use\na single measurement of serum\nnatriuretic peptides (BNP or NT-\nProBNP)\nConsider measuring NT-ProBNP\nas part of a treatment optimisation\nprotocol only in a specialist care\nsetting for people aged under 75\nwho have heart failure with\nreduced ejection fraction and an\neGFR above 60 ml/min/1.73 m2",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-C2",
        "source": "NICE. CG108, 2010.46 NICE. CG187, 2014.47 NICE. NG106, <a href=\"/references#ref-48\" target=\"_blank\" class=\"reference-link\">2018.48<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Coeliac serology in\nknown adult patients on\nfollow up",
        "entry_id": 64,
        "id": 64,
        "lang": "en",
        "recommendation": "IgA tTG can be used to monitor\nresponse to a gluten-free diet.\nRetesting at six to twelve months\ndepending on pre-treatment value",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G1",
        "source": "Wolters Kluwer, <a href=\"/references#ref-49\" target=\"_blank\" class=\"reference-link\">2019.49<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Faecal elastase",
        "entry_id": 65,
        "id": 65,
        "lang": "en",
        "recommendation": "MRI is six months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G2",
        "source": "Molinari I et al. Clin Biochem 2004;37:758–763.50",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Faecal calprotectin\nFaecal calprotectin\nbeing used to\ndiscriminate irritable\nbowel syndrome from\ninflammatory bowel\ndisease in primary care\nusing the York Faecal\nCalprotectin Care\nPathway",
        "entry_id": 66,
        "id": 66,
        "lang": "en",
        "recommendation": "MRI is six months\nChange due to York pathway\nIf initial sample is <100 mcg/g, then\nretesting not required\nIf initial sample is >100 mcg/g, the\nMRI is two weeks.\nIf repeat sample is >250 mcg/g,\nrefer to gastroenterology urgently",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G3",
        "source": "van Rheenen PF et al. BMJ 2010;341:c3369.51 Turvill J et al. Frontline Gastroenterol 2018;9:285–294.52",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Trace elements\n(copper, zinc,\nselenium) in the\nmonitoring of nutrition\nsupport",
        "entry_id": 67,
        "id": 67,
        "lang": "en",
        "recommendation": "Baseline then every two to four\nweeks depending upon results",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G4",
        "source": "NICE.CG32, <a href=\"/references#ref-53\" target=\"_blank\" class=\"reference-link\">2006.53<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Ferritin monitoring for\nhaemochromatosis",
        "entry_id": 68,
        "id": 68,
        "lang": "en",
        "recommendation": "EASL recommends an initial\nretesting interval of three months,\nbut this should be tested more\nfrequently as ferritin approaches\nnormal range\nBCSH 2000 recommends monthly\nferritin during venesection",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G5",
        "source": "European Association for the Study of the Liver. J Hepatol 2010;53:3– 22.54 British Society for Haematology, <a href=\"/references#ref-55\" target=\"_blank\" class=\"reference-link\">2018.55<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Iron deficiency\ndiagnosis",
        "entry_id": 69,
        "id": 69,
        "lang": "en",
        "recommendation": "Repeat iron measurement not\nrequired unless doubt regarding\ndiagnosis",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G7",
        "source": "GAIN, <a href=\"/references#ref-57\" target=\"_blank\" class=\"reference-link\">2015.57<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Iron deficiency\ndiagnosis",
        "entry_id": 70,
        "id": 70,
        "lang": "en",
        "recommendation": "Check FBC two weeks post-iron\ntherapy\nOnce Hb normalised check FBC\nafter two months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G7",
        "source": "GAIN, <a href=\"/references#ref-57\" target=\"_blank\" class=\"reference-link\">2015.57<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Iron status in CKD",
        "entry_id": 71,
        "id": 71,
        "lang": "en",
        "recommendation": "Monitor iron status no earlier than\none week after receiving IV iron\nand at intervals of one to three\nmonths routinely",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G8",
        "source": "NICE. NG8, <a href=\"/references#ref-58\" target=\"_blank\" class=\"reference-link\">2015.58<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Iron profile/ferritin in a\nnormal patient",
        "entry_id": 72,
        "id": 72,
        "lang": "en",
        "recommendation": "One year",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G9",
        "source": "NICE. CG32, 2006.53 Smellie WS et al. J Clin Pathol 2006;59:781–789.59",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Monitoring vitamin B12\nand folate deficiency",
        "entry_id": 73,
        "id": 73,
        "lang": "en",
        "recommendation": "Repeat measurement of vitamin\nB12 and folate is unnecessary in\npatients with vitamin B12 and folate\ndeficiency\nHowever, vitamin B12 can be\nmeasured one to two months after\nstarting treatment if there is no\nresponse\nCheck FBC and reticulocyte count\nten days post-treatment for\nresponse. Once Hb is normalised,\nthe MRI is eight weeks",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-G10",
        "source": "Clinical Knowledge Summary, 2019.60 GAIN, <a href=\"/references#ref-57\" target=\"_blank\" class=\"reference-link\">2015.57<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "Paraproteins",
        "entry_id": 74,
        "id": 74,
        "lang": "en",
        "recommendation": "Testing at three-month intervals\ninitially",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP1",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "Patients with no\nfeatures of plasma cell\ndyscrasia (e.g.\nanaemia, bone fracture\nor pain located in bone,\nsuppression of other\nimmunoglobulin\nclasses, renal\nimpairment) and a band\nof <15 g/L",
        "entry_id": 75,
        "id": 75,
        "lang": "en",
        "recommendation": "Annual serum protein\nelectrophoresis and quantitation by\ndensitometry without need for\nfurther immunofixation is\nrecommended",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP2",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "Monoclonal\ngammopathy of\nundetermined\nsignificance",
        "entry_id": 76,
        "id": 76,
        "lang": "en",
        "recommendation": "Test at three- to four-monthly\nintervals within the first year of\nidentification. Then six to 12\nmonthly as long as no symptoms of\nprogression",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP3",
        "source": "Bird J et al. Br J Haematol 2009:147;22–42.61",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "Immunoglobulins",
        "entry_id": 77,
        "id": 77,
        "lang": "en",
        "recommendation": "Patients on immunoglobulin\nreplacement therapy must have\ntrough IgG concentrations and liver\nfunction tests performed at least\nquarterly",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "Immunoglobulins",
        "entry_id": 78,
        "id": 78,
        "lang": "en",
        "recommendation": "For other purposes, testing at a\nminimum interval of six months is\nrecommended",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "Myeloma patients on\nactive treatment",
        "entry_id": 79,
        "id": 79,
        "lang": "en",
        "recommendation": "Local guidance and treatment\nregimens should be followed when\nrequesting paraprotein\nconcentrations for patients on\nactive treatment",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP6",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "CRP",
        "entry_id": 80,
        "id": 80,
        "lang": "en",
        "recommendation": "Should not be retested within a 24-\nhour period following an initial\nrequest with the exception of\npaediatric requests",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP7",
        "source": "Hutton HD et al. Ann Clin Biochem 2009;46:155–158.63",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Specific proteins",
        "clinical_situation": "Procalcitonin",
        "entry_id": 81,
        "id": 81,
        "lang": "en",
        "recommendation": "24 hours",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-SP8",
        "source": "Hochreiter M et al. Crit Care 2009; 13:R83.64 Seguela PE et al. Cardiol Young 2011;21:392–399.65",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "α-fetoprotein for HCC\nsurveillance: screening\npatients at high HCC\nrisk",
        "entry_id": 82,
        "id": 82,
        "lang": "en",
        "recommendation": "Six months (UK)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM1",
        "source": "Sturgeon CM et al. Clin Chem 2010:56;e1–48.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "α-fetoprotein for\nmonitoring disease\nrecurrence in HCC",
        "entry_id": 83,
        "id": 83,
        "lang": "en",
        "recommendation": "Three to six months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM2",
        "source": "Sturgeon CM et al. Clin Chem 2010:56;e1–48.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Screening women with\na family history of\novarian cancer with\nCA125",
        "entry_id": 84,
        "id": 84,
        "lang": "en",
        "recommendation": "12 months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM3",
        "source": "Sturgeon CM et al. Clin Chem 2008:54:e11–79.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Using CA125 in\ndiagnostic strategies",
        "entry_id": 85,
        "id": 85,
        "lang": "en",
        "recommendation": "Retesting CA125 when imaging is\nnegative within one month",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM4",
        "source": "NICE. CG122, <a href=\"/references#ref-67\" target=\"_blank\" class=\"reference-link\">2011.67<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Monitoring CA125 in\ndisease recurrence",
        "entry_id": 86,
        "id": 86,
        "lang": "en",
        "recommendation": "One month",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM5",
        "source": "Sturgeon CM et al. Clin Chem 2008:54:e11–79.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Monitoring disease\nrecurrence with CA19.9",
        "entry_id": 87,
        "id": 87,
        "lang": "en",
        "recommendation": "One month",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM6",
        "source": "No available evidence. All Wales Consensus Group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "PSA screening",
        "entry_id": 88,
        "id": 88,
        "lang": "en",
        "recommendation": "When first result is raised, repeat\nonce in the following 6 weeks to\nassess the trend",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM7",
        "source": "Public Health England, <a href=\"/references#ref-68\" target=\"_blank\" class=\"reference-link\">2019.68<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Monitoring disease with\nPSA",
        "entry_id": 89,
        "id": 89,
        "lang": "en",
        "recommendation": "Every three months for first one to\ntwo years\nEvery six months for two years\nAnnually thereafter",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM8",
        "source": "Smellie WS et al. J Clin Pathol 2006;59:1116.69",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Monitoring disease\nrecurrence with CA15.3",
        "entry_id": 90,
        "id": 90,
        "lang": "en",
        "recommendation": "Two months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM9",
        "source": "Molina R et al. Tumour Biol 2005;26;281–293.70",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Serum β-hCG (tumour\nmarker)",
        "entry_id": 91,
        "id": 91,
        "lang": "en",
        "recommendation": "After evacuation of a molar\npregnancy, hCG concentration\nshould be monitored every week\nuntil normalisation then every\nmonth during the first year",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM12",
        "source": "Sturgeon CM et al. Clin Chem 2008;54:1935– <a href=\"/references#ref-72\" target=\"_blank\" class=\"reference-link\">1939.72<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Serum β-hCG (tumour\nmarker)",
        "entry_id": 92,
        "id": 92,
        "lang": "en",
        "recommendation": "After resection, prolonged marker\nhalf-life (>3 days for hCG) is a\nreliable indicator of residual tumour\nand a significant predictor of\nsurvival",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM12",
        "source": "Sturgeon CM et al. Clin Chem 2008;54:1935– <a href=\"/references#ref-72\" target=\"_blank\" class=\"reference-link\">1939.72<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumour markers",
        "clinical_situation": "Serum β-hCG (tumour\nmarker)",
        "entry_id": 93,
        "id": 93,
        "lang": "en",
        "recommendation": "If rate of change in tumour marker\nconcentration changes velocity, an\nurgent repeat to confirm the result\nis reasonable",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TM12",
        "source": "Sturgeon CM et al. Clin Chem 2008;54:1935– <a href=\"/references#ref-72\" target=\"_blank\" class=\"reference-link\">1939.72<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Anticonvulsant drugs\n(carbamazepine,\nphenytoin)",
        "entry_id": 94,
        "id": 94,
        "lang": "en",
        "recommendation": "Five half-lives after dosage change\n(four to five days) during initial\ndose optimisation, unless toxicity is\nsuspected. The kinetics of\nphenytoin are highly variable\nbetween individuals and when\nmetabolism is saturated, a small\ndose change results in a\ndisproportionate increase in\nplasma concentration. There is a\nsignificant risk of overdose and\ntherefore when titrating dose\nchanges check up to every 12\nhours depending on clinical\ncondition and therapy. This will be\nmore frequent on IV therapy for\nstatus epilepticus.\nNote: carbamazepine induces its\nown metabolism and\nconcentrations should be\nconfirmed two to three months after\ncommencing therapy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Digoxin",
        "entry_id": 95,
        "id": 95,
        "lang": "en",
        "recommendation": "Five half-lives after dosage change\n(i.e. approx. seven days) during\ninitial dose optimisation, unless\ntoxicity is suspected. When renal\nfunction has changed significantly\nrecognise the proportionate\ndecrease in clearance. In overdose\nsituations, up to every four hours\ndepending on clinical condition and\ntherapy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Aminoglycoside\nantibiotics\n(gentamicin,\ntobramycin)",
        "entry_id": 96,
        "id": 96,
        "lang": "en",
        "recommendation": "Every 24 hours at start of therapy\non high-dose parenteral regimens,\nless frequently when stable.\nEspecially important in the elderly,\npatients with impaired renal\nfunction and those with cystic\nfibrosis. This only applies to once-\ndaily dosing. If patient is on\nmultiple doses per day, refer to\nlocal guidance",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD3",
        "source": "Consult local hospital guidelines",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Immunosuppressive\ndrugs (ciclosporin,\ntacrolimus, sirolimus)",
        "entry_id": 97,
        "id": 97,
        "lang": "en",
        "recommendation": "Initially three per week after\ntransplantation, less frequently\nwhen stable. Concentrations\nshould also be checked when any\nmedication with possible\ninteractions is prescribed, the\ndosage is changed, the formulation\nis changed or when there is\nunexplained graft dysfunction",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD4",
        "source": "Baker R et al. The Renal Association, <a href=\"/references#ref-74\" target=\"_blank\" class=\"reference-link\">2011.74<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Theophylline",
        "entry_id": 98,
        "id": 98,
        "lang": "en",
        "recommendation": "Five half-lives after dosage change\n(i.e. approx. two days) during initial\ndose optimisation on oral\nregimens. Note smoking\nsignificantly reduces the half-life.\nDaily on IV aminophylline. In\noverdose situations requiring\nhaemodialysis, every four hours",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD5",
        "source": "Consensus opinion of the relevant expert working group.",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Methotrexate (high\ndose IV)",
        "entry_id": 99,
        "id": 99,
        "lang": "en",
        "recommendation": "24 hours after completion of\ntherapy then every 24 hours until\nplasma methotrexate is below cut-\noff concentration for toxicity\n(1 mol/L at 48 hours or according\nto local protocol)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD6",
        "source": "See product literature. Plard C et al. Cancer Chemother Pharmacol 2007;60: 609–620.75",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Lithium",
        "entry_id": 100,
        "id": 100,
        "lang": "en",
        "recommendation": "Days four to seven of treatment\nthen every week until dosage has\nremained constant for four weeks,\nthen every three months on\nstabilised regimens. Check\nconcentration when preparation\nchanged, when fluid intake\nchanges or when interacting drugs\nare added/withdrawn. 100% renal\nclearance, so is dependent on\nrenal function. Up to every four\nhours in overdose situations\nrequiring intensive therapy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD7",
        "source": "Joint Formulary Committee. British National Formulary (77th edition), <a href=\"/references#ref-76\" target=\"_blank\" class=\"reference-link\">2019.76<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutic drug monitoring",
        "clinical_situation": "Clozapine",
        "entry_id": 101,
        "id": 101,
        "lang": "en",
        "recommendation": "Induces its own metabolism and is\ninduced further by smoking.\nApproximately four days to reach\nnew steady-state after dose\nchange or smoking cessation with\npotentially fatal consequences due\nto the rapid increase to toxic\nconcentrations",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-TD8",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Occupational lead\nexposure (chronic)",
        "entry_id": 102,
        "id": 102,
        "lang": "en",
        "recommendation": "Initial blood lead concentration\nbefore commencing work or within\n14 days of starting\nBlood lead concentration\nmonitoring performed at least every\n12 months unless significantly\nexposed to metallic lead and its\ncompounds, in which case the\nblood lead should be measured\nevery three months\nIf the blood lead concentration is\n≥30 μg/dL in adult males (≥20\nμg/dL in women of childbearing\nage), monitor at least every six\nmonths\nIf the blood lead concentration is\n≥40 μg/dL in adult males (≥25\nμg/dL in women of childbearing\nage), monitor at least every three\nmonths\nIf the blood lead concentration is\n≥60 μg/dL in adult males (≥30\nμg/dL in women of childbearing\nage), repeat measurement of blood\nlead within two weeks",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O1",
        "source": "Health and Safety Executive Books, <a href=\"/references#ref-77\" target=\"_blank\" class=\"reference-link\">2002.77<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Acute lead poisoning\nin adults",
        "entry_id": 103,
        "id": 103,
        "lang": "en",
        "recommendation": "If baseline blood lead concentration\nis <50 μg/dL and the patient is\nasymptomatic and not pregnant,\nrepeat blood lead concentration\nafter two weeks following removal\nfrom exposure\nIf baseline blood lead concentration\nis ≥50 μg/dL, monitor blood lead\nconcentrations daily during\nchelation therapy and measure 24-\nhour urine lead excretion to assist\nin deciding the duration of\ntreatment. Repeat the blood lead\nmeasurement one week after the\nend of chelation treatment",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O2",
        "source": "TOXBASE.78",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Acute lead poisoning\nin children",
        "entry_id": 104,
        "id": 104,
        "lang": "en",
        "recommendation": "If baseline blood lead concentration\nis 10–50 μg/dL, repeat blood lead\nmeasurement in one month\nfollowing removal from exposure\nIf baseline blood lead concentration\nis >50 μg/dL, monitor blood lead\ndaily during chelation therapy and\nmeasure 24-hour urine lead\nexcretion to assist in deciding the\nduration of therapy. Repeat the\nblood lead measurement one week\nafter the end of treatment",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O3",
        "source": "TOXBASE.78",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Amphetamine toxicity",
        "entry_id": 105,
        "id": 105,
        "lang": "en",
        "recommendation": "Retesting is not indicated in the\nsame acute episode",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Benzodiazepine\ntoxicity",
        "entry_id": 106,
        "id": 106,
        "lang": "en",
        "recommendation": "Retesting is not indicated in the\nsame acute episode",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Cocaine toxicity",
        "entry_id": 107,
        "id": 107,
        "lang": "en",
        "recommendation": "Retesting is not indicated in the\nsame acute episode",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O6",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Opiate toxicity\nincluding morphine,\ncodeine and heroin",
        "entry_id": 108,
        "id": 108,
        "lang": "en",
        "recommendation": "Retesting is not indicated in the\nsame acute episode",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O7",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Occupational/toxicology",
        "clinical_situation": "Opioid toxicity\nincluding methadone",
        "entry_id": 109,
        "id": 109,
        "lang": "en",
        "recommendation": "Retesting is not indicated in the\nsame acute episode",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-O8",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Urine β-hCG\n(pregnancy)",
        "entry_id": 110,
        "id": 110,
        "lang": "en",
        "recommendation": "Urine pregnancy test can be\nrepeated at three days after a\nnegative result or approx. 28 days\nafter period commences",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P1",
        "source": "Manufacturer’s instructions",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Serum β-hCG\n(pregnancy)",
        "entry_id": 111,
        "id": 111,
        "lang": "en",
        "recommendation": "Serum β-hCG test: do not repeat if\npositive. Repeat after three days if\nnegative and no menstrual period\nhas occurred",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P2",
        "source": "Serum β-hCG doubling time = 1.5– 2 days",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Serum β-hCG (ectopic\npregnancy)",
        "entry_id": 112,
        "id": 112,
        "lang": "en",
        "recommendation": "48-hour repeat interval",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P3",
        "source": "NICE. NG126, <a href=\"/references#ref-79\" target=\"_blank\" class=\"reference-link\">2019.79<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Serum β-hCG (tumour\nmarker)",
        "entry_id": 113,
        "id": 113,
        "lang": "en",
        "recommendation": "After evacuation of a molar\npregnancy, the β-hCG\nconcentration should be monitored\nevery week until normalisation and\nthen every month during the first\nyear",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P4",
        "source": "Bidart JM et al. Clin Chem 1999;45:1695– <a href=\"/references#ref-71\" target=\"_blank\" class=\"reference-link\">1707.71<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "LFTs in obstetric\ncholestasis",
        "entry_id": 114,
        "id": 114,
        "lang": "en",
        "recommendation": "Once obstetric cholestasis is\ndiagnosed, it is reasonable to\nmeasure LFTs weekly until delivery\nPostnatally, LFTs should be\ndeferred for at least 10 days",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P5",
        "source": "RCOG. Obstetric Cholestasis: Green- top Guideline No 43, <a href=\"/references#ref-80\" target=\"_blank\" class=\"reference-link\">2011.80<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Bile acids in obstetric\ncholestasis",
        "entry_id": 115,
        "id": 115,
        "lang": "en",
        "recommendation": "Weekly monitoring.\nTwice-weekly monitoring advised in\nlater weeks if clinical state\nchanging",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P6",
        "source": "No evidence available but reflects expert opinion and practice",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Measurement of urate\nin pre-eclampsia",
        "entry_id": 116,
        "id": 116,
        "lang": "en",
        "recommendation": "Awaiting expert advice whilst not\nadmitted: twice-weekly urate",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P7",
        "source": "No evidence but reflects the practice of tertiary centre of excellent",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Urine protein in pre-\neclampsia",
        "entry_id": 117,
        "id": 117,
        "lang": "en",
        "recommendation": "At each antenatal visit to screen for\npre-eclampsia\nOnce diagnosed do not repeat\nquantification of proteinuria\nOnly repeat if clinically indicated,\nfor example, if new symptoms and\nsigns develop or if there is\nuncertainty over diagnosis",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P8",
        "source": "NICE. CG62, 2008.81 NICE. NG133, <a href=\"/references#ref-82\" target=\"_blank\" class=\"reference-link\">2019.82<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "LFT/renal in pre-\neclampsia",
        "entry_id": 118,
        "id": 118,
        "lang": "en",
        "recommendation": "At least daily when the results are\nabnormal but more often if the\nclinical condition\nIf mild hypertension*, perform tests\ntwice weekly\nIf moderate hypertension*, perform\ntests three times a week\nIf severe hypertension*, perform\ntests three times a week\n*See source guidelines for\ndefinitions of hypertension",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P9",
        "source": "RCOG. Green-top Guideline No 10A, 2006.83 NICE. NG133, <a href=\"/references#ref-82\" target=\"_blank\" class=\"reference-link\">2019.82<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Monitoring of\nthyrotoxicosis\ntreatment in pregnant\nwomen (UK)",
        "entry_id": 119,
        "id": 119,
        "lang": "en",
        "recommendation": "In women taking anti-thyroid drugs,\nTFTs should be performed prior to\nconception, at time of confirmation\nof pregnancy or at antenatal\nbooking\nNewly diagnosed hyperthyroid\npatients require monthly testing\nduring pregnancy until stabilised\nPregnant women receiving anti-\nthyroid drugs should be tested\nfrequently (perhaps monthly)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P10",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Monitoring of\nthyrotoxicosis\ntreatment in pregnant\nwomen (USA)",
        "entry_id": 120,
        "id": 120,
        "lang": "en",
        "recommendation": "fT4 and TSH should be monitored\napproximately every two to six\nweeks in women treated with anti-\nthyroid drugs in pregnancy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P11",
        "source": "Stagnaro-Green A et al. Thyroid 2011;21:1081– <a href=\"/references#ref-84\" target=\"_blank\" class=\"reference-link\">1125.84<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Pregnancy subclinical\nhypothyroidism",
        "entry_id": 121,
        "id": 121,
        "lang": "en",
        "recommendation": "Women with subclinical\nhypothyroidism who are not\ninitially treated should be\nmonitored for progression to overt\nhypothyroidism. Serum fT4 and\nTSH should be measured every\nfour weeks until 16–20 weeks\ngestation and at least once\nbetween 26–32 weeks\n(Euthyroid women [not receiving\nLT4] who are anti-thyroid antibody\npositive should be monitored\nduring pregnancy. Serum fT4 and\nTSH should be measured every\nfour weeks until 16–20 weeks\ngestation and at least once\nbetween 26 and 32 weeks)",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P12",
        "source": "Stagnaro-Green A et al. Thyroid 2011;21:1081– <a href=\"/references#ref-84\" target=\"_blank\" class=\"reference-link\">1125.84<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Women with diabetes\nwho are planning to\nbecome pregnant",
        "entry_id": 122,
        "id": 122,
        "lang": "en",
        "recommendation": "Monthly measurement of HbA1C",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P13",
        "source": "NICE. NG3, <a href=\"/references#ref-85\" target=\"_blank\" class=\"reference-link\">2015.85<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Assessing glycaemic\ncontrol using HbA1c in\npregnancy",
        "entry_id": 123,
        "id": 123,
        "lang": "en",
        "recommendation": "HbA1C should not be used\nroutinely for assessing glycaemic\ncontrol in the second and third\ntrimesters of pregnancy however\nconsider measuring HbA1C for\nwomen with pre-existing diabetes\nto assess risk to pregnancy",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P14",
        "source": "NICE. NG3, <a href=\"/references#ref-85\" target=\"_blank\" class=\"reference-link\">2015.85<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "For management of\nhyponatraemia in\nlabour and the\nimmediate postpartum\nperiod, women require\nsodium monitoring if\nthey are:\n• on an oxytocin\ninfusion (includes\ninduction and\naugmentation of\nlabour, treatment of\npostpartum\nhaemorrhage)\n• in labour and require\nIV insulin and\ndextrose\n• noted to have a\nblood sodium below\n130 mmol/L for any\nreason\n• have a positive fluid\nbalance of greater\nthan 1,500 ml",
        "entry_id": 124,
        "id": 124,
        "lang": "en",
        "recommendation": "Refers to measurement of sodium\nWomen on insulin infusions:\nMRI is 4 hours\nDuring labour:\nSodium >129 mmol/L\nMRI is 8 hours\nSodium 129–125 mmol/L\nMRI is 4 hours\nSodium <125 mmol/L\nMRI is 2 hours\nDelivery or completion of\noxytocin infusion:\nSodium >129 mmol/L\nRetesting not required\nSodium 129–125 mmol/L AND\nasymptomatics\nMRI is 4 hours\nSodium <125 mmol/L OR\nsymptomatic <130 mmol/L\nMRI is 2 hours",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P15",
        "source": "GAIN, <a href=\"/references#ref-86\" target=\"_blank\" class=\"reference-link\">2017.86<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.12 Pregnancy related",
        "clinical_situation": "Women with type 1\ndiabetes are three-\ntimes more likely to\ndevelop post-partum\nthyroid dysfunction",
        "entry_id": 125,
        "id": 125,
        "lang": "en",
        "recommendation": "Serum TSH, fT4 and thyroid\nperoxidase antibody status should\nbe established preconception, at\nbooking when pregnant and at\nthree months post-partum",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-P16",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.13 Paediatric related",
        "clinical_situation": "HbA1C monitoring in\nchildren and young\npeople with type 1\ndiabetes",
        "entry_id": 126,
        "id": 126,
        "lang": "en",
        "recommendation": "Two months",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-CH1",
        "source": "NICE. NG18, <a href=\"/references#ref-87\" target=\"_blank\" class=\"reference-link\">2004.87<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.13 Paediatric related",
        "clinical_situation": "Coeliac serology in\nknown paediatric\npatients on follow up",
        "entry_id": 127,
        "id": 127,
        "lang": "en",
        "recommendation": "Testing at six months in children",
        "section": "Biochemistry",
        "subsection": null,
        "ref": "B-CH2",
        "source": "Murch S et al. Arch Dis Child 2013;98:806–811.88",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Normal follow up",
        "entry_id": 129,
        "id": 129,
        "lang": "en",
        "recommendation": "A repeat would be indicated on\nclinical grounds if there were a\nsignificant change in the patient’s\ncondition",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC1",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Inpatient monitoring of\na stable patient",
        "entry_id": 130,
        "id": 130,
        "lang": "en",
        "recommendation": "An inpatient with a normal\nadmission FBC should not have a\nrepeat within the average length of\nstay of four days",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC2",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Inpatient monitoring of\nan unstable patient\nwho is not actively\nbleeding or a patient\nreceiving cytotoxic\ndrugs",
        "entry_id": 131,
        "id": 131,
        "lang": "en",
        "recommendation": "Not usually required more than\nonce daily",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC3",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Patients with major\nbleeding",
        "entry_id": 132,
        "id": 132,
        "lang": "en",
        "recommendation": "Repeat interval should be\ndetermined by the clinical situation.\nShould be repeated at least every\nhour for massive haemorrhage",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC4",
        "source": "Thomas D et al. Anaesthesia 2010;65:1153– <a href=\"/references#ref-89\" target=\"_blank\" class=\"reference-link\">1161.89<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Pregnant on\nhaematinic\nsupplements (iron,\nfolate, B12)",
        "entry_id": 133,
        "id": 133,
        "lang": "en",
        "recommendation": "Repeat after at least 14 days",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC5",
        "source": "BCSH, <a href=\"/references#ref-90\" target=\"_blank\" class=\"reference-link\">2011.90<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Routine pregnancy\nmonitoring",
        "entry_id": 134,
        "id": 134,
        "lang": "en",
        "recommendation": "At booking, 28 weeks and\npostpartum",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC6",
        "source": "NICE. CG62, 2008.81 BCSH, <a href=\"/references#ref-90\" target=\"_blank\" class=\"reference-link\">2011.90<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Hypertensive\ndisorders of\npregnancy*\n*FBC in combination\nwith renal and liver\nfunction",
        "entry_id": 135,
        "id": 135,
        "lang": "en",
        "recommendation": "Once only if moderate antenatal\ngestational hypertension\n(<160/110) without proteinuria.\nWeekly if severe gestational\nhypertension. Twice weekly if mild\nantenatal hypertension with pre-\neclampsia, three times weekly if\nmoderate to severe. As clinically\nindicated in peripartum period (may\nrequire multiple repeats over 24\nhours) and then repeat 48 hours\nafter delivery/step down from\ncritical care and stop monitoring if\nnormal values",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC7",
        "source": "NICE. NG133, <a href=\"/references#ref-82\" target=\"_blank\" class=\"reference-link\">2019.82<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Inpatients with\nsuspected platelet\nalloantibodies or\nreceiving HLA\nmatched platelets",
        "entry_id": 136,
        "id": 136,
        "lang": "en",
        "recommendation": "Repeat one hour after completion\nof platelet transfusion",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC8",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Patients with anaemia\nof chronic kidney\ndisease",
        "entry_id": 137,
        "id": 137,
        "lang": "en",
        "recommendation": "Every two to four weeks in the\ninduction phase of ESA therapy\nand every one to three months in\nthe maintenance phase of ESA\ntherapy",
        "section": "Haematology",
        "subsection": "FBC",
        "ref": "H-FBC9",
        "source": "NICE. NG8, <a href=\"/references#ref-58\" target=\"_blank\" class=\"reference-link\">2015.58<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Temporal\narteritis/polymyalgia\nrheumatica",
        "entry_id": 139,
        "id": 139,
        "lang": "en",
        "recommendation": "Every three months following first\nmonth of treatment",
        "section": "Haematology",
        "subsection": "ESR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.1 Haematology general",
        "clinical_situation": "Rheumatoid arthritis",
        "entry_id": 140,
        "id": 140,
        "lang": "en",
        "recommendation": "Every month until treatment has\ncontrolled the disease (NICE CG79\nrecommends use of CRP)",
        "section": "Haematology",
        "subsection": "ESR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patients with major\nbleeding",
        "entry_id": 141,
        "id": 141,
        "lang": "en",
        "recommendation": "Repeat interval should be\ndetermined by the clinical situation\nand the coagulation screen must\ninclude fibrinogen. Should be\nrepeated at least every hour for\nmassive haemorrhage",
        "section": "Haematology",
        "subsection": null,
        "ref": "H-CS1",
        "source": "Thomas D et al. Anaesthesia 2010;65:1153– <a href=\"/references#ref-89\" target=\"_blank\" class=\"reference-link\">1161.89<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patients with acute\ncoagulopathy",
        "entry_id": 142,
        "id": 142,
        "lang": "en",
        "recommendation": "Usually no more than once daily if\nnot receiving coagulation factors\nand no active bleeding",
        "section": "Haematology",
        "subsection": null,
        "ref": "H-CS2",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patients with chronic\nliver disease",
        "entry_id": 144,
        "id": 144,
        "lang": "en",
        "recommendation": "Every three months if otherwise\nstable",
        "section": "Haematology",
        "subsection": "PT",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patients being\ninitiated on VKA",
        "entry_id": 146,
        "id": 146,
        "lang": "en",
        "recommendation": "No more than once daily",
        "section": "Haematology",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Unstable inpatient\non VKA",
        "entry_id": 147,
        "id": 147,
        "lang": "en",
        "recommendation": "No more than once daily",
        "section": "Haematology",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Stable outpatient on\nVKA",
        "entry_id": 148,
        "id": 148,
        "lang": "en",
        "recommendation": "Usually no more than once weekly\nand up to 12 weeks when very\nstable",
        "section": "Haematology",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patient requiring\nurgent reversal of\nVKA (or to treat any\nacquired deficiency\nof vitamin K\ndependent\ncoagulation factors)\nwith vitamin K",
        "entry_id": 149,
        "id": 149,
        "lang": "en",
        "recommendation": "Repeat only after at least six hours\nfollowing IV dose and the following\nday after an oral dose",
        "section": "Haematology",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patient requiring\nurgent reversal of\nVKA with a four-\nfactor PCC",
        "entry_id": 150,
        "id": 150,
        "lang": "en",
        "recommendation": "Repeat within an hour of\nadministration",
        "section": "Haematology",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patient receiving\nintravenous infusion\nof unfractionated\nheparin",
        "entry_id": 152,
        "id": 152,
        "lang": "en",
        "recommendation": "Repeat 6 hours after dose\nadjustment (2 hours if previous\nAPTT ratio >5.0) and daily when\nAPTT in the target range",
        "section": "Haematology",
        "subsection": "APTT",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patients receiving\nintravenous infusion\nof a parenteral direct\nthrombin inhibitor\n(bivalirudin,\nargatroban)",
        "entry_id": 153,
        "id": 153,
        "lang": "en",
        "recommendation": "Repeat two hours after each dose\nadjustment then daily when in the\ntarget range",
        "section": "Haematology",
        "subsection": "APTT",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patients with acute\ncoagulopathy",
        "entry_id": 155,
        "id": 155,
        "lang": "en",
        "recommendation": "Usually no more than daily if not\nreceiving coagulation factors and\nno active bleeding",
        "section": "Haematology",
        "subsection": "Clauss fibrinogen assay",
        "ref": "H-CS2",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patients with major\nbleeding",
        "entry_id": 156,
        "id": 156,
        "lang": "en",
        "recommendation": "Repeat interval should be\ndetermined by the clinical situation.\nShould be repeated at least every\nhour in massive haemorrhage",
        "section": "Haematology",
        "subsection": "Clauss fibrinogen assay",
        "ref": "H-CS1",
        "source": "Thomas D et al. Anaesthesia 2010;65:1153– <a href=\"/references#ref-89\" target=\"_blank\" class=\"reference-link\">1161.89<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Patient on\ntherapeutic dose of\nLMWH with\nsignificant renal\nimpairment, extreme\nweight, pregnancy or\nother indication for\nmeasurement",
        "entry_id": 158,
        "id": 158,
        "lang": "en",
        "recommendation": "At least three days after initiation or\ndose adjustment, then no more\nthan once weekly if the dose is\nunchanged",
        "section": "Haematology",
        "subsection": "Anti-Xa assay",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Investigation of\nsuspected\nantiphospholipid\nsyndrome",
        "entry_id": 160,
        "id": 160,
        "lang": "en",
        "recommendation": "Repeat after 12 weeks if abnormal",
        "section": "Haematology",
        "subsection": "LA screen ",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Investigation for\nantiphospholipid\nsyndrome after\ncompletion of\nanticoagulation",
        "entry_id": 161,
        "id": 161,
        "lang": "en",
        "recommendation": "At least seven days after stopping\nanticoagulation",
        "section": "Haematology",
        "subsection": "LA screen ",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "A patient under\ninvestigation for\nsuspected\ncoagulation factor\ndeficiency",
        "entry_id": 163,
        "id": 163,
        "lang": "en",
        "recommendation": "An abnormal result can be\nrepeated for confirmation at a\nclinically appropriate interval",
        "section": "Haematology",
        "subsection": "CFA",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "A patient receiving\ncoagulation factor\nreplacement therapy",
        "entry_id": 164,
        "id": 164,
        "lang": "en",
        "recommendation": "An assay immediately before and\nup to 60 minutes after\nadministration and then as clinically\nindicated, usually no more than\nonce daily (either trough, peak or\nboth)",
        "section": "Haematology",
        "subsection": "CFA",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Surveillance in\npatients with severe\nhaemophilia A or B",
        "entry_id": 166,
        "id": 166,
        "lang": "en",
        "recommendation": "After every third factor ED or every\nthree months (whichever is sooner)\nuntil 20 ED, then every three to six\nmonths until 150 ED (then\none to two times per year in severe\nhaemophilia A only)",
        "section": "Haematology",
        "subsection": "Coagulation factor inhibitor testing",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Surveillance after\nchange of factor\nconcentrate in\nsevere haemophilia\nA",
        "entry_id": 167,
        "id": 167,
        "lang": "en",
        "recommendation": "Before the change and then twice\nin the first six months after the\nchange",
        "section": "Haematology",
        "subsection": "Coagulation factor inhibitor testing",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Surveillance in\npatients with\nmoderate or mild\nhaemophilia A",
        "entry_id": 168,
        "id": 168,
        "lang": "en",
        "recommendation": "Annually if exposed to factor\nconcentrate or after intensive\nexposure (>5 ED) or surgery",
        "section": "Haematology",
        "subsection": "Coagulation factor inhibitor testing",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Monitoring of ITT\nduring treatment",
        "entry_id": 169,
        "id": 169,
        "lang": "en",
        "recommendation": "Monthly",
        "section": "Haematology",
        "subsection": "Coagulation factor inhibitor testing",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "After completion of\nsuccessful ITT",
        "entry_id": 170,
        "id": 170,
        "lang": "en",
        "recommendation": "Monthly for six months then every\ntwo months for up to a year",
        "section": "Haematology",
        "subsection": "Coagulation factor inhibitor testing",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Haematology coagulation",
        "clinical_situation": "Monitoring patients\nwith newly\ndiagnosed acquired\ncoagulation factor\ninhibitor",
        "entry_id": 171,
        "id": 171,
        "lang": "en",
        "recommendation": "Monthly until six months after\nremission",
        "section": "Haematology",
        "subsection": "Coagulation factor inhibitor testing",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "A first-time patient\nprior to transfusion",
        "entry_id": 173,
        "id": 173,
        "lang": "en",
        "recommendation": "A second sample should be\nrequested prior to transfusion",
        "section": "Haematology",
        "subsection": "Blood group and antibody screen",
        "ref": "H-BGAS1",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "A patient who has\nnot had a\ntransfusion or\npregnancy within the\nprevious three\nmonths",
        "entry_id": 174,
        "id": 174,
        "lang": "en",
        "recommendation": "The original sample can be valid\nfor up to three months",
        "section": "Haematology",
        "subsection": "Blood group and antibody screen",
        "ref": "H-BGAS2",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "A patient who has\nhad a transfusion or\npregnancy within the\nprevious three\nmonths",
        "entry_id": 175,
        "id": 175,
        "lang": "en",
        "recommendation": "The original sample is valid for up\nto three days",
        "section": "Haematology",
        "subsection": "Blood group and antibody screen",
        "ref": "H-BGAS3",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "A pregnant woman\nwho requires blood\non standby for\nobstetric\nemergencies (e.g.\nplacenta praevia)",
        "entry_id": 176,
        "id": 176,
        "lang": "en",
        "recommendation": "A sample may be considered valid\nfor up to seven days",
        "section": "Haematology",
        "subsection": "Blood group and antibody screen",
        "ref": "H-BGAS4",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "A chronically\ntransfused patient\nwith no red cell\nalloantibodies",
        "entry_id": 177,
        "id": 177,
        "lang": "en",
        "recommendation": "A sample may be considered valid\nfor up to seven days after individual\nrisk assessment",
        "section": "Haematology",
        "subsection": "Blood group and antibody screen",
        "ref": "H-BGAS5",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "A pregnant woman\nover 20 weeks\ngestation who has\nanti-D, -c or -K\nantibodies",
        "entry_id": 178,
        "id": 178,
        "lang": "en",
        "recommendation": "Repeat with quantification of c and\nD antibodies, and anti-K by titration\nevery four weeks until 28 weeks\nand then every two weeks until\ndelivery",
        "section": "Haematology",
        "subsection": "Blood group and antibody screen",
        "ref": "H-BGAS6",
        "source": "White J et al. Transfus Med 2016;26:246–263.98",
        "level_of_evidence": "C"
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "An antenatal\nsensitising event in\nRhD-negative\nwomen after 20\nweeks gestation who\nare at risk of\ndeveloping RhD\nantibodies",
        "entry_id": 180,
        "id": 180,
        "lang": "en",
        "recommendation": "Repeat for each new sensitising\nevent unless there is an ongoing\nsensitising event (e.g. intermittent\nuterine bleeding) then repeat no\nmore frequently than every two\nweeks",
        "section": "Haematology",
        "subsection": "Estimation of FMH",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "FMH >4 ml in RhD-\nnegative women\nafter 20 weeks\ngestation who are at\nrisk of developing\nRhD antibodies\n(RhD-positive baby\nor fetal RhD status\nunknown)",
        "entry_id": 181,
        "id": 181,
        "lang": "en",
        "recommendation": "Repeat 48 hours after IV anti-D or\n72 hours after IM anti-D and repeat\nprocess until no detectable fetal\ncells",
        "section": "Haematology",
        "subsection": "Estimation of FMH",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.3 Haematology transfusion (general and screening group in PBLC)",
        "clinical_situation": "After cell salvage in\nRhD-negative\nwomen",
        "entry_id": 182,
        "id": 182,
        "lang": "en",
        "recommendation": "Check 30–45 minutes after\nreinfusion of salvaged cells then as\nper FMH1",
        "section": "Haematology",
        "subsection": "Estimation of FMH",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "A3 ganglionic\nreceptor antibody",
        "entry_id": 183,
        "id": 183,
        "lang": "en",
        "recommendation": "Repeat testing once diagnosis is\nconfirmed is of limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-1",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Acetyl choline\nreceptor antibody",
        "entry_id": 184,
        "id": 184,
        "lang": "en",
        "recommendation": "Frequency determined by clinical\ncontext. Every six months while on\ntreatment",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-2",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Adrenal cortex\nantibody",
        "entry_id": 185,
        "id": 185,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-3",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "aPL antibody",
        "entry_id": 186,
        "id": 186,
        "lang": "en",
        "recommendation": "Once diagnosis is confirmed using\nBCSH guidelines, repeat testing is\nof limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-4",
        "source": "Keeling D et al. Br J Haematol 2012;157:47–58.94",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Alpha-1 antitrypsin\ngenotype",
        "entry_id": 187,
        "id": 187,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-5",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "AMPA receptor\nantibody",
        "entry_id": 188,
        "id": 188,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-6",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Anti-nuclear\nantibody (HEP2)",
        "entry_id": 189,
        "id": 189,
        "lang": "en",
        "recommendation": "Once diagnosis is established,\nrepeat testing is of limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-7",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Aquaporin 4\nantibodies (NMO)\nCSF",
        "entry_id": 190,
        "id": 190,
        "lang": "en",
        "recommendation": "Repeat testing guided by clinical\ncontext and discussion with\nspecialist laboratory service\nproviding assay",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-8",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Aquaporin 4\nantibodies (NMO)\nserum",
        "entry_id": 191,
        "id": 191,
        "lang": "en",
        "recommendation": "Repeat testing guided by clinical\ncontext and discussion with\nspecialist laboratory service\nproviding assay",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-9",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Basal ganglia\nantibody",
        "entry_id": 192,
        "id": 192,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-10",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Beta-2 microglobulin",
        "entry_id": 193,
        "id": 193,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-11",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Beta-2 glycoprotein I\nantibody",
        "entry_id": 194,
        "id": 194,
        "lang": "en",
        "recommendation": "Once diagnosis is confirmed using\nBCSH guidelines, repeat testing is\nof limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-12",
        "source": "Keeling D et al. Br J Haematol 2012;157:47–58.94",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "C3/4",
        "entry_id": 195,
        "id": 195,
        "lang": "en",
        "recommendation": "90 days (earlier frequency of\ntesting maybe required in\nexceptional cases)",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-13",
        "source": "Consensus of surveyed labs",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "C3 nephritic factor",
        "entry_id": 196,
        "id": 196,
        "lang": "en",
        "recommendation": "Not routinely required if positive.\nOnly allowed if C3 below reference\nrange",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-14",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Cardiac muscle\nantibody",
        "entry_id": 197,
        "id": 197,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-15",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Cardiolipin antibody",
        "entry_id": 198,
        "id": 198,
        "lang": "en",
        "recommendation": "Once diagnosis is confirmed using\nBCSH guidelines, repeat testing is\nof limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-16",
        "source": "Keeling D et al. Br J Haematol 2012;157:47–58.94",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "CCP",
        "entry_id": 199,
        "id": 199,
        "lang": "en",
        "recommendation": "Repeat testing once diagnosis is\nconfirmed is of limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-17",
        "source": "Consensus of surveyed labs NICE. NG100, <a href=\"/references#ref-100\" target=\"_blank\" class=\"reference-link\">2018.100<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "CD62 ligand\nshedding",
        "entry_id": 200,
        "id": 200,
        "lang": "en",
        "recommendation": "Discuss with lab",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-18",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Complement C1q",
        "entry_id": 201,
        "id": 201,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-19",
        "source": "Tarzi MD et al. Clin Exp Immunol 2007; 149:513–516.101",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Complement 1\ninhibitor\nimmunochemical",
        "entry_id": 202,
        "id": 202,
        "lang": "en",
        "recommendation": "Only once to confirm; repeat\ntesting limited to exceptional cases\nGenerally, only performed if C4 is\nlow or with compatible clinical\ninformation",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-20",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Complement AP100",
        "entry_id": 203,
        "id": 203,
        "lang": "en",
        "recommendation": "Only once to confirm\nOnly allowed with compatible\nclinical information",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-21",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Complement C2",
        "entry_id": 204,
        "id": 204,
        "lang": "en",
        "recommendation": "Only once to confirm\nOnly allowed with compatible\nclinical information",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-22",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Complement CH100",
        "entry_id": 205,
        "id": 205,
        "lang": "en",
        "recommendation": "Only once to confirm\nOnly allowed with compatible\nclinical information",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-23",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Complement factor\nB",
        "entry_id": 206,
        "id": 206,
        "lang": "en",
        "recommendation": "Only once to confirm\nOnly allowed with compatible\nclinical information",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-24",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Complement factor\nH",
        "entry_id": 207,
        "id": 207,
        "lang": "en",
        "recommendation": "Only allowed with compatible\nclinical information",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-25",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "CSF oligoclonal",
        "entry_id": 208,
        "id": 208,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-26",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Cryoglobulin screen",
        "entry_id": 209,
        "id": 209,
        "lang": "en",
        "recommendation": "After initial confirmation of\ncryoglobulin, which may\nrequire testing more than once,\nrepeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-27",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Cryoglobulin type",
        "entry_id": 210,
        "id": 210,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-28",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "dsDNA Ab ELISA",
        "entry_id": 211,
        "id": 211,
        "lang": "en",
        "recommendation": "Every three to six months while on\ntreatment",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-29",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Endomysial antibody\n(IgA)",
        "entry_id": 212,
        "id": 212,
        "lang": "en",
        "recommendation": "Not routinely required\nOnly for confirmation of tTg\npositives",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-30",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Endomysial antibody\n(IgG)",
        "entry_id": 213,
        "id": 213,
        "lang": "en",
        "recommendation": "Only for patients with complete IgA\ndeficiency and confirmation of\npositive tTG IgG\nIndicate that this test should not be\nundertaken and refer to relevant\nNICE guidelines",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-31",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "ENA RNP, Sm, Ro,\nLa, Scl, Jo1 and\ncentromere",
        "entry_id": 214,
        "id": 214,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-32",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "GABA receptor\nantibody",
        "entry_id": 215,
        "id": 215,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-33",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "GAD65 antibody",
        "entry_id": 216,
        "id": 216,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-34",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Ganglioside GD1b\nantibody",
        "entry_id": 217,
        "id": 217,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-35",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Ganglioside GM1\nantibody",
        "entry_id": 218,
        "id": 218,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-36",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Ganglioside GQ1b\nantibody",
        "entry_id": 219,
        "id": 219,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-37",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "GBM antibody",
        "entry_id": 220,
        "id": 220,
        "lang": "en",
        "recommendation": "Every three to six months while on\ntreatment or more frequent if\nreceiving plasma exchange therapy",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-38",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Glycine receptor\nantibody",
        "entry_id": 221,
        "id": 221,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-39",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Hib antibody",
        "entry_id": 222,
        "id": 222,
        "lang": "en",
        "recommendation": "Repeat testing to assess response\nto test immunisation. Serial\nmonitoring of limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-40",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Histone antibody",
        "entry_id": 223,
        "id": 223,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-41",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "IA2 antibody",
        "entry_id": 224,
        "id": 224,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-42",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "IgA low level",
        "entry_id": 225,
        "id": 225,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-43",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "IgE",
        "entry_id": 226,
        "id": 226,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-44",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "IgG low level",
        "entry_id": 227,
        "id": 227,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-45",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "IgG subclasses\n(1, 2, 3, 4)",
        "entry_id": 228,
        "id": 228,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-46",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "IgG4",
        "entry_id": 229,
        "id": 229,
        "lang": "en",
        "recommendation": "Repeat testing of limited value,\nalthough it may be useful for\nmonitoring in certain patients",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-47",
        "source": "Abraham M et al. Expert Rev Clin Immunol 2017;13:867–875.102",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Insulin antibody",
        "entry_id": 230,
        "id": 230,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-48",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Intrinsic factor\nantibody",
        "entry_id": 231,
        "id": 231,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-49",
        "source": "Khan S et al. J Clin Path 2009;62:439– 441.103",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Islet cell antibody",
        "entry_id": 232,
        "id": 232,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-50",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Liver antibody line\nblot, including M2-\nPDH",
        "entry_id": 233,
        "id": 233,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-51",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Liver autoantibodies",
        "entry_id": 234,
        "id": 234,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-52",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Lymphocyte\nphenotype CD3, 4,\n8, 19, 56",
        "entry_id": 235,
        "id": 235,
        "lang": "en",
        "recommendation": "Discuss with lab",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-53",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Leucocyte adhesion\nmolecules",
        "entry_id": 236,
        "id": 236,
        "lang": "en",
        "recommendation": "Discuss with lab",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-54",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Lymphocyte\nphenotyping\nextended panel",
        "entry_id": 237,
        "id": 237,
        "lang": "en",
        "recommendation": "Discuss with lab",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-55",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Mast cell tryptase",
        "entry_id": 238,
        "id": 238,
        "lang": "en",
        "recommendation": "Three samples over a 24-hour\nperiod for assessment of\nanaphylaxis\n(Resuscitation Council UK\nguidelines advise that samples\nshould be taken at as close to time\n0 as possible, and 2 hours after\nonset with a baseline sample\ngreater than 24 hours.)\nRepeat testing may be required in\nmastocytosis. Frequency to be\ndetermined by clinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-56",
        "source": "NICE. CG134, <a href=\"/references#ref-104\" target=\"_blank\" class=\"reference-link\">2011.104<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "MPO ANCA",
        "entry_id": 239,
        "id": 239,
        "lang": "en",
        "recommendation": "On treatment: six months or more\nfrequent if receiving plasma\nexchange therapy\nOff treatment: annually",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-57",
        "source": "Ntatsaki E et al. Rheumatology 2014;53:2306– <a href=\"/references#ref-105\" target=\"_blank\" class=\"reference-link\">2309.105<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Muscle-specific\nkinase antibody",
        "entry_id": 240,
        "id": 240,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-58",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "MAG antibody",
        "entry_id": 241,
        "id": 241,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-59",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "MOG antibody",
        "entry_id": 242,
        "id": 242,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-60",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Myositis antibody\nprofile",
        "entry_id": 243,
        "id": 243,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-61",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Neutrophil\ncytoplasmic antibody",
        "entry_id": 244,
        "id": 244,
        "lang": "en",
        "recommendation": "On treatment: six months or more\nfrequent if receiving plasma\nexchange therapy\nOff treatment: annually",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-62",
        "source": "Ntatsaki E et al. Rheumatology 2014;53:2306– <a href=\"/references#ref-105\" target=\"_blank\" class=\"reference-link\">2309.105<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Neutrophil oxidative\nburst",
        "entry_id": 245,
        "id": 245,
        "lang": "en",
        "recommendation": "Discuss with lab",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-63",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "NMDA receptor\nantibody CSF",
        "entry_id": 246,
        "id": 246,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-64",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "NMDA receptor\nantibody serum",
        "entry_id": 247,
        "id": 247,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-65",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Ovarian antibody",
        "entry_id": 248,
        "id": 248,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-66",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Paraneoplastic\nantibody profile",
        "entry_id": 249,
        "id": 249,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-67",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Paraprotein\n(monolonal band)\nquantitation",
        "entry_id": 250,
        "id": 250,
        "lang": "en",
        "recommendation": "Three months",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-68",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Parathyroid antibody",
        "entry_id": 251,
        "id": 251,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-69",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Parietal cell antibody",
        "entry_id": 252,
        "id": 252,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-70",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Pemphigoid\nantibody",
        "entry_id": 253,
        "id": 253,
        "lang": "en",
        "recommendation": "On treatment: six months\nOff treatment: annually",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-71",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Pemphigus antibody",
        "entry_id": 254,
        "id": 254,
        "lang": "en",
        "recommendation": "On treatment: six months\nOff treatment: annually",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-72",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Phospholipase A2\nreceptor antibody",
        "entry_id": 255,
        "id": 255,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-73",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Pituitary antibody",
        "entry_id": 256,
        "id": 256,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-74",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "PR3 ANCA",
        "entry_id": 257,
        "id": 257,
        "lang": "en",
        "recommendation": "On treatment: six months or more\nfrequent if receiving plasma\nexchange therapy\nOff treatment: annually",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-75",
        "source": "Ntatsaki E et al. Rheumatology 2014;53:2306– <a href=\"/references#ref-105\" target=\"_blank\" class=\"reference-link\">2309.105<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Protein (serum)\nelectrophoresis",
        "entry_id": 258,
        "id": 258,
        "lang": "en",
        "recommendation": "Three months",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-77",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Protein (serum)\nelectrophoresis",
        "entry_id": 259,
        "id": 259,
        "lang": "en",
        "recommendation": "Annually for MGUS",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-77",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Quantiferon TB IFN\ngamma",
        "entry_id": 260,
        "id": 260,
        "lang": "en",
        "recommendation": "Discuss with lab",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-78",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Rheumatoid factor",
        "entry_id": 261,
        "id": 261,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-79",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Scleroderma\nantibody profile",
        "entry_id": 262,
        "id": 262,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-80",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Serotype-specific\nanti-pneumococcal\nantibody (APA)",
        "entry_id": 263,
        "id": 263,
        "lang": "en",
        "recommendation": "Repeat testing to assess response\nto test immunisation. Serial\nmonitoring of limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-81",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Serum amyloid A",
        "entry_id": 264,
        "id": 264,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-82",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Serum free light\nchains",
        "entry_id": 265,
        "id": 265,
        "lang": "en",
        "recommendation": "If available, local guidance and\ntreatment regimens should be\nfollowed when requesting\nparaprotein concentrations for\npatients on active treatment\nIf no local advice or treatment\nregimens are available, then the\nMRI is three months. This is only\nfor diagnosis/monitoring of\namyloidosis, non-secretory\nmyeloma and light chain only\nmyeloma",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-83",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Serum\nimmunofixation",
        "entry_id": 266,
        "id": 266,
        "lang": "en",
        "recommendation": "Not routinely required unless there\nis a change in serum\nelectrophoresis\nNot performed as follow up to\nelectrophoresis unless for\nremission confirmation",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-84",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Skeletal (striated)\nmuscle antibody",
        "entry_id": 267,
        "id": 267,
        "lang": "en",
        "recommendation": "Not routinely required\nComment on ordering that imaging\nis superior for thymoma\ninvestigation",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-85",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Specific IgE",
        "entry_id": 268,
        "id": 268,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-86",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Submaxillary gland\nantibody",
        "entry_id": 269,
        "id": 269,
        "lang": "en",
        "recommendation": "Never",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-87",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Tetanus antibody",
        "entry_id": 270,
        "id": 270,
        "lang": "en",
        "recommendation": "Repeat testing to assess response\nto test immunisation. Serial\nmonitoring of limited value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-88",
        "source": "Consensus of surveyed labs",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "tIgE",
        "entry_id": 271,
        "id": 271,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-89",
        "source": "Consensus of surveyed labs",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Thyroid peroxidase\nantibody",
        "entry_id": 272,
        "id": 272,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-90",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "T-lymphocyte subset\nCD3, 4, 8",
        "entry_id": 273,
        "id": 273,
        "lang": "en",
        "recommendation": "Discuss with lab",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-91",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "tTg IgA antibody",
        "entry_id": 274,
        "id": 274,
        "lang": "en",
        "recommendation": "IgA tTG can be used to monitor\nresponse to a gluten-free diet\nRetesting at six to twelve months\ndepending on pre-treatment value",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-92",
        "source": "Wolters Kluwer, <a href=\"/references#ref-49\" target=\"_blank\" class=\"reference-link\">2019.49<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "tTg IgG antibody",
        "entry_id": 275,
        "id": 275,
        "lang": "en",
        "recommendation": "Retesting at six to twelve months\nOnly in IgA-deficient patients",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-93",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Urine\nelectrophoresis",
        "entry_id": 276,
        "id": 276,
        "lang": "en",
        "recommendation": "Not routinely required",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-94",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "Urine Free Light\nChain Quant",
        "entry_id": 277,
        "id": 277,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-95",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "VGCC antibody",
        "entry_id": 278,
        "id": 278,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-96",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "VGKC antibody CSF",
        "entry_id": 279,
        "id": 279,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-97",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunology recommendations",
        "clinical_situation": "VGKC antibody\nserum",
        "entry_id": 280,
        "id": 280,
        "lang": "en",
        "recommendation": "Repeat testing of limited value.\nFrequency to be determined by\nclinical context",
        "section": "Immunology",
        "subsection": null,
        "ref": "I-98",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "AFB microscopy and\nculture",
        "entry_id": 281,
        "id": 281,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-1",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Antrum washings",
        "entry_id": 282,
        "id": 282,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-2",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "ASO titre",
        "entry_id": 283,
        "id": 283,
        "lang": "en",
        "recommendation": "14 days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-3",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Aspirates and fluids\nfrom sterile sites",
        "entry_id": 284,
        "id": 284,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-4",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Blood culture",
        "entry_id": 285,
        "id": 285,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-5",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Borrelia burgdorferi\n(Lyme)",
        "entry_id": 286,
        "id": 286,
        "lang": "en",
        "recommendation": "14 days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-6",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "CSF",
        "entry_id": 287,
        "id": 287,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-7",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Chlamydia NAAT",
        "entry_id": 288,
        "id": 288,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-8",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "GC NAAT",
        "entry_id": 289,
        "id": 289,
        "lang": "en",
        "recommendation": "14 days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-9",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "CFT",
        "entry_id": 290,
        "id": 290,
        "lang": "en",
        "recommendation": "14 days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-10",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Cough swab",
        "entry_id": 291,
        "id": 291,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-11",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "CSF for molecular\ninvestigation, e.g.\nMeningococcus",
        "entry_id": 292,
        "id": 292,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-12",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "CSF microscopy and\nculture",
        "entry_id": 293,
        "id": 293,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-13",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Drug monitoring:\nglycopeptides\n(vancomycin,\nteicoplanin, etc.)",
        "entry_id": 294,
        "id": 294,
        "lang": "en",
        "recommendation": "24 hours",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-14",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Drug monitoring:\naminoglycoside\n(gentamicin,\namikacin, etc.)\nNote: this only\napplies to once-daily\ndosing. If patient is\non multiple doses\nper day please refer\nto local guidance",
        "entry_id": 295,
        "id": 295,
        "lang": "en",
        "recommendation": "24 hours",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-15",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Ear swab",
        "entry_id": 296,
        "id": 296,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-16",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Ear/nose and throat\nswab",
        "entry_id": 297,
        "id": 297,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-17",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Endocervical swab",
        "entry_id": 298,
        "id": 298,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-18",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Eye swab on same\neye",
        "entry_id": 299,
        "id": 299,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-19",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Faeces –\nClostridium difficile",
        "entry_id": 300,
        "id": 300,
        "lang": "en",
        "recommendation": "Repeated testing after a first\npositive sample during the same\ndiarrhoeal episode is not\nrecommended in an endemic\nsituation\nRepeated testing after a first\nnegative sample during the same\ndiarrhoeal episode may be useful\nin selected cases with ongoing\nclinical suspicion during an\nepidemic situation or in cases with\nhigh clinical suspicion during\nendemic situations\nDependent on result:\nConfirmed positive: 28 days\nEquivocal*: 24 hours\nNegative: 24 hours\nA test of cure is not recommended\n*GDH positive/toxin negative",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-20",
        "source": "Crobach MJT et al. Clin Microbiol Infect 2016;22:S63– S81.106",
        "level_of_evidence": "A"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Faeces – ova, cysts\nand parasites",
        "entry_id": 301,
        "id": 301,
        "lang": "en",
        "recommendation": "24 hours",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-21",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Faeces – routine",
        "entry_id": 302,
        "id": 302,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-22",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Genital swab (GC\nonly)",
        "entry_id": 303,
        "id": 303,
        "lang": "en",
        "recommendation": "14 days if symptoms remain after\ntreatment (see also M-9)",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-23",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Genital swab\nmicroscopy and\nculture",
        "entry_id": 304,
        "id": 304,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-24",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Helicobacter pylori –\nnegative serology",
        "entry_id": 305,
        "id": 305,
        "lang": "en",
        "recommendation": "28 days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-25",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Helicobacter pylori –\npositive serology",
        "entry_id": 306,
        "id": 306,
        "lang": "en",
        "recommendation": "Never",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-26",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "High vaginal swab",
        "entry_id": 307,
        "id": 307,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-27",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "IUCD",
        "entry_id": 308,
        "id": 308,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-28",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "IUCD for\nActinomyces",
        "entry_id": 309,
        "id": 309,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-29",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Joint fluids,\nmicroscopy and\nculture",
        "entry_id": 310,
        "id": 310,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-30",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Mouth swab",
        "entry_id": 311,
        "id": 311,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-31",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "MRSA screen",
        "entry_id": 312,
        "id": 312,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-32",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "MRSA post-\neradication therapy",
        "entry_id": 313,
        "id": 313,
        "lang": "en",
        "recommendation": "48 hours",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-33",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "M. pneumoniae only",
        "entry_id": 314,
        "id": 314,
        "lang": "en",
        "recommendation": "14 days (if CFT antibody tested; if\nPCR used no repeat)\nWhen testing for Mycoplasma IgM,\na second sample should be taken\nseven to ten days after a negative\nif the initial sample was taken early\nin the illness",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-34",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Nasal swab",
        "entry_id": 315,
        "id": 315,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-35",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Nasopharyngeal\naspirate",
        "entry_id": 316,
        "id": 316,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-36",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "PD fluids,\nmicroscopy and\nculture",
        "entry_id": 317,
        "id": 317,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-37",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Peritoneal fluid",
        "entry_id": 318,
        "id": 318,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-38",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Pernasal swab (for\npertussis)",
        "entry_id": 319,
        "id": 319,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-39",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Pernasal swabs",
        "entry_id": 320,
        "id": 320,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-40",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Pleural\neffusion/chest fluids",
        "entry_id": 321,
        "id": 321,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-41",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Pleural fluid",
        "entry_id": 322,
        "id": 322,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-42",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Pneumocystis\njirovecii (DIF/PCR)",
        "entry_id": 323,
        "id": 323,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-43",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Pus swab",
        "entry_id": 324,
        "id": 324,
        "lang": "en",
        "recommendation": "Three days or once per episode of\ndrainage",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-44",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Pus/exudate",
        "entry_id": 325,
        "id": 325,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-45",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Seminal fluid",
        "entry_id": 326,
        "id": 326,
        "lang": "en",
        "recommendation": "28 days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-46",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Skin, nail and hair\nfor mycology",
        "entry_id": 327,
        "id": 327,
        "lang": "en",
        "recommendation": "Three months",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-47",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Sputum (this\nexcludes\ninvestigation of TB,\nsee M-56)",
        "entry_id": 328,
        "id": 328,
        "lang": "en",
        "recommendation": "Three days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-48",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Syphilis",
        "entry_id": 329,
        "id": 329,
        "lang": "en",
        "recommendation": "14 days after a negative result in\nan at-risk individual\nFor treatment response, test rapid\nplasma regain (RPR) three monthly",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-49",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Throat swab",
        "entry_id": 330,
        "id": 330,
        "lang": "en",
        "recommendation": "Dependent on result:\nPositive: seven days\nNegative: three days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-50",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Tissue/bone\nmicroscopy and\nculture",
        "entry_id": 331,
        "id": 331,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-51",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Tissues and\nbiopsies",
        "entry_id": 332,
        "id": 332,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-52",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Toxoplasma IgG\nscreen negative",
        "entry_id": 333,
        "id": 333,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-53",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Toxoplasma IgG\nscreen positive",
        "entry_id": 334,
        "id": 334,
        "lang": "en",
        "recommendation": "Never",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-54",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Tuberculosis",
        "entry_id": 335,
        "id": 335,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-55",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Urethral swab",
        "entry_id": 336,
        "id": 336,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-56",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Urine for\ntuberculosis",
        "entry_id": 337,
        "id": 337,
        "lang": "en",
        "recommendation": "N/A",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-57",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Urine, microscopy\nand culture",
        "entry_id": 338,
        "id": 338,
        "lang": "en",
        "recommendation": "Three days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-58",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Wound and ulcer\nswab",
        "entry_id": 339,
        "id": 339,
        "lang": "en",
        "recommendation": "Seven days",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-59",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "Aspergillus GM\n(Bio-Rad Platelia\nAspergillus ELISA)",
        "entry_id": 340,
        "id": 340,
        "lang": "en",
        "recommendation": "Twice-weekly serial screening for\nblood GM in high-risk haematology\npatients*:\n• single negative sample can be\nused to exclude IA\n• two consecutive positive\nsamples provide good positive\npredictive value\n• reduction of the GM index\nduring the first two weeks of\nantifungal therapy is a reliable\npredictor of treatment response\nDiagnostic GM on BAL is the most\nsensitive test\n*Neutropenic patients and\nallogeneic stem cell transplantation\nrecipients during the early\nengraftment phase, who are not on\nmould-active antifungal prophylaxis\nor treatment",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-60",
        "source": "Maertens J et al. Blood 2001;97:1604– 1610.107 Furfaro E et al. Transpl Infect Dis 2012;14:E38– E39.108 Leeflang MM et al. Cochrane Database Syst Rev 2008;4: CD007394.109 Chai LY et al. J Clin Microbiol 2012;50:2330– 2336.110 Nouer SA et al. Clin Infect Dis 2011;53:671–676.111 Bergeron A et al. J Clin Microbiol 2012;50:823–830.112 Schelenz S et al. Lancet Infect Dis 2015;15:461–474.113 Lass-Florl C. Med Mycol 2019;57:S155– S160.114",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 General microbiology",
        "clinical_situation": "BDG",
        "entry_id": 341,
        "id": 341,
        "lang": "en",
        "recommendation": "Twice-weekly screening for\nseverely ill intensive care unit\npatients and patients with\nhaematological malignancies and\npost-allogeneic hematopoietic stem\ncell transplants:\n• single negative sample can be\nused to exclude diagnosis of\nmost invasive fungal infection\n(notable exceptions include\nmucoraceous mould infection,\ncryptococcosis, some\ndimorphic fungi and other rare\nfungi) repeating positive BDG\nresults is not clinically helpful\nas it may take several weeks to\nclear from system",
        "section": "Microbiology",
        "subsection": null,
        "ref": "M-61",
        "source": "Eggimann P et al. Crit Care 2011;15:1017.115 Cuenca-Estrella M et al. Clin Microbiol Infect 2012;18:S9– S18.116 Hammarström H et al. Eur J Clin Microbiol Infect Dis 2015;34:917–925.117 Schelenz S et al. Lancet Infect Dis 2015;15:461–474.113 Rautemaa- Richardson R et al. J Antimicrob Chemother 2018;73:3488– <a href=\"/references#ref-118\" target=\"_blank\" class=\"reference-link\">3495.118<sup>ref</sup></a>",
        "level_of_evidence": ""
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Maternal infection\nwith HIV",
        "entry_id": 342,
        "id": 342,
        "lang": "en",
        "recommendation": "Non-breastfed infant\nTest infant blood (EDTA) for HIV\nproviral DNA PCR:\n• during the first 48 hours\n• at two weeks (if high risk*)\n• at six weeks (or two weeks\nafter cessation of prophylaxis)\n• at 12 weeks (or eight weeks\nafter cessation of prophylaxis)\nOn other occasions if additional\nrisk:\n• test HIV Ag/Ab for\nseroreversion at 18–24 months\nBreastfed infant\nTest infant blood (EDTA) for HIV\nproviral DNA PCR:\n• during the first 48 hours\n• at two weeks\n• monthly for the duration of\nbreastfeeding\n• at four and eight weeks after\ncessation of breastfeeding\nOn other occasions if additional\nrisk:\n• test HIV Ag/Ab for\nseroreversion at 18–24 months\n*High risk denotes a detectable\nmaternal HIV RNA viraemia at 36\nweeks and at birth)",
        "section": "Virology",
        "subsection": null,
        "ref": "V-1",
        "source": "British HIV Association, <a href=\"/references#ref-119\" target=\"_blank\" class=\"reference-link\">2018.119<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Maternal infection\nwith hepatitis B",
        "entry_id": 343,
        "id": 343,
        "lang": "en",
        "recommendation": "Test infant blood (clotted or dried\nblood spot) for HBsAg at 12\nmonths of age",
        "section": "Virology",
        "subsection": null,
        "ref": "V-2",
        "source": "Public Health England, <a href=\"/references#ref-120\" target=\"_blank\" class=\"reference-link\">2021.120<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Confirmed viraemic\nHCV infection in\npregnancy",
        "entry_id": 344,
        "id": 344,
        "lang": "en",
        "recommendation": "Test infant blood (EDTA) for HCV\nRNA PCR at two to three months\nof age. If detected, repeat HCV\nRNA PCR at six months of age\nIn addition, test infant blood\n(clotted or dried blood spot) for\nanti-HCV at 12–18 months\nThere is no further follow up if anti-\nHCV negative and the HCV RNA\nPCR at two to three months was\nalso negative\nIf anti-HCV is positive, perform a\nfurther HCV RNA PCR and refer to\nthe PHE algorithm",
        "section": "Virology",
        "subsection": null,
        "ref": "V-3",
        "source": "Public Health England, <a href=\"/references#ref-121\" target=\"_blank\" class=\"reference-link\">2018.121<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Renal failure –\nBBV status of patients\nstarting HD in the UK",
        "entry_id": 345,
        "id": 345,
        "lang": "en",
        "recommendation": "Test HIV Ag/Ab, Anti-HCV and\nHBsAg pre-dialysis\nInclude HCV RNA PCR if current\nrisk factors for HCV acquisition\nAnti-HBV should be checked prior\nto immunisation, especially in\npatients with risk factors for\nprevious HBV exposure",
        "section": "Virology",
        "subsection": null,
        "ref": "V-4",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Ongoing surveillance\nfor HIV in the\nprevalent HD\npopulation",
        "entry_id": 346,
        "id": 346,
        "lang": "en",
        "recommendation": "Test HIV Ag/Ab three-monthly (if\nrisk factors)",
        "section": "Virology",
        "subsection": null,
        "ref": "V-5",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Ongoing surveillance\nfor HCV in the\nprevalent HD\npopulation",
        "entry_id": 347,
        "id": 347,
        "lang": "en",
        "recommendation": "Test anti-HCV three-monthly\n(include HCV RNA PCR if there\nare current risk factors for HCV\nacquisition)",
        "section": "Virology",
        "subsection": null,
        "ref": "V-6",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Ongoing surveillance\nfor HBV in the\nprevalent HD\npopulation",
        "entry_id": 348,
        "id": 348,
        "lang": "en",
        "recommendation": "Test HBsAg three-monthly (if anti-\nHBs >100 IU/mL, then can\nconsider testing six monthly)",
        "section": "Virology",
        "subsection": null,
        "ref": "V-7",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Renal failure –\nenhanced surveillance\nfor those at\nintermediate/high risk\nfor new BBV following\ndialysis abroad (all\nBBV testing) or if a\nnew BBV infection is\nidentified in the HD\nunit (only for the\nspecific BBV infection)\nFor HCV",
        "entry_id": 349,
        "id": 349,
        "lang": "en",
        "recommendation": "Test HCV RNA PCR or HCV\nantigen or HCV antigen/antibody\nevery two weeks for three months",
        "section": "Virology",
        "subsection": null,
        "ref": "V-8",
        "source": "Department of Health, 2002.123 The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Renal failure –\nenhanced surveillance\nfor those at\nintermediate/high risk\nfor new BBV following\ndialysis abroad (all\nBBV testing) or if a\nnew BBV infection is\nidentified in the HD\nunit (only for the\nspecific BBV infection)\nFor HBV",
        "entry_id": 350,
        "id": 350,
        "lang": "en",
        "recommendation": "Test HBsAg or HBV PCR every\ntwo weeks for three months\n(independent of anti-HBs level)",
        "section": "Virology",
        "subsection": null,
        "ref": "V-9",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Renal failure –\nenhanced surveillance\nfor those at\nintermediate/high risk\nfor new BBV following\ndialysis abroad (all\nBBV testing) or if a\nnew BBV infection is\nidentified in the HD\nunit (only for the\nspecific BBV infection)\nFor HIV",
        "entry_id": 351,
        "id": 351,
        "lang": "en",
        "recommendation": "Test HIV Ag/Ab or HIV RNA PCR\nevery two weeks for three months\n(only if risk following dialysis away\nfrom base)",
        "section": "Virology",
        "subsection": null,
        "ref": "V-10",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Potential significant\nexposure to HBsAg\npositive material,\nhepatitis B susceptible",
        "entry_id": 352,
        "id": 352,
        "lang": "en",
        "recommendation": "Assess risk and\nrecipient HBV\nimmunity\nCollect baseline blood\nfor storage from\nrecipient\nIntervene with HBV\nvaccine ± HBIG as\nappropriate to\nscenario\nTest HBsAg at three\nmonths\nTest HBsAg, anti-HBc\nat six months\nTest anti-HBs one to\ntwo months after\nvaccine course",
        "section": "Virology",
        "subsection": null,
        "ref": "V-11",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Potential significant\nexposure to HIV\npositive material but\nno post-exposure\nprophylaxis given\n(Note: if the recipient\nis taking PREP then\nbe aware that this can\nalter the HIV Ag/Ab\nresponses and the\ncase should be\ndiscussed with a\nconsultant virologist)",
        "entry_id": 353,
        "id": 353,
        "lang": "en",
        "recommendation": "Collect baseline blood\nfor storage\nIf exposed to\nOccupational Health\n(OH), the guidance\nstates that minimum\ntesting should be an\nHIV Ag/Ab test 12\nweeks after exposure.\nHowever, earlier\ntesting can also occur\nin addition to this if\nrequired (at four\nweeks post-exposure)\nIn a non-occupational\nhealth setting, the\nBASHH guidance\nshould be followed\nstating that a negative\nHIV Ag/Ab test on a\nfourth-generation\nassay performed at 4\nweeks post-exposure\nis likely to exclude HIV\ninfection. A further test\nat eight weeks post-\nexposure need only be\nconsidered following\nan event assessed as\ncarrying a high risk of\ninfection",
        "section": "Virology",
        "subsection": null,
        "ref": "V-12",
        "source": "Department of Health and Social Care, 2008.124 BASHH guidelines, <a href=\"/references#ref-125\" target=\"_blank\" class=\"reference-link\">2019.125<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Potential significant\nexposure to HIV\npositive material and\npost-exposure\nprophylaxis given",
        "entry_id": 354,
        "id": 354,
        "lang": "en",
        "recommendation": "Collect baseline blood\nfor storage\nThe DOH OH\nguidance states that\nminimum testing\nshould be an HIV\nAg/Ab test 12 weeks\nafter cessation of PEP\nIn addition, an earlier\ntest can be performed\nas well (at four to six\nweeks post-cessation\nPEP)",
        "section": "Virology",
        "subsection": null,
        "ref": "V-13",
        "source": "Department of Health and Social Care, 2008.124 BASHH guidelines, <a href=\"/references#ref-125\" target=\"_blank\" class=\"reference-link\">2019.125<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "6.1 Congenital/perinatal blood-borne viral infection – testing in asymptomatic infants",
        "clinical_situation": "Potential significant\nexposure to HCV-\npositive material",
        "entry_id": 355,
        "id": 355,
        "lang": "en",
        "recommendation": "Test at six weeks by\nHCV RNA PCR and\nby both HCV RNA\nPCR and anti-HCV at\n12 weeks\nIf negative, test at 24\nweeks with anti-HCV\nalone",
        "section": "Virology",
        "subsection": null,
        "ref": "V-14",
        "source": "Ramsay ME. Commun Dis Public Health 1999;2:258– 262.126",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Normale Nachsorge",
        "entry_id": 1,
        "id": 356,
        "lang": "de",
        "recommendation": "Eine Wiederholung wäre aus\r klinischen Gründen indiziert wenn\r sich der Zustand des Patienten\r signifikant verändert hat und dies\r auf ein akutes Nierenproblem (oder\r ein anderes elektrolytbezogenes\r Problem) hindeutet",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Screening auf Diabetes bei\r asymptomatischen\r Patienten",
        "entry_id": 53,
        "id": 357,
        "lang": "de",
        "recommendation": "Erwachsene <45 Jahre alt mit\r normalem Gewicht und ohne\r Risikofaktor: Screening nicht\r empfohlen\r Erwachsene >45 Jahre alt mit\r normalem Gewicht (BMI <25\r kg/m2) und ohne Risikofaktor*:\r drei Jahre\r Erwachsene >18 Jahre alt mit BMI\r ≥25 kg/m2 und 1 Risikofaktor*:\r drei Jahre, falls Ergebnis normal\r ist\r *Risikofaktor(en) aufgelistet in\r Tabelle 4 von Diabetes Care\r 2012;35(S1):S11– S63.32",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E17",
        "source": "Diabetes Care 2012;35(S1):S11– S63.32",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Diabetes-Diagnose mittels\r HbA1c bei einem\r asymptomatischen\r Patienten (nicht bei\r Kindern oder jungen\r Erwachsenen zu\r verwenden)",
        "entry_id": 54,
        "id": 358,
        "lang": "de",
        "recommendation": "Die Diagnose sollte nicht auf\r Basis eines einzelnen abnormalen\r Plasma-Glucose- oder HbA1c-\r Werts gestellt werden. Mindestens\r ein zusätzliches HbA1c- oder\r Plasma-Glucose-Testergebnis mit\r einem Wert im diabetischen\r Bereich ist innerhalb von zwei\r Wochen nach der ersten Messung\r erforderlich, entweder nüchtern,\r aus einer zufälligen\r (gelegentlichen) Probe oder aus\r dem OGTT",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E18",
        "source": "WHO, <a href=\"/references#ref-33\" target=\"_blank\" class=\"reference-link\">2011.33<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "HbA1c-Überwachung von\r Patienten mit Typ-2-\r Diabetes",
        "entry_id": 55,
        "id": 359,
        "lang": "de",
        "recommendation": "Zwei- bis sechsmonatige Intervalle\r (auf individuelle Bedürfnisse\r zugeschnitten) bis die\r Blutzuckerkonzentration bei\r unveränderter Therapie stabil ist;\r eine Messung in einem Intervall\r von weniger als drei Monaten als\r Indikator für die Richtung der\r Veränderung verwenden, nicht als\r neuen stabilen Zustand\r Sechsmonatige Intervalle sobald\r die Blutzuckerkonzentration und\r blutzuckersenkende Therapie\r stabil sind",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E19",
        "source": "NICE. NG28, <a href=\"/references#ref-34\" target=\"_blank\" class=\"reference-link\">2015.34<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Diagnose männlicher\r Androgendefizit",
        "entry_id": 56,
        "id": 360,
        "lang": "de",
        "recommendation": "Wiederholung der Testosteron-\r Messung zur Bestätigung der\r Diagnose empfohlen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E20",
        "source": "Bhasin S et al. J Clin Endocrinol Metab 2010;95:2536– <a href=\"/references#ref-35\" target=\"_blank\" class=\"reference-link\">2559.35<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Überwachung männlicher\r Patienten mit\r Androgendefizit unter\r Ersatztherapie",
        "entry_id": 57,
        "id": 361,
        "lang": "de",
        "recommendation": "Testosteron-Wert drei bis sechs\r Monate nach Beginn der\r Testosteron-Therapie messen\r Testosteron alle drei bis vier\r Monate im ersten Jahr messen\r Messung von PSA. Bitte siehe B-\r TM7",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E21",
        "source": "Bhasin S et al. J Clin Endocrinol Metab 2010;95:2536– 2559.35 Petak SM et al. Endocr Pract 2002;8:440–456.36",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Weiblicher\r Androgenüberschuss",
        "entry_id": 58,
        "id": 362,
        "lang": "de",
        "recommendation": "Falls Testosteron-Messung durch\r eine Immunoassay-Methode erhöht\r gefunden wurde, Messung mit\r einer LCMS-Methode bestätigen\r Danach sollte die Messung jährlich\r wiederholt werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E22",
        "source": "Martin KA et al. J Clin Endocrinol Metab 2008;93:1105– 1120.37 Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Östradiol",
        "entry_id": 59,
        "id": 363,
        "lang": "de",
        "recommendation": "Keine Evidenz, Leitlinie oder\r Konsens existiert für\r Wiederholungsfrequenz\r Für Patienten die IVF durchlaufen\r können Proben täglich genommen\r werden\r Für Patienten die Implantat-\r Behandlung (HRT) erhalten wird\r ein Prä-Implantat-Wert kontrolliert\r um Tachyphylaxie zu vermeiden.\r Frequenz hängt von Implantat-\r Frequenz ab\r Für Patienten die Implantat-\r Behandlung erhalten wird ein Prä-\r Implantat-Wert kontrolliert um\r Tachyphylaxie zu vermeiden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E23",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Wachstumshormonmangel",
        "entry_id": 60,
        "id": 364,
        "lang": "de",
        "recommendation": "IGF-1 ist der nützlichste Marker\r für die Überwachung und sollte\r mindestens jährlich gemessen\r werden. Die Bewertung sollte nicht\r früher als sechs Wochen nach\r einer Dosisänderung durchgeführt\r werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E24",
        "source": "Ho KK et al. Eur J Endocrinol 2007;157:695– 700.38",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Akromegalie: nach\r Operation\r Akromegalie: medizinische\r Therapie\r Akromegalie: medizinische\r Therapie mit GH-Rezeptor-\r Antagonisten\r Akromegalie: nach\r Strahlentherapie",
        "entry_id": 61,
        "id": 365,
        "lang": "de",
        "recommendation": "Sowohl GH als auch IGF-1 nach\r drei Monaten messen. Falls normal,\r dann bei jährlicher Nachsorge\r Sowohl GH als auch IGF-1 nach\r drei Monaten messen. Falls normal,\r dann bei jährlicher Nachsorge\r Nur IGF-1 in sechsmonatigen\r Abständen nach Dosistitration\r messen. Monatliche Überwachung\r der LFTs für die ersten sechs\r Monate\r Messung von GH und IGF-1\r jährlich",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E25",
        "source": "Growth Hormone Research Society, Pituitary Society. J Clin Endocrinol Metab 2004;89:3099– <a href=\"/references#ref-39\" target=\"_blank\" class=\"reference-link\">3102.39<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.6 Kardial",
        "clinical_situation": "Troponin verwenden:\r allgemein\r Troponin verwenden: ACS\r Troponin verwenden:\r Herzchirurgie\r Troponin verwenden:\r Nierenversagen",
        "entry_id": 62,
        "id": 366,
        "lang": "de",
        "recommendation": "MRI weitgehend abhängig vom\r verwendeten Hersteller-Assay und\r dem klinischen Szenario. MRI\r sollte gemäß dem verwendeten\r lokalen Protokoll implementiert\r werden\r Algorithmen die mit hochsensitiven\r Troponin-Assays entwickelt\r wurden erfordern üblicherweise\r mehrere Proben. Eine zweite\r Probe ist ein bis zwei Stunden\r nach Vorstellung erforderlich. Die\r Sensitivität für Myokardinfarkt ist\r fast 100%\r Für Standard-Troponin-Assays:\r falls die erste Blutprobe für\r Troponin nicht erhöht ist, sollte\r eine zweite Probe nach sechs bis\r neun Stunden gewonnen werden.\r Manchmal ist eine dritte Probe\r nach 12–24 Stunden erforderlich\r Einzelmessung 24 Stunden nach\r Operation gibt beste Korrelation\r mit Ergebnis. Serielle Proben\r gerechtfertigt falls sich der\r klinische Zustand verschlechtert\r und/oder neue EKG-Veränderungen\r zur ACS-Bewertung\r Troponin-Konzentrationen sind\r üblicherweise bei CKD-Patienten\r erhöht (besonders bei\r hochsensitiven Assays). Serielle\r Proben werden bei vermutetem\r ACS wie oben erforderlich sein",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-C1",
        "source": "Wu AHB et al. Clin Chem 2018;64:645– 655.40 Boeddinghaus J et al. Clin Chem 2018;64:1347– 1360.41 Hamm CW et al. Eur Heart J 2011;32:2999– 3054.42 Thygesen K et al. Eur Heart J 2010;31:2197– 2204.43 Croal BL et al. Circulation 2006;114:1468– 1475.44 Khan NA et al. Circulation 2005;112:3088– 3096.45 Consensus opinion of the relevant expert working group",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.6 Kardial",
        "clinical_situation": "BNP (NT-ProBNP)\r verwenden:\r Primärversorgung\r (Herzinsuffizienz-Triage)\r Sekundärversorgung (akute\r Insuffizienz)\r Therapeutische Führung bei\r Herzinsuffizienz",
        "entry_id": 63,
        "id": 367,
        "lang": "de",
        "recommendation": "Sollte nur einmal gemessen\r werden außer es gibt eine\r wiederholte Episode von\r vermuteter Herzinsuffizienz mit\r einer Änderung in der klinischen\r Präsentation und die Diagnose\r Herzinsuffizienz wurde zuvor\r ausgeschlossen. Einzelzeitpunkt-\r Verwendung ausreichend für NICE-\r Leitlinien-Zwecke\r Bei Personen die sich mit neuer\r vermuteter akuter Herzinsuffizienz\r vorstellen, eine einzelne Messung\r von Serum-natriuretischen Peptiden\r (BNP oder NT-ProBNP) verwenden\r NT-ProBNP-Messung als Teil eines\r Behandlungsoptimierungsprotokolls\r nur in spezialisierter\r Versorgungsumgebung für\r Personen unter 75 Jahren mit\r Herzinsuffizienz mit reduzierter\r Ejektionsfraktion und einer eGFR\r über 60 ml/min/1.73 m2 erwägen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-C2",
        "source": "NICE. CG108, 2010.46 NICE. CG187, 2014.47 NICE. NG106, <a href=\"/references#ref-48\" target=\"_blank\" class=\"reference-link\">2018.48<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Überwachung eines stabilen\r stationären Patienten ohne\r intravenöse Flüssigkeiten",
        "entry_id": 2,
        "id": 368,
        "lang": "de",
        "recommendation": "Ein stationärer Patient mit einem\r Aufnahme-Natrium im\r Referenzbereich sollte während der\r durchschnittlichen Aufenthaltsdauer\r von vier Tagen keine Wiederholung\r des Natriumwerts erhalten",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Überwachung eines stabilen\r stationären Patienten mit\r intravenösen Flüssigkeiten\r (Erwachsene und Kinder)",
        "entry_id": 3,
        "id": 369,
        "lang": "de",
        "recommendation": "Tägliche Überwachung von U&E\r und Glucose",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R3",
        "source": "GAIN, <a href=\"/references#ref-6\" target=\"_blank\" class=\"reference-link\">2010.6<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Bei symptomatischen Patienten\r oder nach Gabe von\r hypertonischer\r Kochsalzlösung",
        "entry_id": 4,
        "id": 370,
        "lang": "de",
        "recommendation": "Die Überwachung sollte häufiger\r erfolgen, d.h. alle zwei bis vier\r Stunden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R4",
        "source": "GAIN, <a href=\"/references#ref-6\" target=\"_blank\" class=\"reference-link\">2010.6<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Patient mit diagnostizierter\r AKI",
        "entry_id": 5,
        "id": 371,
        "lang": "de",
        "recommendation": "U&E-Kontrolle bei Aufnahme und\r innerhalb von 24 Stunden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R5",
        "source": "The Renal Association, <a href=\"/references#ref-7\" target=\"_blank\" class=\"reference-link\">2011.7<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Überwachung von\r ACE-Hemmern",
        "entry_id": 6,
        "id": 372,
        "lang": "de",
        "recommendation": "Innerhalb einer Woche nach Beginn\r und eine Woche nach jeder\r Dosistitration, dann jährlich (außer\r häufiger erforderlich aufgrund\r eingeschränkter Nierenfunktion)\r Medikamente mit Trimethoprim\r können ebenfalls zu einem\r deutlichen Anstieg des\r Serumkreatinins führen ohne die\r Nierenfunktion direkt zu\r beeinträchtigen. Das\r Serumkreatinin sollte wiederholt\r werden um ein genaueres\r Serumkreatinin (und eGFR) zu\r erhalten 48 Stunden nachdem\r trimethoprimhaltige Medikamente\r abgesetzt wurden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R6",
        "source": "NICE Clinical Knowledge Summary, 2019.8 GAIN, <a href=\"/references#ref-9\" target=\"_blank\" class=\"reference-link\">2015.9<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Diuretikatherapie",
        "entry_id": 7,
        "id": 373,
        "lang": "de",
        "recommendation": "Vor Therapiebeginn und nach vier\r Wochen, dann alle sechs\r Monate/jährlich oder häufiger bei\r älteren Patienten oder Patienten\r mit Nierenerkrankungen, Störungen\r die den Elektrolytstatus\r beeinflussen oder Patienten die\r andere Medikamente einnehmen\r (z.B. Kortikosteroide, Digoxin)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R7",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-8\" target=\"_blank\" class=\"reference-link\">2019.8<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Überwachung der\r Kaliumkonzentrationen bei\r Patienten unter Digoxin",
        "entry_id": 8,
        "id": 374,
        "lang": "de",
        "recommendation": "Acht Tage nach Beginn oder\r Änderung der Digoxin-Therapie\r und/oder Zugabe/Wegnahme eines\r interagierenden Medikaments,\r dann jährlich bei unveränderter\r Situation",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R8",
        "source": "NICE Clinical Knowledge Summary, 2019.10 NICE Clinical Knowledge Summary, <a href=\"/references#ref-10\" target=\"_blank\" class=\"reference-link\">2019.11<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Überwachung der\r Kaliumkonzentrationen bei\r Patienten unter Digoxin\r und Diuretika",
        "entry_id": 9,
        "id": 375,
        "lang": "de",
        "recommendation": "Regelmäßige Überwachung",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R9",
        "source": "National Public Health Service for Wales, <a href=\"/references#ref-12\" target=\"_blank\" class=\"reference-link\">2008.12<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Aminosalicylate",
        "entry_id": 10,
        "id": 376,
        "lang": "de",
        "recommendation": "Bei älteren Patienten alle drei\r Monate im ersten Jahr, dann alle\r sechs Monate für die nächsten vier\r Jahre, danach jährlich basierend\r auf persönlichen Risikofaktoren",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R10",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-13\" target=\"_blank\" class=\"reference-link\">2019.13<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Carbamazepin",
        "entry_id": 11,
        "id": 377,
        "lang": "de",
        "recommendation": "Sechs Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R11",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-13\" target=\"_blank\" class=\"reference-link\">2019.13<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Antipsychotika",
        "entry_id": 12,
        "id": 378,
        "lang": "de",
        "recommendation": "12 Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R12",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-14\" target=\"_blank\" class=\"reference-link\">2019.14<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "eGFR-EPI: CKD",
        "entry_id": 13,
        "id": 379,
        "lang": "de",
        "recommendation": "Wiederholung in 14 Tagen bei\r neuen Befunden einer reduzierten\r GFR und/oder Bestätigung einer\r eGFR <60 mL/min/1.73 m2\r *eGFR nach MDRD nicht gültig bei\r AKI",
        "section": "Biochemie",
        "subsection": null,
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "eGFR-EPI: Radiologische\r Verfahren/Kontrastmittelgabe",
        "entry_id": 14,
        "id": 380,
        "lang": "de",
        "recommendation": "eGFR oder Kreatinin innerhalb der\r letzten sieben Tage bei Patienten\r mit akuter Erkrankung oder\r Nierenerkrankung\r eGFR für Angiographie: <60\r mL/min/1.73 m2 sollte lokale\r Richtlinien für\r Kontrastmitteldosierung auslösen\r eGFR für Gadolinium: <30\r mL/min/1.73 m2 Hochrisiko-Mittel\r kontraindiziert\r eGFR: 30–59 mL/min/1.73 m2\r niedrigste mögliche Dosis kann\r verwendet werden und nicht\r innerhalb von sieben Tagen\r wiederholt",
        "section": "Biochemie",
        "subsection": null,
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "eGFR: Cockcroft-Gault",
        "entry_id": 15,
        "id": 381,
        "lang": "de",
        "recommendation": "Zur Schätzung von Chemotherapie-\r und Medikamentendosierungen.\r Innerhalb von 24 Stunden außer\r bei sich schnell ändernden\r Kreatininkonzentrationen oder\r Flüssigkeitsbalance",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-R13c",
        "source": "None (inferred from British National Formulary)",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.1 Niere (bezieht sich auf die Messung von U&E, sofern nicht anders angegeben)",
        "clinical_situation": "Iohexol GFR",
        "entry_id": 16,
        "id": 382,
        "lang": "de",
        "recommendation": "72 Stunden zur Vermeidung von\r Kontamination (basierend auf\r Halbwertszeit von Iohexol von zwei\r Stunden)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Nicht-akute Situation außer\r bei anderen klinischen\r Indikationen",
        "entry_id": 17,
        "id": 383,
        "lang": "de",
        "recommendation": "Untersuchung in dreimonatigen\r Abständen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Akute Situationen",
        "entry_id": 18,
        "id": 384,
        "lang": "de",
        "recommendation": "Untersuchung in 48-Stunden-\r Abständen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Akute Hypo-/\r Hyperkalzämie, TPN und\r ITU-Patienten",
        "entry_id": 19,
        "id": 385,
        "lang": "de",
        "recommendation": "Kann häufigere Überwachung\r erfordern",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B3",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "ALP und Gesamtprotein in\r akuter Situation",
        "entry_id": 20,
        "id": 386,
        "lang": "de",
        "recommendation": "Untersuchung in wöchentlichen\r Abständen. ALP muss\r möglicherweise häufiger\r kontrolliert werden, aber\r wahrscheinlich nur im Kontext\r akuter cholestatischer\r Veränderungen. Siehe\r Leberempfehlungen (Abschnitt\r 2.3)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Vitamin D-Anfrage: keine\r klinischen Anzeichen und\r Symptome",
        "entry_id": 21,
        "id": 387,
        "lang": "de",
        "recommendation": "Nicht erneut testen (unabhängig\r vom Ergebnis da möglicherweise\r keine Indikation zum\r ursprünglichen Test bestand)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Vitamin D-Anfrage:\r Cholecalciferol- oder\r Ergocalciferol-Therapie für\r jede klinische Indikation, bei\r der die Baseline-Vitamin-D-\r Konzentration ausreichend\r war",
        "entry_id": 22,
        "id": 388,
        "lang": "de",
        "recommendation": "Nicht erneut testen, außer\r anderweitig klinisch indiziert, z.B.\r kranker Zöliakie- oder Morbus\r Crohn-Patient",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B6",
        "source": "Sattar N et al. Lancet 2012;379:95–96.18 Sattar N et al. Lancet 2012;379: 1700–1701.19",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Vitamin D-Anfrage:\r Cholecalciferol- oder\r Ergocalciferol-Therapie für\r jede klinische Indikation, bei\r der die Baseline-Vitamin-D-\r Konzentration niedrig war\r und eine Grunderkrankung\r vorliegt die die Absorption\r negativ beeinflussen\r könnte",
        "entry_id": 23,
        "id": 389,
        "lang": "de",
        "recommendation": "Wiederholung nach drei bis sechs\r Monaten unter empfohlener\r Ersatzdosis",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B7",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Vitamin D-Anfrage:\r Calcitriol- oder\r Alphacalcidol-Therapie",
        "entry_id": 24,
        "id": 390,
        "lang": "de",
        "recommendation": "Vitamin D nicht messen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B8",
        "source": "Consensus opinion of the relevant expert working group (GPP)",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.2 Knochen (bezieht sich auf die Messung des Knochenprofils, sofern nicht anders angegeben)",
        "clinical_situation": "Biochemische Untersuchung\r bei CKD-MBD: CKD Stadien\r 3–5",
        "entry_id": 25,
        "id": 391,
        "lang": "de",
        "recommendation": "Für Stadium 3b progressiv,\r Knochenprofil alle sechs Monate\r testen, PTH bei Baseline und\r 25OHVitD bei Baseline\r Für Stadium 4, Knochenprofil alle\r drei Monate testen, PTH alle sechs\r Monate und 25OHVitD bei Baseline\r Für Stadium 5, Knochenprofil jeden\r Monat testen, PTH alle drei Monate\r und 25OHVitD bei Baseline\r Für Stadium 5D, Knochenprofil\r jeden Monat testen, PTH alle drei\r Monate und 25OHVitD bei Baseline",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-B9",
        "source": "The Renal Association, <a href=\"/references#ref-20\" target=\"_blank\" class=\"reference-link\">2015.20<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Leber (bezieht sich auf die Messung von LFTs, sofern nicht anders angegeben)",
        "clinical_situation": "Nicht-akute Situation",
        "entry_id": 26,
        "id": 392,
        "lang": "de",
        "recommendation": "Untersuchung in ein- bis\r dreimonatigen Abständen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-L1",
        "source": "Smellie S et al. ACB Venture Publications, <a href=\"/references#ref-21\" target=\"_blank\" class=\"reference-link\">2011.21<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.3 Leber (bezieht sich auf die Messung von LFTs, sofern nicht anders angegeben)",
        "clinical_situation": "Akute stationäre Situation",
        "entry_id": 27,
        "id": 393,
        "lang": "de",
        "recommendation": "Untersuchung in 72-Stunden-\r Abständen in akuter Situation\r (außer denen in L4)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-L2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Leber (bezieht sich auf die Messung von LFTs, sofern nicht anders angegeben)",
        "clinical_situation": "GGT und konjugiertes\r Bilirubin in akuter\r Situation",
        "entry_id": 28,
        "id": 394,
        "lang": "de",
        "recommendation": "Untersuchung in wöchentlichen\r Abständen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-L3",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Leber (bezieht sich auf die Messung von LFTs, sofern nicht anders angegeben)",
        "clinical_situation": "Akute Vergiftung (z.B.\r Paracetamol), TPN,\r Leberstation, akute\r Leberverletzung und ITU-\r Patienten",
        "entry_id": 29,
        "id": 395,
        "lang": "de",
        "recommendation": "Kann häufigere Überwachung\r erfordern",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-L4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.3 Leber (bezieht sich auf die Messung von LFTs, sofern nicht anders angegeben)",
        "clinical_situation": "Neugeborenengelbsucht",
        "entry_id": 30,
        "id": 396,
        "lang": "de",
        "recommendation": "Diese Empfehlungen dürfen nicht\r für die Behandlung von\r Neugeborenengelbsucht verwendet\r werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-L5",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.3 Leber (bezieht sich auf die Messung von LFTs, sofern nicht anders angegeben)",
        "clinical_situation": "Einleitung oder Änderung\r von Therapien zur primären\r oder sekundären\r kardiovaskulären\r Krankheitsprävention\r (LFTs)",
        "entry_id": 31,
        "id": 397,
        "lang": "de",
        "recommendation": "Drei Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-L6",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-22\" target=\"_blank\" class=\"reference-link\">2019.22<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.4 Lipide (bezieht sich auf die Messung des Lipidprofils [nicht-nüchtern], sofern nicht anders angegeben)",
        "clinical_situation": "Niedrigrisikofälle für IHD-\r Bewertung",
        "entry_id": 32,
        "id": 398,
        "lang": "de",
        "recommendation": "Drei Jahre",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-LP1",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.4 Lipide (bezieht sich auf die Messung des Lipidprofils [nicht-nüchtern], sofern nicht anders angegeben)",
        "clinical_situation": "Höhere Risikofälle für\r IHD-Bewertung und die\r unter stabiler Behandlung\r stehen",
        "entry_id": 33,
        "id": 399,
        "lang": "de",
        "recommendation": "Ein Jahr",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-LP2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.4 Lipide (bezieht sich auf die Messung des Lipidprofils [nicht-nüchtern], sofern nicht anders angegeben)",
        "clinical_situation": "Einleitung oder Änderung\r von Therapien zur primären\r oder sekundären Prävention\r (einschließlich Nicht-HDL-\r Cholesterin)",
        "entry_id": 34,
        "id": 400,
        "lang": "de",
        "recommendation": "Drei Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-LP3",
        "source": "NICE Clinical Knowledge Summary, <a href=\"/references#ref-22\" target=\"_blank\" class=\"reference-link\">2019.22<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.4 Lipide (bezieht sich auf die Messung des Lipidprofils [nicht-nüchtern], sofern nicht anders angegeben)",
        "clinical_situation": "Bei der Bewertung von\r Triglyceridämie zur\r Beobachtung der\r Auswirkungen von Diät-\r und Alkoholänderungen",
        "entry_id": 35,
        "id": 401,
        "lang": "de",
        "recommendation": "Eine Woche",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-LP4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.4 Lipide (bezieht sich auf die Messung des Lipidprofils [nicht-nüchtern], sofern nicht anders angegeben)",
        "clinical_situation": "Bei Patienten unter TPN\r oder mit\r hypertriglyceridämie-\r induzierter Pankreatitis",
        "entry_id": 36,
        "id": 402,
        "lang": "de",
        "recommendation": "Ein Tag",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-LP5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Schilddrüsenfunktionstestung\r bei einer gesunden Person\r ohne klinische Symptome",
        "entry_id": 37,
        "id": 403,
        "lang": "de",
        "recommendation": "Drei Jahre",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Hyperthyreose:\r Überwachung der\r Behandlung bei Morbus\r Basedow",
        "entry_id": 38,
        "id": 404,
        "lang": "de",
        "recommendation": "Nachsorge in den ersten ein bis\r zwei Monaten nach\r Radioiodtherapie bei Morbus\r Basedow. Messung von fT4 und\r Gesamt-T3. Falls der Patient\r thyreotoxisch bleibt, sollte die\r biochemische Überwachung in vier-\r bis sechswöchigen Abständen\r fortgesetzt werden\r Nach Thyreoidektomie bei Morbus\r Basedow (und Beginn von\r Levothyroxin) sollte Serum-TSH\r sechs bis acht Wochen\r postoperativ gemessen werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E2",
        "source": "Bahn Chair RS et al. Thyroid 2011;21:593–646.24",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Hyperthyreose:\r Überwachung der\r Behandlung bei toxischer\r multinodulärer Struma und\r toxischem Adenom",
        "entry_id": 39,
        "id": 405,
        "lang": "de",
        "recommendation": "Nachsorge in den ersten ein bis\r zwei Monaten nach\r Radioiodtherapie bei toxischer\r multinodulärer Struma und\r toxischem Adenom. Messung von\r fT4 und Gesamt-T3 und TSH.\r Sollte in ein- bis zweimonatigen\r Abständen wiederholt werden bis\r stabile Ergebnisse vorliegen, dann\r jährlich danach\r Nach Operation bei toxischer\r multinodulärer Struma und Beginn\r einer Thyroxintherapie sollte TSH\r ein- bis zweimal monatlich\r gemessen werden bis stabil und\r dann jährlich\r Nach Operation bei toxischem\r Adenom sollten TSH- und fT4-\r Konzentrationen vier bis sechs\r Wochen postoperativ gemessen\r werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E3",
        "source": "Bahn Chair RS et al. Thyroid 2011;21:593–646.24",
        "level_of_evidence": ""
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "UK Schilddrüsenleitlinien",
        "entry_id": 40,
        "id": 406,
        "lang": "de",
        "recommendation": "TFTs sollten alle vier bis sechs\r Wochen für mindestens sechs\r Monate nach Radioiodbehandlung\r durchgeführt werden. Sobald fT4\r im Referenzbereich bleibt sollte die\r Testfrequenz auf jährlich reduziert\r werden. Lebenslange jährliche\r Nachsorge ist erforderlich\r Unbegrenzte Überwachung nach\r Radioiod oder Thyreoidektomie für\r die Entwicklung einer\r Hypothyreose oder das\r Wiederauftreten einer\r Hyperthyreose erforderlich. TFTs\r sollten vier bis acht Wochen nach\r Behandlung beurteilt werden, dann\r dreimonatlich für bis zu ein Jahr,\r dann jährlich danach. TFTs sollten\r alle vier bis sechs Wochen nach\r Beginn von Thionamiden\r durchgeführt werden. Testung in\r dreimonatigen Abständen wird\r empfohlen sobald die\r Erhaltungsdosis erreicht ist\r Bei Patienten die mit 'Block and\r Replace' behandelt werden, TSH\r und T4 in vier- bis\r sechswöchigen Abständen\r bewerten, dann nach weiteren drei\r Monaten sobald die\r Erhaltungsdosis erreicht ist, dann\r alle sechs Monate danach",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E4",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Hypothyreose:\r Überwachung der\r Behandlung",
        "entry_id": 41,
        "id": 407,
        "lang": "de",
        "recommendation": "Die Mindestzeit um stabile\r Konzentrationen nach einer\r Thyroxin-Dosisänderung zu\r erreichen beträgt zwei Monate und\r TFTs sollten normalerweise nicht\r vor Ablauf dieser Zeit beurteilt\r werden\r Patienten die auf Langzeit-\r Thyroxintherapie stabilisiert sind\r sollten jährlich Serum-TSH\r kontrolliert bekommen\r Ein jährliches fT4 sollte bei allen\r Patienten mit sekundärer\r Hypothyreose die auf\r Thyroxintherapie stabilisiert sind\r durchgeführt werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E5",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Überwachung subklinischer\r Hyperthyreose bei\r Erwachsenen",
        "entry_id": 42,
        "id": 408,
        "lang": "de",
        "recommendation": "Falls ein Serum-TSH unter dem\r Referenzbereich aber >0.1 mU/L\r gefunden wird, sollte die Messung\r ein bis zwei Monate später\r zusammen mit T4 und T3\r wiederholt werden nach\r Ausschluss von nicht-\r thyreoidalen Erkrankungen und\r Medikamenteninterferenzen. Dies\r wird später in den Leitlinien\r widersprochen wenn die Autoren\r angeben dass ein drei- bis\r sechsmonatiges\r Wiederholungsintervall\r angemessen ist außer der Patient\r ist älter oder hat eine\r zugrundeliegende\r Gefäßerkrankung\r Falls keine Behandlung\r unternommen wird, sollte Serum-\r TSH langfristig alle sechs bis 12\r Monate gemessen werden, mit\r Nachsorge mit fT4 und fT3 falls\r das Serum-TSH-Ergebnis niedrig\r ist",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E6",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Überwachung subklinischer\r Hypothyreose bei\r Erwachsenen",
        "entry_id": 43,
        "id": 409,
        "lang": "de",
        "recommendation": "Patienten mit subklinischer\r Hypothyreose sollten das Muster\r innerhalb von drei bis sechs\r Monaten bestätigt bekommen um\r vorübergehende Ursachen für\r erhöhtes TSH auszuschließen\r Personen mit subklinischer\r Hypothyreose die ATPOab positiv\r sind sollten TSH und fT4 jährlich\r kontrolliert bekommen\r Personen mit subklinischer\r Hypothyreose die ATPOab negativ\r sind sollten TSH und fT4 alle drei\r Jahre kontrolliert bekommen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E7",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Nachsorge von Patienten\r die ein differenziertes\r (papilläres und follikuläres)\r Schilddrüsenkarzinom und\r eine totale Thyreoidektomie\r und 131I-Ablation hatten",
        "entry_id": 44,
        "id": 410,
        "lang": "de",
        "recommendation": "TSH und fT4 sollten gemessen\r werden während die Levothyroxin-\r Dosis steigt (alle sechs Wochen)\r bis das Serum-TSH <0.1 mIU/L\r ist. Danach sollten sie jährlich\r gemessen werden außer klinisch\r indiziert/schwanger\r Proben für Tg sollten nicht früher\r als sechs Wochen nach\r Thyreoidektomie oder 131I-\r Ablation/Therapie gesammelt\r werden. TSH, fT4/fT3 (je nachdem\r was supplementiert wird) und TgAb\r sollten angefordert werden wenn\r Tg gemessen wird. Falls TgAb\r nachweisbar sind, sollte die\r Messung alle sechs Monate\r wiederholt werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E8",
        "source": "British Thyroid Association, Royal College of Physicians, <a href=\"/references#ref-26\" target=\"_blank\" class=\"reference-link\">2014.26<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Nachsorge von Patienten\r die ein medulläres\r Schilddrüsenkarzinom und\r chirurgische Resektion\r hatten",
        "entry_id": 45,
        "id": 411,
        "lang": "de",
        "recommendation": "Ein Baseline-CEA und nüchtern-\r Calcitonin sollte vor der Operation\r genommen werden. Postoperative\r Proben sollten nicht früher als 15\r Tage nach Thyreoidektomie\r gemessen werden und Plasma-\r Calcitonin-Konzentrationen sind\r am aussagekräftigsten sechs\r Monate nach der Operation\r Mindestens vier Messungen von\r Calcitonin über einen zwei- bis\r dreijährigen Zeitraum können\r genommen werden um eine genaue\r Schätzung der Calcitonin-\r Verdoppelungszeit zu liefern. CEA\r ist bei etwa 30% der MTC-\r Patienten erhöht und bei diesen\r Patienten ist die CEA-\r Verdoppelungszeit vergleichbar\r informativ zur Calcitonin-\r Verdoppelungszeit\r Calcitonin-Überwachung sollte\r lebenslang fortgesetzt werden\r TFTs sollten gemäß Leitlinien für\r Hypothyreose gemessen werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E9",
        "source": "British Thyroid Association, Royal College of Physicians, 2014.26 Laure Giraudet A et al. Eur J Endocrinol 2008;158: 239– 246.27",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Anaplastisches\r Schilddrüsenkarzinom",
        "entry_id": 46,
        "id": 412,
        "lang": "de",
        "recommendation": "Es besteht keine Notwendigkeit\r für eine Überwachung der\r Schilddrüsenfunktion außer der\r Patient ist auf\r Schilddrüsenersatztherapie, dann\r gemäß Hypothyreose",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E10",
        "source": "British Thyroid Association, Royal College of Physicians, <a href=\"/references#ref-26\" target=\"_blank\" class=\"reference-link\">2014.26<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Patienten unter Amiodaron",
        "entry_id": 47,
        "id": 413,
        "lang": "de",
        "recommendation": "Sollten Schilddrüsenfunktion vor\r Behandlungsbeginn testen lassen\r und dann routinemäßig alle sechs\r Monate danach überwacht werden\r während der Behandlung und bis\r zu 12 Monate nach Beendigung\r der Therapie",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E11",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Patienten unter Lithium",
        "entry_id": 48,
        "id": 414,
        "lang": "de",
        "recommendation": "Schilddrüsenfunktion vor\r Behandlungsbeginn testen und\r dann routinemäßig alle sechs bis\r 12 Monate während der\r Behandlung überwachen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E12",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Progesteron-Testung bei\r Frauen mit verlängerten\r unregelmäßigen\r Menstruationszyklen",
        "entry_id": 49,
        "id": 415,
        "lang": "de",
        "recommendation": "Wöchentliche Testung bei\r Patienten mit unregelmäßigem\r Zyklus ab Tag 21 bis zur nächsten\r Menstruation",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E13",
        "source": "NICE. CG156, <a href=\"/references#ref-28\" target=\"_blank\" class=\"reference-link\">2013.28<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Diagnose vorzeitiger\r Ovarialinsuffizienz bei\r Frauen unter 40 Jahren mit\r möglichen menopausalen\r Symptomen",
        "entry_id": 50,
        "id": 416,
        "lang": "de",
        "recommendation": "Zwei Tests vier bis sechs Wochen\r auseinander bei Frauen mit\r möglicher früher oder vorzeitiger\r Menopause",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E14",
        "source": "NICE NG23 <a href=\"/references#ref-29\" target=\"_blank\" class=\"reference-link\">2019.29<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Patienten mit vermuteter\r medikamenteninduzierter\r Hyperprolaktinämie",
        "entry_id": 51,
        "id": 417,
        "lang": "de",
        "recommendation": "Medikament für drei Tage\r absetzen und Prolaktin erneut\r messen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E15",
        "source": "Casanueva FFet al. Clin Endocrinol (Oxf) 2006;65:265–273.30 Melmed S et al. J Clin Endocrinol Metab 2011;96:273– 288.31",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.5 Endokrin-bezogen (für schwangerschaftsbezogene Endokrinologie siehe 2.12)",
        "clinical_situation": "Patienten mit\r Hyperprolaktinämie die\r Dopaminagonist-Therapie\r beginnen",
        "entry_id": 52,
        "id": 418,
        "lang": "de",
        "recommendation": "Prolaktin-Messung nach einem\r Monat wiederholen zur\r Therapiesteuerung",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-E16",
        "source": "Melmed S et al. J Clin Endocrinol Metab 2011;96:273– 288.31",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Zöliakie-Serologie bei\r bekannten erwachsenen\r Patienten in der Nachsorge",
        "entry_id": 64,
        "id": 419,
        "lang": "de",
        "recommendation": "IgA tTG kann zur Überwachung der\r Antwort auf eine glutenfreie Diät\r verwendet werden. Nachtestung\r nach sechs bis zwölf Monaten\r abhängig vom Vorbehandlungswert",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G1",
        "source": "Wolters Kluwer, <a href=\"/references#ref-49\" target=\"_blank\" class=\"reference-link\">2019.49<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Fäkale Elastase",
        "entry_id": 65,
        "id": 420,
        "lang": "de",
        "recommendation": "MRI ist sechs Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G2",
        "source": "Molinari I et al. Clin Biochem 2004;37:758–763.50",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Fäkales Calprotectin\r Fäkales Calprotectin zur\r Unterscheidung von\r Reizdarmsyndrom und\r entzündlicher\r Darmerkrankung in der\r Primärversorgung mit dem\r York Fäkales Calprotectin\r Versorgungspfad",
        "entry_id": 66,
        "id": 421,
        "lang": "de",
        "recommendation": "MRI ist sechs Monate\r Änderung aufgrund York-Pfad\r Falls erste Probe <100 mcg/g ist,\r dann keine Nachtestung\r erforderlich\r Falls erste Probe >100 mcg/g ist,\r MRI ist zwei Wochen.\r Falls Wiederholungsprobe >250\r mcg/g ist, dringend an\r Gastroenterologie überweisen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G3",
        "source": "van Rheenen PF et al. BMJ 2010;341:c3369.51 Turvill J et al. Frontline Gastroenterol 2018;9:285–294.52",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Spurenelemente (Kupfer,\r Zink, Selen) bei der\r Überwachung der\r Ernährungsunterstützung",
        "entry_id": 67,
        "id": 422,
        "lang": "de",
        "recommendation": "Baseline dann alle zwei bis vier\r Wochen abhängig von den\r Ergebnissen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G4",
        "source": "NICE.CG32, <a href=\"/references#ref-53\" target=\"_blank\" class=\"reference-link\">2006.53<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Ferritin-Überwachung bei\r Hämochromatose",
        "entry_id": 68,
        "id": 423,
        "lang": "de",
        "recommendation": "EASL empfiehlt ein anfängliches\r Nachtestungsintervall von drei\r Monaten, aber dies sollte häufiger\r getestet werden wenn sich Ferritin\r dem Normalbereich nähert\r BCSH 2000 empfiehlt monatliches\r Ferritin während Aderlass",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G5",
        "source": "European Association for the Study of the Liver. J Hepatol 2010;53:3– 22.54 British Society for Haematology, <a href=\"/references#ref-55\" target=\"_blank\" class=\"reference-link\">2018.55<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Eisenmangel-Diagnose",
        "entry_id": 69,
        "id": 424,
        "lang": "de",
        "recommendation": "Wiederholung der Eisenmessung\r nicht erforderlich außer Zweifel\r bezüglich Diagnose",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G7",
        "source": "GAIN, <a href=\"/references#ref-57\" target=\"_blank\" class=\"reference-link\">2015.57<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Eisenmangel-Diagnose",
        "entry_id": 70,
        "id": 425,
        "lang": "de",
        "recommendation": "FBC zwei Wochen nach\r Eisentherapie kontrollieren\r Sobald Hb normalisiert FBC nach\r zwei Monaten kontrollieren",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G7",
        "source": "GAIN, <a href=\"/references#ref-57\" target=\"_blank\" class=\"reference-link\">2015.57<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Eisenstatus bei CKD",
        "entry_id": 71,
        "id": 426,
        "lang": "de",
        "recommendation": "Eisenstatus nicht früher als eine\r Woche nach Erhalt von IV-Eisen\r überwachen und routinemäßig in\r Abständen von ein bis drei\r Monaten",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G8",
        "source": "NICE. NG8, <a href=\"/references#ref-58\" target=\"_blank\" class=\"reference-link\">2015.58<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Eisenprofil/Ferritin bei\r einem normalen Patienten",
        "entry_id": 72,
        "id": 427,
        "lang": "de",
        "recommendation": "Ein Jahr",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G9",
        "source": "NICE. CG32, 2006.53 Smellie WS et al. J Clin Pathol 2006;59:781–789.59",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.7 Gastrointestinal",
        "clinical_situation": "Überwachung von Vitamin\r B12- und Folatmangel",
        "entry_id": 73,
        "id": 428,
        "lang": "de",
        "recommendation": "Wiederholungsmessung von\r Vitamin B12 und Folat ist bei\r Patienten mit Vitamin B12- und\r Folatmangel unnötig\r Jedoch kann Vitamin B12 ein bis\r zwei Monate nach\r Behandlungsbeginn gemessen\r werden falls keine Antwort vorliegt\r FBC und Retikulozytenzahl zehn\r Tage nach Behandlung auf\r Antwort kontrollieren. Sobald Hb\r normalisiert ist, ist das MRI acht\r Wochen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-G10",
        "source": "Clinical Knowledge Summary, 2019.60 GAIN, <a href=\"/references#ref-57\" target=\"_blank\" class=\"reference-link\">2015.57<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "Paraproteine",
        "entry_id": 74,
        "id": 429,
        "lang": "de",
        "recommendation": "Testung in dreimonatigen\r Abständen anfänglich",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP1",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "Patienten ohne Merkmale\r einer Plasmazell-Dyskrasie\r (z.B. Anämie,\r Knochenfraktur oder\r knochenlokalisierte\r Schmerzen, Suppression\r anderer Immunglobulin-\r Klassen,\r Nierenbeeinträchtigung)\r und einer Bande von <15\r g/L",
        "entry_id": 75,
        "id": 430,
        "lang": "de",
        "recommendation": "Jährliche Serum-Protein-\r Elektrophorese und\r Quantifizierung durch\r Densitometrie ohne Bedarf für\r weitere Immunfixation wird\r empfohlen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP2",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "Monoklonale Gammopathie\r unbestimmter Bedeutung",
        "entry_id": 76,
        "id": 431,
        "lang": "de",
        "recommendation": "Test in drei- bis viermonatigen\r Abständen innerhalb des ersten\r Jahres der Identifikation. Dann\r sechs bis 12 monatlich solange\r keine Progressionssymptome",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP3",
        "source": "Bird J et al. Br J Haematol 2009:147;22–42.61",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "Immunglobuline",
        "entry_id": 77,
        "id": 432,
        "lang": "de",
        "recommendation": "Patienten unter Immunglobulin-\r Ersatztherapie müssen Talspiegel-\r IgG-Konzentrationen und\r Leberfunktionstests mindestens\r vierteljährlich durchgeführt\r bekommen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "Immunglobuline",
        "entry_id": 78,
        "id": 433,
        "lang": "de",
        "recommendation": "Für andere Zwecke wird Testung\r in einem Mindestintervall von\r sechs Monaten empfohlen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "Myelom-Patienten unter\r aktiver Behandlung",
        "entry_id": 79,
        "id": 434,
        "lang": "de",
        "recommendation": "Lokale Leitlinien und\r Behandlungsregime sollten befolgt\r werden beim Anfordern von\r Paraprotein-Konzentrationen für\r Patienten unter aktiver\r Behandlung",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP6",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "CRP",
        "entry_id": 80,
        "id": 435,
        "lang": "de",
        "recommendation": "Sollte nicht innerhalb eines 24-\r Stunden-Zeitraums nach einer\r ersten Anfrage erneut getestet\r werden mit Ausnahme\r pädiatrischer Anfragen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP7",
        "source": "Hutton HD et al. Ann Clin Biochem 2009;46:155–158.63",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.8 Spezifische Proteine",
        "clinical_situation": "Procalcitonin",
        "entry_id": 81,
        "id": 436,
        "lang": "de",
        "recommendation": "24 Stunden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-SP8",
        "source": "Hochreiter M et al. Crit Care 2009; 13:R83.64 Seguela PE et al. Cardiol Young 2011;21:392–399.65",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "α-Fetoprotein für HCC-\r Überwachung: Screening\r von Patienten mit hohem\r HCC-Risiko",
        "entry_id": 82,
        "id": 437,
        "lang": "de",
        "recommendation": "Sechs Monate (UK)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM1",
        "source": "Sturgeon CM et al. Clin Chem 2010:56;e1–48.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "α-Fetoprotein zur\r Überwachung von\r Krankheitsrezidiv bei HCC",
        "entry_id": 83,
        "id": 438,
        "lang": "de",
        "recommendation": "Drei bis sechs Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM2",
        "source": "Sturgeon CM et al. Clin Chem 2010:56;e1–48.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "Screening von Frauen mit\r Familiengeschichte von\r Eierstockkrebs mit CA125",
        "entry_id": 84,
        "id": 439,
        "lang": "de",
        "recommendation": "12 Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM3",
        "source": "Sturgeon CM et al. Clin Chem 2008:54:e11–79.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "CA125 in diagnostischen\r Strategien verwenden",
        "entry_id": 85,
        "id": 440,
        "lang": "de",
        "recommendation": "CA125-Nachtestung wenn\r Bildgebung negativ ist innerhalb\r eines Monats",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM4",
        "source": "NICE. CG122, <a href=\"/references#ref-67\" target=\"_blank\" class=\"reference-link\">2011.67<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "CA125-Überwachung bei\r Krankheitsrezidiv",
        "entry_id": 86,
        "id": 441,
        "lang": "de",
        "recommendation": "Ein Monat",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM5",
        "source": "Sturgeon CM et al. Clin Chem 2008:54:e11–79.66",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "Überwachung von\r Krankheitsrezidiv mit\r CA19.9",
        "entry_id": 87,
        "id": 442,
        "lang": "de",
        "recommendation": "Ein Monat",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM6",
        "source": "No available evidence. All Wales Consensus Group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "PSA-Screening",
        "entry_id": 88,
        "id": 443,
        "lang": "de",
        "recommendation": "Wenn erstes Ergebnis erhöht ist,\r einmal in den folgenden 6 Wochen\r wiederholen um den Trend zu\r bewerten",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM7",
        "source": "Public Health England, <a href=\"/references#ref-68\" target=\"_blank\" class=\"reference-link\">2019.68<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "Krankheitsüberwachung\r mit PSA",
        "entry_id": 89,
        "id": 444,
        "lang": "de",
        "recommendation": "Alle drei Monate für die ersten ein\r bis zwei Jahre\r Alle sechs Monate für zwei Jahre\r Jährlich danach",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM8",
        "source": "Smellie WS et al. J Clin Pathol 2006;59:1116.69",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "Überwachung von\r Krankheitsrezidiv mit\r CA15.3",
        "entry_id": 90,
        "id": 445,
        "lang": "de",
        "recommendation": "Zwei Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM9",
        "source": "Molina R et al. Tumour Biol 2005;26;281–293.70",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "Serum β-hCG\r (Tumormarker)",
        "entry_id": 91,
        "id": 446,
        "lang": "de",
        "recommendation": "Nach Ausräumung einer\r Blasenmole sollte die hCG-\r Konzentration jede Woche\r überwacht werden bis zur\r Normalisierung dann jeden Monat\r während des ersten Jahres",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM12",
        "source": "Sturgeon CM et al. Clin Chem 2008;54:1935– <a href=\"/references#ref-72\" target=\"_blank\" class=\"reference-link\">1939.72<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "Serum β-hCG\r (Tumormarker)",
        "entry_id": 92,
        "id": 447,
        "lang": "de",
        "recommendation": "Nach Resektion ist verlängerte\r Marker-Halbwertszeit (>3 Tage für\r hCG) ein zuverlässiger Indikator\r für Resttumor und ein\r signifikanter Prädiktor für\r Überleben",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM12",
        "source": "Sturgeon CM et al. Clin Chem 2008;54:1935– <a href=\"/references#ref-72\" target=\"_blank\" class=\"reference-link\">1939.72<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.9 Tumormarker",
        "clinical_situation": "Serum β-hCG\r (Tumormarker)",
        "entry_id": 93,
        "id": 448,
        "lang": "de",
        "recommendation": "Falls sich die Änderungsrate der\r Tumormarker-Konzentration in der\r Geschwindigkeit ändert, ist eine\r dringende Wiederholung zur\r Bestätigung des Ergebnisses\r angemessen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TM12",
        "source": "Sturgeon CM et al. Clin Chem 2008;54:1935– <a href=\"/references#ref-72\" target=\"_blank\" class=\"reference-link\">1939.72<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Antikonvulsiva\r (Carbamazepin, Phenytoin)",
        "entry_id": 94,
        "id": 449,
        "lang": "de",
        "recommendation": "Fünf Halbwertszeiten nach\r Dosisänderung (vier bis fünf Tage)\r während anfänglicher\r Dosisoptimierung, außer Toxizität\r wird vermutet. Die Kinetik von\r Phenytoin ist zwischen Individuen\r sehr variabel und wenn der\r Metabolismus gesättigt ist, führt\r eine kleine Dosisänderung zu\r einem unverhältnismäßigen\r Anstieg der Plasmakonzentration.\r Es besteht ein signifikantes\r Überdosierungsrisiko und daher\r bei Dosistitration bis zu alle 12\r Stunden kontrollieren abhängig\r vom klinischen Zustand und der\r Therapie. Dies wird bei IV-Therapie\r für Status epilepticus häufiger\r sein.\r Hinweis: Carbamazepin induziert\r seinen eigenen Metabolismus und\r Konzentrationen sollten zwei bis\r drei Monate nach Therapiebeginn\r bestätigt werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD1",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Digoxin",
        "entry_id": 95,
        "id": 450,
        "lang": "de",
        "recommendation": "Fünf Halbwertszeiten nach\r Dosisänderung (d.h. etwa sieben\r Tage) während anfänglicher\r Dosisoptimierung, außer Toxizität\r wird vermutet. Wenn sich die\r Nierenfunktion signifikant geändert\r hat, die proportionale Abnahme\r der Clearance erkennen. In\r Überdosierungssituationen bis zu\r alle vier Stunden abhängig vom\r klinischen Zustand und der\r Therapie",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD2",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Aminoglykosid-Antibiotika\r (Gentamicin, Tobramycin)",
        "entry_id": 96,
        "id": 451,
        "lang": "de",
        "recommendation": "Alle 24 Stunden zu\r Therapiebeginn bei hochdosierten\r parenteralen Regimen, weniger\r häufig wenn stabil. Besonders\r wichtig bei älteren Patienten,\r Patienten mit eingeschränkter\r Nierenfunktion und denen mit\r zystischer Fibrose. Dies gilt nur für\r einmal tägliche Dosierung. Falls\r Patient mehrere Dosen pro Tag\r erhält, lokale Leitlinien\r konsultieren",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD3",
        "source": "Consult local hospital guidelines",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Immunsuppressive\r Medikamente (Ciclosporin,\r Tacrolimus, Sirolimus)",
        "entry_id": 97,
        "id": 452,
        "lang": "de",
        "recommendation": "Anfänglich dreimal pro Woche\r nach Transplantation, weniger\r häufig wenn stabil.\r Konzentrationen sollten auch\r kontrolliert werden wenn ein\r Medikament mit möglichen\r Interaktionen verschrieben wird,\r die Dosierung geändert wird, die\r Formulierung geändert wird oder\r bei unerklärlicher\r Transplantatdysfunktion",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD4",
        "source": "Baker R et al. The Renal Association, <a href=\"/references#ref-74\" target=\"_blank\" class=\"reference-link\">2011.74<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Theophyllin",
        "entry_id": 98,
        "id": 453,
        "lang": "de",
        "recommendation": "Fünf Halbwertszeiten nach\r Dosisänderung (d.h. etwa zwei\r Tage) während anfänglicher\r Dosisoptimierung bei oralen\r Regimen. Hinweis: Rauchen\r reduziert die Halbwertszeit\r signifikant. Täglich bei IV-\r Aminophyllin. In\r Überdosierungssituationen die\r Hämodialyse erfordern, alle vier\r Stunden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD5",
        "source": "Consensus opinion of the relevant expert working group.",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Methotrexat (hochdosiert\r IV)",
        "entry_id": 99,
        "id": 454,
        "lang": "de",
        "recommendation": "24 Stunden nach\r Therapieabschluss dann alle 24\r Stunden bis Plasma-Methotrexat\r unter Cut-off-Konzentration für\r Toxizität ist (1 mol/L nach 48\r Stunden oder gemäß lokalem\r Protokoll)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD6",
        "source": "See product literature. Plard C et al. Cancer Chemother Pharmacol 2007;60: 609–620.75",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Lithium",
        "entry_id": 100,
        "id": 455,
        "lang": "de",
        "recommendation": "Tag vier bis sieben der\r Behandlung dann jede Woche bis\r die Dosierung vier Wochen\r konstant geblieben ist, dann alle\r drei Monate bei stabilisierten\r Regimen. Konzentration\r kontrollieren wenn Präparat\r geändert wird, wenn sich\r Flüssigkeitsaufnahme ändert oder\r wenn interagierende Medikamente\r zugegeben/abgesetzt werden.\r 100% renale Clearance, daher\r abhängig von Nierenfunktion. Bis\r zu alle vier Stunden in\r Überdosierungssituationen die\r intensive Therapie erfordern",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD7",
        "source": "Joint Formulary Committee. British National Formulary (77th edition), <a href=\"/references#ref-76\" target=\"_blank\" class=\"reference-link\">2019.76<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.10 Therapeutisches Medikamentenmonitoring",
        "clinical_situation": "Clozapin",
        "entry_id": 101,
        "id": 456,
        "lang": "de",
        "recommendation": "Induziert seinen eigenen\r Metabolismus und wird durch\r Rauchen weiter induziert. Etwa\r vier Tage um neuen Steady-State\r nach Dosisänderung oder\r Rauchstopp zu erreichen mit\r potentiell tödlichen Konsequenzen\r aufgrund des schnellen Anstiegs\r zu toxischen Konzentrationen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-TD8",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Berufliche Bleiexposition\r (chronisch)",
        "entry_id": 102,
        "id": 457,
        "lang": "de",
        "recommendation": "Anfängliche Blutblei-\r Konzentration vor Arbeitsbeginn\r oder innerhalb von 14 Tagen nach\r Beginn\r Blutblei-\r Konzentrationsüberwachung\r mindestens alle 12 Monate\r durchgeführt außer signifikanter\r Exposition gegenüber\r metallischem Blei und seinen\r Verbindungen, in diesem Fall\r sollte Blutblei alle drei Monate\r gemessen werden\r Falls Blutblei-Konzentration ≥30\r μg/dL bei erwachsenen Männern\r (≥20 μg/dL bei Frauen im\r gebärfähigen Alter), mindestens\r alle sechs Monate überwachen\r Falls Blutblei-Konzentration ≥40\r μg/dL bei erwachsenen Männern\r (≥25 μg/dL bei Frauen im\r gebärfähigen Alter), mindestens\r alle drei Monate überwachen\r Falls Blutblei-Konzentration ≥60\r μg/dL bei erwachsenen Männern\r (≥30 μg/dL bei Frauen im\r gebärfähigen Alter),\r Wiederholungsmessung von\r Blutblei innerhalb von zwei\r Wochen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O1",
        "source": "Health and Safety Executive Books, <a href=\"/references#ref-77\" target=\"_blank\" class=\"reference-link\">2002.77<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Akute Bleivergiftung bei\r Erwachsenen",
        "entry_id": 103,
        "id": 458,
        "lang": "de",
        "recommendation": "Falls Baseline-Blutblei-\r Konzentration <50 μg/dL ist und\r der Patient asymptomatisch und\r nicht schwanger ist, Blutblei-\r Konzentration nach zwei Wochen\r nach Entfernung von der\r Exposition wiederholen\r Falls Baseline-Blutblei-\r Konzentration ≥50 μg/dL ist,\r Blutblei-Konzentrationen täglich\r während Chelat-Therapie\r überwachen und 24-Stunden-\r Urin-Blei-Ausscheidung messen\r um bei der Entscheidung über\r Behandlungsdauer zu helfen.\r Blutblei-Messung eine Woche\r nach Ende der Chelat-Behandlung\r wiederholen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O2",
        "source": "TOXBASE.78",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Akute Bleivergiftung bei\r Kindern",
        "entry_id": 104,
        "id": 459,
        "lang": "de",
        "recommendation": "Falls Baseline-Blutblei-\r Konzentration 10–50 μg/dL ist,\r Blutblei-Messung einen Monat\r nach Entfernung von der\r Exposition wiederholen\r Falls Baseline-Blutblei-\r Konzentration >50 μg/dL ist,\r Blutblei täglich während Chelat-\r Therapie überwachen und 24-\r Stunden-Urin-Blei-Ausscheidung\r messen um bei der Entscheidung\r über Therapiedauer zu helfen.\r Blutblei-Messung eine Woche\r nach Behandlungsende\r wiederholen",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O3",
        "source": "TOXBASE.78",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Amphetamin-Toxizität",
        "entry_id": 105,
        "id": 460,
        "lang": "de",
        "recommendation": "Nachtestung ist in derselben\r akuten Episode nicht indiziert",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O4",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Benzodiazepin-Toxizität",
        "entry_id": 106,
        "id": 461,
        "lang": "de",
        "recommendation": "Nachtestung ist in derselben\r akuten Episode nicht indiziert",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O5",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Kokain-Toxizität",
        "entry_id": 107,
        "id": 462,
        "lang": "de",
        "recommendation": "Nachtestung ist in derselben\r akuten Episode nicht indiziert",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O6",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Opiat-Toxizität\r einschließlich Morphin,\r Codein und Heroin",
        "entry_id": 108,
        "id": 463,
        "lang": "de",
        "recommendation": "Nachtestung ist in derselben\r akuten Episode nicht indiziert",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O7",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.11 Arbeitsmedizin/Toxikologie",
        "clinical_situation": "Opioid-Toxizität\r einschließlich Methadon",
        "entry_id": 109,
        "id": 464,
        "lang": "de",
        "recommendation": "Nachtestung ist in derselben\r akuten Episode nicht indiziert",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-O8",
        "source": "Consensus opinion of the relevant expert working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Urin β-hCG\r (Schwangerschaft)",
        "entry_id": 110,
        "id": 465,
        "lang": "de",
        "recommendation": "Urin-Schwangerschaftstest kann\r drei Tage nach negativem Ergebnis\r oder etwa 28 Tage nach\r Periodenbeginn wiederholt werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P1",
        "source": "Manufacturer’s instructions",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Serum β-hCG\r (Schwangerschaft)",
        "entry_id": 111,
        "id": 466,
        "lang": "de",
        "recommendation": "Serum β-hCG-Test: nicht\r wiederholen falls positiv. Nach drei\r Tagen wiederholen falls negativ\r und keine Menstruation\r aufgetreten ist",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P2",
        "source": "Serum β-hCG doubling time = 1.5– 2 days",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Serum β-hCG\r (Eileiterschwangerschaft)",
        "entry_id": 112,
        "id": 467,
        "lang": "de",
        "recommendation": "48-Stunden-\r Wiederholungsintervall",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P3",
        "source": "NICE. NG126, <a href=\"/references#ref-79\" target=\"_blank\" class=\"reference-link\">2019.79<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Serum β-hCG\r (Tumormarker)",
        "entry_id": 113,
        "id": 468,
        "lang": "de",
        "recommendation": "Nach Ausräumung einer\r Blasenmole sollte die β-hCG-\r Konzentration jede Woche\r überwacht werden bis zur\r Normalisierung und dann jeden\r Monat während des ersten Jahres",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P4",
        "source": "Bidart JM et al. Clin Chem 1999;45:1695– <a href=\"/references#ref-71\" target=\"_blank\" class=\"reference-link\">1707.71<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "LFTs bei geburtshilflicher\r Cholestase",
        "entry_id": 114,
        "id": 469,
        "lang": "de",
        "recommendation": "Sobald geburtshilfliche\r Cholestase diagnostiziert ist, ist es\r angemessen LFTs wöchentlich bis\r zur Entbindung zu messen\r Postnatal sollten LFTs für\r mindestens 10 Tage aufgeschoben\r werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P5",
        "source": "RCOG. Obstetric Cholestasis: Green- top Guideline No 43, <a href=\"/references#ref-80\" target=\"_blank\" class=\"reference-link\">2011.80<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Gallensäuren bei\r geburtshilflicher\r Cholestase",
        "entry_id": 115,
        "id": 470,
        "lang": "de",
        "recommendation": "Wöchentliche Überwachung.\r Zweimal wöchentliche\r Überwachung in späteren Wochen\r empfohlen falls sich der klinische\r Zustand ändert",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P6",
        "source": "No evidence available but reflects expert opinion and practice",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Harnsäuremessung bei\r Präeklampsie",
        "entry_id": 116,
        "id": 471,
        "lang": "de",
        "recommendation": "Während des Wartens auf\r Expertenrat ohne Aufnahme:\r zweimal wöchentlich Harnsäure",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P7",
        "source": "No evidence but reflects the practice of tertiary centre of excellent",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Urinprotein bei\r Präeklampsie",
        "entry_id": 117,
        "id": 472,
        "lang": "de",
        "recommendation": "Bei jedem pränatalen Besuch zum\r Screening auf Präeklampsie\r Sobald diagnostiziert keine\r Wiederholung der Proteinurie-\r Quantifizierung\r Nur wiederholen falls klinisch\r indiziert, zum Beispiel falls neue\r Symptome und Zeichen auftreten\r oder Unsicherheit über Diagnose\r besteht",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P8",
        "source": "NICE. CG62, 2008.81 NICE. NG133, <a href=\"/references#ref-82\" target=\"_blank\" class=\"reference-link\">2019.82<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "LFT/Niere bei\r Präeklampsie",
        "entry_id": 118,
        "id": 473,
        "lang": "de",
        "recommendation": "Mindestens täglich wenn die\r Ergebnisse abnormal sind aber\r häufiger falls der klinische\r Zustand\r Bei milder Hypertonie*, Tests\r zweimal wöchentlich durchführen\r Bei moderater Hypertonie*, Tests\r dreimal wöchentlich durchführen\r Bei schwerer Hypertonie*, Tests\r dreimal wöchentlich durchführen\r *Siehe Quellleitlinien für\r Definitionen von Hypertonie",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P9",
        "source": "RCOG. Green-top Guideline No 10A, 2006.83 NICE. NG133, <a href=\"/references#ref-82\" target=\"_blank\" class=\"reference-link\">2019.82<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Überwachung der\r Thyreotoxikose-Behandlung\r bei schwangeren Frauen\r (UK)",
        "entry_id": 119,
        "id": 474,
        "lang": "de",
        "recommendation": "Bei Frauen die\r Schilddrüsenhemmer einnehmen,\r sollten TFTs vor der Empfängnis,\r zum Zeitpunkt der\r Schwangerschaftsbestätigung\r oder bei pränataler Anmeldung\r durchgeführt werden\r Neu diagnostizierte hyperthyreote\r Patienten benötigen monatliche\r Testung während der\r Schwangerschaft bis stabilisiert\r Schwangere Frauen die\r Schilddrüsenhemmer erhalten\r sollten häufig getestet werden\r (möglicherweise monatlich)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P10",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Überwachung der\r Thyreotoxikose-Behandlung\r bei schwangeren Frauen\r (USA)",
        "entry_id": 120,
        "id": 475,
        "lang": "de",
        "recommendation": "fT4 und TSH sollten etwa alle\r zwei bis sechs Wochen bei Frauen\r überwacht werden die mit\r Schilddrüsenhemmern in der\r Schwangerschaft behandelt\r werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P11",
        "source": "Stagnaro-Green A et al. Thyroid 2011;21:1081– <a href=\"/references#ref-84\" target=\"_blank\" class=\"reference-link\">1125.84<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Schwangerschafts-\r subklinische Hypothyreose",
        "entry_id": 121,
        "id": 476,
        "lang": "de",
        "recommendation": "Frauen mit subklinischer\r Hypothyreose die initial nicht\r behandelt werden sollten auf\r Progression zu manifester\r Hypothyreose überwacht werden.\r Serum fT4 und TSH sollten alle\r vier Wochen bis zur 16–20.\r Schwangerschaftswoche und\r mindestens einmal zwischen 26–\r 32 Wochen gemessen werden\r (Euthyreote Frauen [die kein LT4\r erhalten] die Schilddrüsen-\r Antikörper-positiv sind sollten\r während der Schwangerschaft\r überwacht werden. Serum fT4 und\r TSH sollten alle vier Wochen bis\r zur 16–20. Schwangerschaftswoche\r und mindestens einmal zwischen\r 26 und 32 Wochen gemessen\r werden)",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P12",
        "source": "Stagnaro-Green A et al. Thyroid 2011;21:1081– <a href=\"/references#ref-84\" target=\"_blank\" class=\"reference-link\">1125.84<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Frauen mit Diabetes die\r schwanger werden möchten",
        "entry_id": 122,
        "id": 477,
        "lang": "de",
        "recommendation": "Monatliche Messung von HbA1C",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P13",
        "source": "NICE. NG3, <a href=\"/references#ref-85\" target=\"_blank\" class=\"reference-link\">2015.85<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Bewertung der\r glykämischen Kontrolle\r mittels HbA1c in der\r Schwangerschaft",
        "entry_id": 123,
        "id": 478,
        "lang": "de",
        "recommendation": "HbA1C sollte nicht routinemäßig\r zur Bewertung der glykämischen\r Kontrolle im zweiten und dritten\r Trimester der Schwangerschaft\r verwendet werden jedoch HbA1C-\r Messung für Frauen mit\r vorbestehendem Diabetes erwägen\r um Schwangerschaftsrisiko zu\r bewerten",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P14",
        "source": "NICE. NG3, <a href=\"/references#ref-85\" target=\"_blank\" class=\"reference-link\">2015.85<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Für das Management von\r Hyponatriämie unter der\r Geburt und in der\r unmittelbaren postpartalen\r Periode benötigen Frauen\r Natrium-Überwachung falls\r sie:\r • unter Oxytocin-Infusion\r stehen (einschließlich\r Geburtseinleitung und -\r verstärkung, Behandlung\r postpartaler Blutung)\r • unter der Geburt stehen\r und IV-Insulin und Dextrose\r benötigen\r • ein Blutnatrium unter 130\r mmol/L aus irgendeinem\r Grund haben\r • eine positive\r Flüssigkeitsbilanz von mehr\r als 1.500 ml haben",
        "entry_id": 124,
        "id": 479,
        "lang": "de",
        "recommendation": "Bezieht sich auf Natriummessung\r Frauen unter Insulin-Infusionen:\r MRI ist 4 Stunden\r Während der Geburt:\r Natrium >129 mmol/L\r MRI ist 8 Stunden\r Natrium 129–125 mmol/L\r MRI ist 4 Stunden\r Natrium <125 mmol/L\r MRI ist 2 Stunden\r Entbindung oder Abschluss der\r Oxytocin-Infusion:\r Natrium >129 mmol/L\r Nachtestung nicht erforderlich\r Natrium 129–125 mmol/L UND\r asymptomatisch\r MRI ist 4 Stunden\r Natrium <125 mmol/L ODER\r symptomatisch <130 mmol/L\r MRI ist 2 Stunden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P15",
        "source": "GAIN, <a href=\"/references#ref-86\" target=\"_blank\" class=\"reference-link\">2017.86<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.12 Schwangerschaftsbezogen",
        "clinical_situation": "Frauen mit Typ-1-Diabetes\r haben ein dreifach erhöhtes\r Risiko für postpartale\r Schilddrüsendysfunktion",
        "entry_id": 125,
        "id": 480,
        "lang": "de",
        "recommendation": "Serum TSH, fT4 und\r Schilddrüsenperoxidase-\r Antikörper-Status sollten\r präkonzeptionell, bei Anmeldung\r während Schwangerschaft und\r drei Monate postpartal bestimmt\r werden",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-P16",
        "source": "Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation, <a href=\"/references#ref-25\" target=\"_blank\" class=\"reference-link\">2006.25<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "2.13 Pädiatrisch-bezogen",
        "clinical_situation": "HbA1C-Überwachung bei\r Kindern und Jugendlichen\r mit Typ-1-Diabetes",
        "entry_id": 126,
        "id": 481,
        "lang": "de",
        "recommendation": "Zwei Monate",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-CH1",
        "source": "NICE. NG18, <a href=\"/references#ref-87\" target=\"_blank\" class=\"reference-link\">2004.87<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "2.13 Pädiatrisch-bezogen",
        "clinical_situation": "Zöliakie-Serologie bei\r bekannten pädiatrischen\r Patienten in der Nachsorge",
        "entry_id": 127,
        "id": 482,
        "lang": "de",
        "recommendation": "Testung alle sechs Monate bei\r Kindern",
        "section": "Biochemie",
        "subsection": null,
        "ref": "B-CH2",
        "source": "Murch S et al. Arch Dis Child 2013;98:806–811.88",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Normale Nachsorge",
        "entry_id": 129,
        "id": 483,
        "lang": "de",
        "recommendation": "Eine Wiederholung wäre aus\r klinischen Gründen indiziert falls\r sich der Zustand des Patienten\r signifikant verändert hat",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC1",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Überwachung eines stabilen\r stationären Patienten",
        "entry_id": 130,
        "id": 484,
        "lang": "de",
        "recommendation": "Ein stationärer Patient mit\r normalem Aufnahme-FBC sollte\r keine Wiederholung innerhalb der\r durchschnittlichen\r Aufenthaltsdauer von vier Tagen\r erhalten",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC2",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Überwachung eines instabilen\r stationären Patienten der\r nicht aktiv blutet oder eines\r Patienten unter zytotoxischen\r Medikamenten",
        "entry_id": 131,
        "id": 485,
        "lang": "de",
        "recommendation": "Normalerweise nicht häufiger als\r einmal täglich erforderlich",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC3",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Patienten mit schwerer\r Blutung",
        "entry_id": 132,
        "id": 486,
        "lang": "de",
        "recommendation": "Wiederholungsintervall sollte\r durch die klinische Situation\r bestimmt werden. Sollte\r mindestens stündlich bei massiver\r Blutung wiederholt werden",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC4",
        "source": "Thomas D et al. Anaesthesia 2010;65:1153– <a href=\"/references#ref-89\" target=\"_blank\" class=\"reference-link\">1161.89<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Schwangere unter\r hämatinischen Supplementen\r (Eisen, Folat, B12)",
        "entry_id": 133,
        "id": 487,
        "lang": "de",
        "recommendation": "Wiederholung nach mindestens 14\r Tagen",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC5",
        "source": "BCSH, <a href=\"/references#ref-90\" target=\"_blank\" class=\"reference-link\">2011.90<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Routine\r Schwangerschaftsüberwachung",
        "entry_id": 134,
        "id": 488,
        "lang": "de",
        "recommendation": "Bei Anmeldung, 28 Wochen und\r postpartal",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC6",
        "source": "NICE. CG62, 2008.81 BCSH, <a href=\"/references#ref-90\" target=\"_blank\" class=\"reference-link\">2011.90<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Hypertensive\r Schwangerschaftserkrankungen*\r *FBC in Kombination mit\r Nieren- und Leberfunktion",
        "entry_id": 135,
        "id": 489,
        "lang": "de",
        "recommendation": "Nur einmal bei moderater\r pränataler Gestationshypertonie\r (<160/110) ohne Proteinurie.\r Wöchentlich bei schwerer\r Gestationshypertonie. Zweimal\r wöchentlich bei milder pränataler\r Hypertonie mit Präeklampsie,\r dreimal wöchentlich bei moderat\r bis schwer. Nach klinischer\r Indikation in peripartaler Periode\r (kann mehrere Wiederholungen\r über 24 Stunden erfordern) und\r dann 48 Stunden nach\r Entbindung/Herabstufung von\r Intensivversorgung wiederholen\r und Überwachung bei normalen\r Werten beenden",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC7",
        "source": "NICE. NG133, <a href=\"/references#ref-82\" target=\"_blank\" class=\"reference-link\">2019.82<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Stationäre Patienten mit\r vermuteten Thrombozyten-\r Alloantikörpern oder unter\r HLA-angepassten\r Thrombozyten",
        "entry_id": 136,
        "id": 490,
        "lang": "de",
        "recommendation": "Wiederholung eine Stunde nach\r Abschluss der\r Thrombozytentransfusion",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC8",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Patienten mit Anämie bei\r chronischer\r Nierenerkrankung",
        "entry_id": 137,
        "id": 491,
        "lang": "de",
        "recommendation": "Alle zwei bis vier Wochen in der\r Induktionsphase der ESA-Therapie\r und alle ein bis drei Monate in der\r Erhaltungsphase der ESA-\r Therapie",
        "section": "Hämatologie",
        "subsection": "FBC",
        "ref": "H-FBC9",
        "source": "NICE. NG8, <a href=\"/references#ref-58\" target=\"_blank\" class=\"reference-link\">2015.58<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Temporale\r Arteritis/Polymyalgia\r rheumatica",
        "entry_id": 139,
        "id": 492,
        "lang": "de",
        "recommendation": "Alle drei Monate nach dem ersten\r Behandlungsmonat",
        "section": "Hämatologie",
        "subsection": "ESR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.1 Hämatologie allgemein",
        "clinical_situation": "Rheumatoide Arthritis",
        "entry_id": 140,
        "id": 493,
        "lang": "de",
        "recommendation": "Jeden Monat bis die Behandlung\r die Krankheit kontrolliert hat\r (NICE CG79 empfiehlt Verwendung\r von CRP)",
        "section": "Hämatologie",
        "subsection": "ESR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patienten mit schwerer\r Blutung",
        "entry_id": 141,
        "id": 494,
        "lang": "de",
        "recommendation": "Wiederholungsintervall sollte\r durch die klinische Situation\r bestimmt werden und das\r Gerinnungsscreening muss\r Fibrinogen einschließen. Sollte\r mindestens stündlich bei massiver\r Blutung wiederholt werden",
        "section": "Hämatologie",
        "subsection": null,
        "ref": "H-CS1",
        "source": "Thomas D et al. Anaesthesia 2010;65:1153– <a href=\"/references#ref-89\" target=\"_blank\" class=\"reference-link\">1161.89<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patienten mit akuter\r Koagulopathie",
        "entry_id": 142,
        "id": 495,
        "lang": "de",
        "recommendation": "Normalerweise nicht häufiger als\r einmal täglich falls keine\r Gerinnungsfaktoren erhalten\r werden und keine aktive Blutung\r vorliegt",
        "section": "Hämatologie",
        "subsection": null,
        "ref": "H-CS2",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patienten mit chronischer\r Lebererkrankung",
        "entry_id": 144,
        "id": 496,
        "lang": "de",
        "recommendation": "Alle drei Monate falls ansonsten\r stabil",
        "section": "Hämatologie",
        "subsection": "PT",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patienten die auf VKA\r eingestellt werden",
        "entry_id": 146,
        "id": 497,
        "lang": "de",
        "recommendation": "Nicht häufiger als einmal täglich",
        "section": "Hämatologie",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Instabiler stationärer\r Patient unter VKA",
        "entry_id": 147,
        "id": 498,
        "lang": "de",
        "recommendation": "Nicht häufiger als einmal täglich",
        "section": "Hämatologie",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Stabiler ambulanter Patient\r unter VKA",
        "entry_id": 148,
        "id": 499,
        "lang": "de",
        "recommendation": "Normalerweise nicht häufiger als\r einmal wöchentlich und bis zu 12\r Wochen bei sehr stabiler Situation",
        "section": "Hämatologie",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patient der dringende VKA-\r Umkehr benötigt (oder zur\r Behandlung erworbener\r Vitamin-K-abhängiger\r Gerinnungsfaktorenmangel)\r mit Vitamin K",
        "entry_id": 149,
        "id": 500,
        "lang": "de",
        "recommendation": "Wiederholung nur nach\r mindestens sechs Stunden nach\r IV-Dosis und am folgenden Tag\r nach oraler Dosis",
        "section": "Hämatologie",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patient der dringende VKA-\r Umkehr mit einem Vier-\r Faktor-PCC benötigt",
        "entry_id": 150,
        "id": 501,
        "lang": "de",
        "recommendation": "Wiederholung innerhalb einer\r Stunde nach Verabreichung",
        "section": "Hämatologie",
        "subsection": "INR",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patient unter intravenöser\r Infusion von\r unfraktioniertem Heparin",
        "entry_id": 152,
        "id": 502,
        "lang": "de",
        "recommendation": "Wiederholung 6 Stunden nach\r Dosisanpassung (2 Stunden falls\r vorherige APTT-Ratio >5.0) und\r täglich wenn APTT im Zielbereich",
        "section": "Hämatologie",
        "subsection": "APTT",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patienten unter intravenöser\r Infusion eines parenteralen\r direkten Thrombininhibitors\r (Bivalirudin, Argatroban)",
        "entry_id": 153,
        "id": 503,
        "lang": "de",
        "recommendation": "Wiederholung zwei Stunden nach\r jeder Dosisanpassung dann täglich\r wenn im Zielbereich",
        "section": "Hämatologie",
        "subsection": "APTT",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patienten mit akuter\r Koagulopathie",
        "entry_id": 155,
        "id": 504,
        "lang": "de",
        "recommendation": "Normalerweise nicht häufiger als\r täglich falls keine\r Gerinnungsfaktoren erhalten\r werden und keine aktive Blutung\r vorliegt",
        "section": "Hämatologie",
        "subsection": "Clauss-Fibrinogen-Assay",
        "ref": "H-CS2",
        "source": "Consensus of the haematology working group",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patienten mit schwerer\r Blutung",
        "entry_id": 156,
        "id": 505,
        "lang": "de",
        "recommendation": "Wiederholungsintervall sollte\r durch die klinische Situation\r bestimmt werden. Sollte\r mindestens stündlich bei massiver\r Blutung wiederholt werden",
        "section": "Hämatologie",
        "subsection": "Clauss-Fibrinogen-Assay",
        "ref": "H-CS1",
        "source": "Thomas D et al. Anaesthesia 2010;65:1153– <a href=\"/references#ref-89\" target=\"_blank\" class=\"reference-link\">1161.89<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Patient unter therapeutischer\r LMWH-Dosis mit\r signifikanter\r Nierenbeeinträchtigung,\r extremem Gewicht,\r Schwangerschaft oder\r anderer Messindikation",
        "entry_id": 158,
        "id": 506,
        "lang": "de",
        "recommendation": "Mindestens drei Tage nach Beginn\r oder Dosisanpassung, dann nicht\r häufiger als einmal wöchentlich\r falls die Dosis unverändert ist",
        "section": "Hämatologie",
        "subsection": "Anti-Xa-Assay",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Untersuchung bei\r vermutetem Antiphospholipid-\r Syndrom",
        "entry_id": 160,
        "id": 507,
        "lang": "de",
        "recommendation": "Wiederholung nach 12 Wochen\r falls abnormal",
        "section": "Hämatologie",
        "subsection": "LA-Screening",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Untersuchung auf\r Antiphospholipid-Syndrom\r nach Abschluss der\r Antikoagulation",
        "entry_id": 161,
        "id": 508,
        "lang": "de",
        "recommendation": "Mindestens sieben Tage nach\r Beendigung der Antikoagulation",
        "section": "Hämatologie",
        "subsection": "LA-Screening",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Ein Patient unter\r Untersuchung wegen\r vermuteten\r Gerinnungsfaktorenmangels",
        "entry_id": 163,
        "id": 509,
        "lang": "de",
        "recommendation": "Ein abnormales Ergebnis kann zur\r Bestätigung in einem klinisch\r angemessenen Intervall wiederholt\r werden",
        "section": "Hämatologie",
        "subsection": "CFA",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Ein Patient unter\r Gerinnungsfaktor-\r Ersatztherapie",
        "entry_id": 164,
        "id": 510,
        "lang": "de",
        "recommendation": "Ein Assay unmittelbar vor und bis\r zu 60 Minuten nach Verabreichung\r und dann nach klinischer\r Indikation, normalerweise nicht\r häufiger als einmal täglich\r (entweder Talspiegel,\r Spitzenspiegel oder beide)",
        "section": "Hämatologie",
        "subsection": "CFA",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Überwachung bei Patienten\r mit schwerer Hämophilie A\r oder B",
        "entry_id": 166,
        "id": 511,
        "lang": "de",
        "recommendation": "Nach jeder dritten Faktor-ED oder\r alle drei Monate (je nachdem was\r früher ist) bis 20 ED, dann alle drei\r bis sechs Monate bis 150 ED (dann\r ein- bis zweimal pro Jahr nur bei\r schwerer Hämophilie A)",
        "section": "Hämatologie",
        "subsection": "Gerinnungsfaktor-Inhibitor-Testung",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Überwachung nach Wechsel\r des Faktorkonzentrats bei\r schwerer Hämophilie A",
        "entry_id": 167,
        "id": 512,
        "lang": "de",
        "recommendation": "Vor dem Wechsel und dann\r zweimal in den ersten sechs\r Monaten nach dem Wechsel",
        "section": "Hämatologie",
        "subsection": "Gerinnungsfaktor-Inhibitor-Testung",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Überwachung bei Patienten\r mit moderater oder milder\r Hämophilie A",
        "entry_id": 168,
        "id": 513,
        "lang": "de",
        "recommendation": "Jährlich falls Faktorkonzentrat\r exponiert oder nach intensiver\r Exposition (>5 ED) oder Operation",
        "section": "Hämatologie",
        "subsection": "Gerinnungsfaktor-Inhibitor-Testung",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Überwachung der ITT\r während Behandlung",
        "entry_id": 169,
        "id": 514,
        "lang": "de",
        "recommendation": "Monatlich",
        "section": "Hämatologie",
        "subsection": "Gerinnungsfaktor-Inhibitor-Testung",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Nach Abschluss\r erfolgreicher ITT",
        "entry_id": 170,
        "id": 515,
        "lang": "de",
        "recommendation": "Monatlich für sechs Monate dann\r alle zwei Monate für bis zu ein\r Jahr",
        "section": "Hämatologie",
        "subsection": "Gerinnungsfaktor-Inhibitor-Testung",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.2 Hämatologie Gerinnung",
        "clinical_situation": "Überwachung von Patienten\r mit neu diagnostiziertem\r erworbenem\r Gerinnungsfaktor-Inhibitor",
        "entry_id": 171,
        "id": 516,
        "lang": "de",
        "recommendation": "Monatlich bis sechs Monate nach\r Remission",
        "section": "Hämatologie",
        "subsection": "Gerinnungsfaktor-Inhibitor-Testung",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Ein Erstpatient vor\r Transfusion",
        "entry_id": 173,
        "id": 517,
        "lang": "de",
        "recommendation": "Eine zweite Probe sollte vor\r Transfusion angefordert werden",
        "section": "Hämatologie",
        "subsection": "Blutgruppe und Antikörper-Screening",
        "ref": "H-BGAS1",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Ein Patient der keine\r Transfusion oder\r Schwangerschaft in den\r letzten drei Monaten hatte",
        "entry_id": 174,
        "id": 518,
        "lang": "de",
        "recommendation": "Die ursprüngliche Probe kann bis\r zu drei Monate gültig sein",
        "section": "Hämatologie",
        "subsection": "Blutgruppe und Antikörper-Screening",
        "ref": "H-BGAS2",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Ein Patient der eine\r Transfusion oder\r Schwangerschaft in den\r letzten drei Monaten hatte",
        "entry_id": 175,
        "id": 519,
        "lang": "de",
        "recommendation": "Die ursprüngliche Probe ist bis zu\r drei Tage gültig",
        "section": "Hämatologie",
        "subsection": "Blutgruppe und Antikörper-Screening",
        "ref": "H-BGAS3",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Eine schwangere Frau die\r Blut in Bereitschaft für\r geburtshilfliche Notfälle\r benötigt (z.B. Placenta\r praevia)",
        "entry_id": 176,
        "id": 520,
        "lang": "de",
        "recommendation": "Eine Probe kann als gültig für bis\r zu sieben Tage betrachtet werden",
        "section": "Hämatologie",
        "subsection": "Blutgruppe und Antikörper-Screening",
        "ref": "H-BGAS4",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Ein chronisch transfundierter\r Patient ohne Erythrozyten-\r Alloantikörper",
        "entry_id": 177,
        "id": 521,
        "lang": "de",
        "recommendation": "Eine Probe kann als gültig für bis\r zu sieben Tage nach individueller\r Risikobewertung betrachtet\r werden",
        "section": "Hämatologie",
        "subsection": "Blutgruppe und Antikörper-Screening",
        "ref": "H-BGAS5",
        "source": "Milkins C et al. Transfus Med 2013;23:3–35.97",
        "level_of_evidence": "D"
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Eine schwangere Frau über\r 20 Schwangerschaftswochen\r die Anti-D-, -c- oder -K-\r Antikörper hat",
        "entry_id": 178,
        "id": 522,
        "lang": "de",
        "recommendation": "Wiederholung mit Quantifizierung\r von c- und D-Antikörpern und Anti-\r K durch Titration alle vier Wochen\r bis 28 Wochen und dann alle zwei\r Wochen bis zur Entbindung",
        "section": "Hämatologie",
        "subsection": "Blutgruppe und Antikörper-Screening",
        "ref": "H-BGAS6",
        "source": "White J et al. Transfus Med 2016;26:246–263.98",
        "level_of_evidence": "C"
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Ein pränatales\r sensibilisierendes Ereignis\r bei RhD-negativen Frauen\r nach 20\r Schwangerschaftswochen die\r risikobehaftet für RhD-\r Antikörperentwicklung sind",
        "entry_id": 180,
        "id": 523,
        "lang": "de",
        "recommendation": "Wiederholung für jedes neue\r sensibilisierende Ereignis außer\r es gibt ein andauerndes\r sensibilisierendes Ereignis (z.B.\r intermittierende Uterusblutung)\r dann nicht häufiger als alle zwei\r Wochen wiederholen",
        "section": "Hämatologie",
        "subsection": "Schätzung von FMH",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "FMH >4 ml bei RhD-\r negativen Frauen nach 20\r Schwangerschaftswochen die\r risikobehaftet für RhD-\r Antikörperentwicklung sind\r (RhD-positives Baby oder\r fetaler RhD-Status\r unbekannt)",
        "entry_id": 181,
        "id": 524,
        "lang": "de",
        "recommendation": "Wiederholung 48 Stunden nach IV-\r Anti-D oder 72 Stunden nach IM-\r Anti-D und Prozess wiederholen\r bis keine nachweisbaren fetalen\r Zellen",
        "section": "Hämatologie",
        "subsection": "Schätzung von FMH",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "3.3 Hämatologie Transfusion (allgemein und Screening-Gruppe in PBLC)",
        "clinical_situation": "Nach Zellsalvage bei RhD-\r negativen Frauen",
        "entry_id": 182,
        "id": 525,
        "lang": "de",
        "recommendation": "Kontrolle 30–45 Minuten nach\r Reinfusion von geretteten Zellen\r dann gemäß FMH1",
        "section": "Hämatologie",
        "subsection": "Schätzung von FMH",
        "ref": "",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Beta-2-Mikroglobulin",
        "entry_id": 193,
        "id": 526,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-11",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Beta-2-Glykoprotein-I-\r Antikörper",
        "entry_id": 194,
        "id": 527,
        "lang": "de",
        "recommendation": "Sobald Diagnose mit BCSH-\r Leitlinien bestätigt ist, ist\r wiederholte Testung von\r begrenztem Wert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-12",
        "source": "Keeling D et al. Br J Haematol 2012;157:47–58.94",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "C3/4",
        "entry_id": 195,
        "id": 528,
        "lang": "de",
        "recommendation": "90 Tage (frühere Testfrequenz\r möglicherweise in\r Ausnahmefällen erforderlich)",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-13",
        "source": "Consensus of surveyed labs",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "C3-nephritischer Faktor",
        "entry_id": 196,
        "id": 529,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich\r falls positiv. Nur erlaubt falls C3\r unter Referenzbereich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-14",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Herzmuskel-Antikörper",
        "entry_id": 197,
        "id": 530,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-15",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Cardiolipin-Antikörper",
        "entry_id": 198,
        "id": 531,
        "lang": "de",
        "recommendation": "Sobald Diagnose mit BCSH-\r Leitlinien bestätigt ist, ist\r wiederholte Testung von\r begrenztem Wert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-16",
        "source": "Keeling D et al. Br J Haematol 2012;157:47–58.94",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "CCP",
        "entry_id": 199,
        "id": 532,
        "lang": "de",
        "recommendation": "Wiederholte Testung nach\r Diagnosebestätigung ist von\r begrenztem Wert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-17",
        "source": "Consensus of surveyed labs NICE. NG100, <a href=\"/references#ref-100\" target=\"_blank\" class=\"reference-link\">2018.100<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "CD62-Ligand-Shedding",
        "entry_id": 200,
        "id": 533,
        "lang": "de",
        "recommendation": "Mit Labor besprechen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-18",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "A3-Ganglionärer-Rezeptor-\r Antikörper",
        "entry_id": 183,
        "id": 534,
        "lang": "de",
        "recommendation": "WiederholteTestungnach\r Diagnosebestätigungistvon\r begrenztemWert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-1",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "Acetylcholin-Rezeptor-\r Antikörper",
        "entry_id": 184,
        "id": 535,
        "lang": "de",
        "recommendation": "Häufigkeitdurchklinischen\r Kontextbestimmt.Allesechs\r MonatewährendderBehandlung",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-2",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "Nebennierenrinden-\r Antikörper",
        "entry_id": 185,
        "id": 536,
        "lang": "de",
        "recommendation": "WiederholteTestungvon\r begrenztemWert.Häufigkeitdurch\r klinischenKontextzubestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-3",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "aPL-Antikörper",
        "entry_id": 186,
        "id": 537,
        "lang": "de",
        "recommendation": "SobaldDiagnosemitBCSH-\r Leitlinienbestätigtist, ist\r wiederholteTestungvon\r begrenztemWert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-4",
        "source": "Keeling D et al. Br J Haematol 2012;157:47–58.94",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "Alpha-1-Antitrypsin-\r Genotyp",
        "entry_id": 187,
        "id": 538,
        "lang": "de",
        "recommendation": "Nichtroutinemäßigerforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-5",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "AMPA-Rezeptor-Antikörper",
        "entry_id": 188,
        "id": 539,
        "lang": "de",
        "recommendation": "WiederholteTestungvon\r begrenztemWert.Häufigkeitdurch\r klinischenKontextzubestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-6",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "Anti-nukleärerAntikörper\r (HEP2)",
        "entry_id": 189,
        "id": 540,
        "lang": "de",
        "recommendation": "SobaldDiagnoseetabliertist, ist\r wiederholteTestungvon\r begrenztemWert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-7",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "Aquaporin-4-Antikörper\r (NMO)CSF",
        "entry_id": 190,
        "id": 541,
        "lang": "de",
        "recommendation": "WiederholteTestunggeleitet\r durchklinischenKontextund\r Diskussionmitspezialisiertem\r LabordienstderdenAssay\r anbietet",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-8",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "Aquaporin-4-Antikörper\r (NMO)Serum",
        "entry_id": 191,
        "id": 542,
        "lang": "de",
        "recommendation": "WiederholteTestunggeleitet\r durchklinischenKontextund\r Diskussionmitspezialisiertem\r LabordienstderdenAssay\r anbietet",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-9",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4Immunologie-Empfehlungen",
        "clinical_situation": "Basalganglien-Antikörper",
        "entry_id": 192,
        "id": 543,
        "lang": "de",
        "recommendation": "WiederholteTestungvon\r begrenztemWert.Häufigkeitdurch\r klinischenKontextzubestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-10",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Komplement C1q",
        "entry_id": 201,
        "id": 544,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-19",
        "source": "Tarzi MD et al. Clin Exp Immunol 2007; 149:513–516.101",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Komplement-1-Inhibitor\r immunochemisch",
        "entry_id": 202,
        "id": 545,
        "lang": "de",
        "recommendation": "Nur einmal zur Bestätigung;\r wiederholte Testung begrenzt auf\r Ausnahmefälle\r Allgemein nur durchgeführt falls\r C4 niedrig ist oder mit\r kompatiblen klinischen\r Informationen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-20",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Komplement AP100",
        "entry_id": 203,
        "id": 546,
        "lang": "de",
        "recommendation": "Nur einmal zur Bestätigung\r Nur mit kompatiblen klinischen\r Informationen erlaubt",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-21",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Komplement C2",
        "entry_id": 204,
        "id": 547,
        "lang": "de",
        "recommendation": "Nur einmal zur Bestätigung\r Nur mit kompatiblen klinischen\r Informationen erlaubt",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-22",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Komplement CH100",
        "entry_id": 205,
        "id": 548,
        "lang": "de",
        "recommendation": "Nur einmal zur Bestätigung\r Nur mit kompatiblen klinischen\r Informationen erlaubt",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-23",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Komplement-Faktor B",
        "entry_id": 206,
        "id": 549,
        "lang": "de",
        "recommendation": "Nur einmal zur Bestätigung\r Nur mit kompatiblen klinischen\r Informationen erlaubt",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-24",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Komplement-Faktor H",
        "entry_id": 207,
        "id": 550,
        "lang": "de",
        "recommendation": "Nur mit kompatiblen klinischen\r Informationen erlaubt",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-25",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "CSF oligoklonal",
        "entry_id": 208,
        "id": 551,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-26",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Kryoglobulin-Screening",
        "entry_id": 209,
        "id": 552,
        "lang": "de",
        "recommendation": "Nach anfänglicher Bestätigung\r von Kryoglobulin, was\r möglicherweise mehr als\r einmaliges Testen erfordert,\r wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-27",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Kryoglobulin-Typ",
        "entry_id": 210,
        "id": 553,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-28",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "dsDNA-Ab ELISA",
        "entry_id": 211,
        "id": 554,
        "lang": "de",
        "recommendation": "Alle drei bis sechs Monate\r während der Behandlung",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-29",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Endomysium-Antikörper\r (IgA)",
        "entry_id": 212,
        "id": 555,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich\r Nur zur Bestätigung von tTG-\r Positiven",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-30",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Endomysium-Antikörper\r (IgG)",
        "entry_id": 213,
        "id": 556,
        "lang": "de",
        "recommendation": "Nur für Patienten mit komplettem\r IgA-Mangel und Bestätigung von\r positivem tTG IgG\r Angeben dass dieser Test nicht\r unternommen werden sollte und\r auf relevante NICE-Leitlinien\r verweisen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-31",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "ENA RNP, Sm, Ro, La, Scl,\r Jo1 und Zentromer",
        "entry_id": 214,
        "id": 557,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-32",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "GABA-Rezeptor-Antikörper",
        "entry_id": 215,
        "id": 558,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-33",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "GAD65-Antikörper",
        "entry_id": 216,
        "id": 559,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-34",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Gangliosid-GD1b-\r Antikörper",
        "entry_id": 217,
        "id": 560,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-35",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Gangliosid-GM1-\r Antikörper",
        "entry_id": 218,
        "id": 561,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-36",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Gangliosid-GQ1b-\r Antikörper",
        "entry_id": 219,
        "id": 562,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-37",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "GBM-Antikörper",
        "entry_id": 220,
        "id": 563,
        "lang": "de",
        "recommendation": "Alle drei bis sechs Monate\r während der Behandlung oder\r häufiger bei Plasmapherese-\r Therapie",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-38",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Glycin-Rezeptor-Antikörper",
        "entry_id": 221,
        "id": 564,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-39",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Hib-Antikörper",
        "entry_id": 222,
        "id": 565,
        "lang": "de",
        "recommendation": "Wiederholte Testung zur\r Bewertung der Antwort auf\r Testimmunisierung. Serielle\r Überwachung von begrenztem\r Wert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-40",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Histon-Antikörper",
        "entry_id": 223,
        "id": 566,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-41",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "IA2-Antikörper",
        "entry_id": 224,
        "id": 567,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-42",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "IgA niedriger Spiegel",
        "entry_id": 225,
        "id": 568,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-43",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "IgE",
        "entry_id": 226,
        "id": 569,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-44",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "IgG niedriger Spiegel",
        "entry_id": 227,
        "id": 570,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-45",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "IgG-Subklassen (1, 2, 3,\r 4)",
        "entry_id": 228,
        "id": 571,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-46",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "IgG4",
        "entry_id": 229,
        "id": 572,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert, obwohl es für\r Überwachung bei bestimmten\r Patienten nützlich sein kann",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-47",
        "source": "Abraham M et al. Expert Rev Clin Immunol 2017;13:867–875.102",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Insulin-Antikörper",
        "entry_id": 230,
        "id": 573,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-48",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Intrinsic-Factor-Antikörper",
        "entry_id": 231,
        "id": 574,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-49",
        "source": "Khan S et al. J Clin Path 2009;62:439– 441.103",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Inselzell-Antikörper",
        "entry_id": 232,
        "id": 575,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-50",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Leber-Antikörper-Line-Blot,\r einschließlich M2-PDH",
        "entry_id": 233,
        "id": 576,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-51",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Leber-Autoantikörper",
        "entry_id": 234,
        "id": 577,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-52",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Lymphozyten-Phänotyp\r CD3, 4, 8, 19, 56",
        "entry_id": 235,
        "id": 578,
        "lang": "de",
        "recommendation": "Mit Labor besprechen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-53",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Leukozyten-\r Adhäsionsmoleküle",
        "entry_id": 236,
        "id": 579,
        "lang": "de",
        "recommendation": "Mit Labor besprechen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-54",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Lymphozyten-\r Phänotypisierung erweiterte\r Panel",
        "entry_id": 237,
        "id": 580,
        "lang": "de",
        "recommendation": "Mit Labor besprechen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-55",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Mastzell-Tryptase",
        "entry_id": 238,
        "id": 581,
        "lang": "de",
        "recommendation": "Drei Proben über einen 24-\r Stunden-Zeitraum zur Bewertung\r von Anaphylaxie\r (Resuscitation Council UK-\r Leitlinien empfehlen dass Proben\r so nah wie möglich zu Zeitpunkt 0\r genommen werden sollen, und 2\r Stunden nach Beginn mit einer\r Baseline-Probe größer als 24\r Stunden.)\r Wiederholte Testung kann bei\r Mastozytose erforderlich sein.\r Häufigkeit durch klinischen\r Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-56",
        "source": "NICE. CG134, <a href=\"/references#ref-104\" target=\"_blank\" class=\"reference-link\">2011.104<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "MPO ANCA",
        "entry_id": 239,
        "id": 582,
        "lang": "de",
        "recommendation": "Unter Behandlung: sechs Monate\r oder häufiger bei Plasmapherese-\r Therapie\r Ohne Behandlung: jährlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-57",
        "source": "Ntatsaki E et al. Rheumatology 2014;53:2306– <a href=\"/references#ref-105\" target=\"_blank\" class=\"reference-link\">2309.105<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Muskelspezifische Kinase-\r Antikörper",
        "entry_id": 240,
        "id": 583,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-58",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "MAG-Antikörper",
        "entry_id": 241,
        "id": 584,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-59",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "MOG-Antikörper",
        "entry_id": 242,
        "id": 585,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-60",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Myositis-Antikörper-Profil",
        "entry_id": 243,
        "id": 586,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-61",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Neutrophile\r zytoplasmatische Antikörper",
        "entry_id": 244,
        "id": 587,
        "lang": "de",
        "recommendation": "Unter Behandlung: sechs Monate\r oder häufiger bei Plasmapherese-\r Therapie\r Ohne Behandlung: jährlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-62",
        "source": "Ntatsaki E et al. Rheumatology 2014;53:2306– <a href=\"/references#ref-105\" target=\"_blank\" class=\"reference-link\">2309.105<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Neutrophile oxidativer\r Burst",
        "entry_id": 245,
        "id": 588,
        "lang": "de",
        "recommendation": "Mit Labor besprechen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-63",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "NMDA-Rezeptor-Antikörper\r CSF",
        "entry_id": 246,
        "id": 589,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-64",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "NMDA-Rezeptor-Antikörper\r Serum",
        "entry_id": 247,
        "id": 590,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-65",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Ovarial-Antikörper",
        "entry_id": 248,
        "id": 591,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-66",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Paraneoplastisches\r Antikörper-Profil",
        "entry_id": 249,
        "id": 592,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-67",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Paraprotein (monoklonale\r Bande) Quantifizierung",
        "entry_id": 250,
        "id": 593,
        "lang": "de",
        "recommendation": "Drei Monate",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-68",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Nebenschilddrüsen-\r Antikörper",
        "entry_id": 251,
        "id": 594,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-69",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Parietalzell-Antikörper",
        "entry_id": 252,
        "id": 595,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-70",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Pemphigoid-Antikörper",
        "entry_id": 253,
        "id": 596,
        "lang": "de",
        "recommendation": "Unter Behandlung: sechs Monate\r Ohne Behandlung: jährlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-71",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Pemphigus-Antikörper",
        "entry_id": 254,
        "id": 597,
        "lang": "de",
        "recommendation": "Unter Behandlung: sechs Monate\r Ohne Behandlung: jährlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-72",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Phospholipase-A2-\r Rezeptor-Antikörper",
        "entry_id": 255,
        "id": 598,
        "lang": "de",
        "recommendation": "Wiederholte Testung von\r begrenztem Wert. Häufigkeit durch\r klinischen Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-73",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Hypophysen-Antikörper",
        "entry_id": 256,
        "id": 599,
        "lang": "de",
        "recommendation": "Nicht routinemäßig erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-74",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "PR3 ANCA",
        "entry_id": 257,
        "id": 601,
        "lang": "de",
        "recommendation": "Unter Behandlung: sechs Monate oder häufiger bei Plasmapherese-Therapie\r Ohne Behandlung: jährlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-75",
        "source": "Ntatsaki E et al. Rheumatology 2014;53:2306– <a href=\"/references#ref-105\" target=\"_blank\" class=\"reference-link\">2309.105<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Protein (Serum) Elektrophorese",
        "entry_id": 258,
        "id": 602,
        "lang": "de",
        "recommendation": "Drei Monate",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-77",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Protein (Serum) Elektrophorese",
        "entry_id": 259,
        "id": 603,
        "lang": "de",
        "recommendation": "Jährlich für MGUS",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-77",
        "source": "Smellie WS et al. J Clin Pathol 2005;58:1016– <a href=\"/references#ref-23\" target=\"_blank\" class=\"reference-link\">1024.23<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Quantiferon TB IFN gamma",
        "entry_id": 260,
        "id": 604,
        "lang": "de",
        "recommendation": "Rücksprache mit Labor",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-78",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Rheumafaktor",
        "entry_id": 261,
        "id": 605,
        "lang": "de",
        "recommendation": "Routinemäßige Wiederholung nicht erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-79",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Sklerodermie-Antikörper-Profil",
        "entry_id": 262,
        "id": 606,
        "lang": "de",
        "recommendation": "Wiederholungstest von begrenztem Wert.\r Häufigkeit je nach klinischem Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-80",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Serotyp-spezifische Anti-Pneumokokken-Antikörper (APA)",
        "entry_id": 263,
        "id": 607,
        "lang": "de",
        "recommendation": "Wiederholungstest zur Bewertung der Antwort auf Testimmunisierung. Serielle Überwachung von begrenztem Wert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-81",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Serum Amyloid A",
        "entry_id": 264,
        "id": 608,
        "lang": "de",
        "recommendation": "Wiederholungstest von begrenztem Wert.\r Häufigkeit je nach klinischem Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-82",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Freie Leichtketten im Serum",
        "entry_id": 265,
        "id": 609,
        "lang": "de",
        "recommendation": "Falls verfügbar, sollten lokale Leitlinien und Behandlungsregime befolgt werden bei der Anforderung von Paraprotein-Konzentrationen für Patienten unter aktiver Behandlung\r Falls keine lokalen Empfehlungen oder Behandlungsregime verfügbar sind, beträgt das MRI drei Monate. Dies gilt nur für Diagnose/Überwachung von Amyloidose, nicht-sekretorischem Myelom und Leichtketten-Myelom",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-83",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Serum-Immunfixation",
        "entry_id": 266,
        "id": 610,
        "lang": "de",
        "recommendation": "Routinemäßig nicht erforderlich, außer bei Veränderung in der Serum-Elektrophorese\r Nicht als Nachkontrolle zur Elektrophorese durchgeführt, außer zur Remissionsbestätigung",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-84",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Skelettmuskel (quergestreift) Antikörper",
        "entry_id": 267,
        "id": 611,
        "lang": "de",
        "recommendation": "Routinemäßig nicht erforderlich\r Hinweis bei Bestellung, dass Bildgebung für Thymom-Untersuchung überlegen ist",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-85",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Spezifisches IgE",
        "entry_id": 268,
        "id": 612,
        "lang": "de",
        "recommendation": "Routinemäßig nicht erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-86",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Speicheldrüsen-Antikörper",
        "entry_id": 269,
        "id": 613,
        "lang": "de",
        "recommendation": "Niemals",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-87",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Tetanus-Antikörper",
        "entry_id": 270,
        "id": 614,
        "lang": "de",
        "recommendation": "Wiederholungstest zur Bewertung der Antwort auf Testimmunisierung. Serielle Überwachung von begrenztem Wert",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-88",
        "source": "Consensus of surveyed labs",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "tIgE",
        "entry_id": 271,
        "id": 615,
        "lang": "de",
        "recommendation": "Wiederholungstest von begrenztem Wert.\r Häufigkeit je nach klinischem Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-89",
        "source": "Consensus of surveyed labs",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Schilddrüsen-Peroxidase-Antikörper",
        "entry_id": 272,
        "id": 616,
        "lang": "de",
        "recommendation": "Routinemäßig nicht erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-90",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "T-Lymphozyten-Subset CD3, 4, 8",
        "entry_id": 273,
        "id": 617,
        "lang": "de",
        "recommendation": "Rücksprache mit Labor",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-91",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "tTg IgA Antikörper",
        "entry_id": 274,
        "id": 618,
        "lang": "de",
        "recommendation": "IgA tTG kann zur Überwachung der Antwort auf glutenfreie Diät verwendet werden\r Wiederholung nach sechs bis zwölf Monaten je nach Ausgangswert vor Behandlung",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-92",
        "source": "Wolters Kluwer, <a href=\"/references#ref-49\" target=\"_blank\" class=\"reference-link\">2019.49<sup>ref</sup></a>",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "tTg IgG Antikörper",
        "entry_id": 275,
        "id": 619,
        "lang": "de",
        "recommendation": "Wiederholung nach sechs bis zwölf Monaten\r Nur bei IgA-defizienten Patienten",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-93",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Urin-Elektrophorese",
        "entry_id": 276,
        "id": 620,
        "lang": "de",
        "recommendation": "Routinemäßig nicht erforderlich",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-94",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "Freie Leichtketten im Urin Quantifizierung",
        "entry_id": 277,
        "id": 621,
        "lang": "de",
        "recommendation": "Wiederholungstest von begrenztem Wert.\r Häufigkeit je nach klinischem Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-95",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "VGCC Antikörper",
        "entry_id": 278,
        "id": 622,
        "lang": "de",
        "recommendation": "Wiederholungstest von begrenztem Wert.\r Häufigkeit je nach klinischem Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-96",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "VGKC Antikörper CSF",
        "entry_id": 279,
        "id": 623,
        "lang": "de",
        "recommendation": "Wiederholungstest von begrenztem Wert.\r Häufigkeit je nach klinischem Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-97",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "4 Immunologie-Empfehlungen",
        "clinical_situation": "VGKC Antikörper Serum",
        "entry_id": 280,
        "id": 624,
        "lang": "de",
        "recommendation": "Wiederholungstest von begrenztem Wert.\r Häufigkeit je nach klinischem Kontext zu bestimmen",
        "section": "Immunologie",
        "subsection": null,
        "ref": "I-98",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "AFB Mikroskopie und Kultur",
        "entry_id": 281,
        "id": 625,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-1",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Antrumspülungen",
        "entry_id": 282,
        "id": 626,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-2",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "ASO Titer",
        "entry_id": 283,
        "id": 627,
        "lang": "de",
        "recommendation": "14 Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-3",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Aspirate und Flüssigkeiten aus sterilen Bereichen",
        "entry_id": 284,
        "id": 628,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-4",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Blutkultur",
        "entry_id": 285,
        "id": 629,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-5",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Borrelia burgdorferi (Lyme)",
        "entry_id": 286,
        "id": 630,
        "lang": "de",
        "recommendation": "14 Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-6",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "CSF",
        "entry_id": 287,
        "id": 631,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-7",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Chlamydien NAAT",
        "entry_id": 288,
        "id": 632,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-8",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "GC NAAT",
        "entry_id": 289,
        "id": 633,
        "lang": "de",
        "recommendation": "14 Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-9",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "CFT",
        "entry_id": 290,
        "id": 634,
        "lang": "de",
        "recommendation": "14 Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-10",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Hustenabstrich",
        "entry_id": 291,
        "id": 635,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-11",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "CSF für molekulare Untersuchung, z.B. Meningokokken",
        "entry_id": 292,
        "id": 636,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-12",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "CSF Mikroskopie und Kultur",
        "entry_id": 293,
        "id": 637,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-13",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Medikamentenüberwachung: Glykopeptide (Vancomycin, Teicoplanin, etc.)",
        "entry_id": 294,
        "id": 638,
        "lang": "de",
        "recommendation": "24 Stunden",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-14",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Medikamentenüberwachung: Aminoglykosid (Gentamicin, Amikacin, etc.)\r Hinweis: Dies gilt nur für einmal tägliche Dosierung. Falls Patient mehrmals täglich Dosen erhält, siehe lokale Leitlinien",
        "entry_id": 295,
        "id": 639,
        "lang": "de",
        "recommendation": "24 Stunden",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-15",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Ohrabstrich",
        "entry_id": 296,
        "id": 640,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-16",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Hals-Nasen-Ohren-Abstrich",
        "entry_id": 297,
        "id": 641,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-17",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Endozervikaler Abstrich",
        "entry_id": 298,
        "id": 642,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-18",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Augenabstrich am gleichen Auge",
        "entry_id": 299,
        "id": 643,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-19",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Stuhl – Clostridium difficile",
        "entry_id": 300,
        "id": 644,
        "lang": "de",
        "recommendation": "Wiederholte Tests nach einer ersten positiven Probe während derselben Durchfall-Episode werden in einer endemischen Situation nicht empfohlen\r Wiederholte Tests nach einer ersten negativen Probe während derselben Durchfall-Episode können in ausgewählten Fällen mit anhaltendem klinischem Verdacht während einer epidemischen Situation oder in Fällen mit hohem klinischem Verdacht während endemischer Situationen nützlich sein\r Abhängig vom Ergebnis:\r Bestätigt positiv: 28 Tage\r Grenzwertig*: 24 Stunden\r Negativ: 24 Stunden\r Ein Heilungstest wird nicht empfohlen\r *GDH positiv/Toxin negativ",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-20",
        "source": "Crobach MJT et al. Clin Microbiol Infect 2016;22:S63– S81.106",
        "level_of_evidence": "A"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Stuhl – Eier, Zysten und Parasiten",
        "entry_id": 301,
        "id": 645,
        "lang": "de",
        "recommendation": "24 Stunden",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-21",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Stuhl – Routine",
        "entry_id": 302,
        "id": 646,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-22",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Genitalabstrich (nur GC)",
        "entry_id": 303,
        "id": 647,
        "lang": "de",
        "recommendation": "14 Tage wenn Symptome nach Behandlung bestehen (siehe auch M-9)",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-23",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Genitalabstrich Mikroskopie und Kultur",
        "entry_id": 304,
        "id": 648,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-24",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Helicobacter pylori – negative Serologie",
        "entry_id": 305,
        "id": 649,
        "lang": "de",
        "recommendation": "28 Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-25",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Helicobacter pylori – positive Serologie",
        "entry_id": 306,
        "id": 650,
        "lang": "de",
        "recommendation": "Niemals",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-26",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Vaginalabstrich",
        "entry_id": 307,
        "id": 651,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-27",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "IUCD",
        "entry_id": 308,
        "id": 652,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-28",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "IUCD für Aktinomyzeten",
        "entry_id": 309,
        "id": 653,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-29",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Gelenkflüssigkeiten, Mikroskopie und Kultur",
        "entry_id": 310,
        "id": 654,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-30",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Mundabstrich",
        "entry_id": 311,
        "id": 655,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-31",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "MRSA Screening",
        "entry_id": 312,
        "id": 656,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-32",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "MRSA nach Eradikationstherapie",
        "entry_id": 313,
        "id": 657,
        "lang": "de",
        "recommendation": "48 Stunden",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-33",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "M. pneumoniae nur",
        "entry_id": 314,
        "id": 658,
        "lang": "de",
        "recommendation": "14 Tage (bei CFT Antikörper-Test; bei PCR keine Wiederholung)\r Bei Test auf Mycoplasma IgM sollte eine zweite Probe sieben bis zehn Tage nach einem negativen Ergebnis genommen werden, wenn die erste Probe früh in der Erkrankung genommen wurde",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-34",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Nasenabstrich",
        "entry_id": 315,
        "id": 659,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-35",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Nasopharyngeales Aspirat",
        "entry_id": 316,
        "id": 660,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-36",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "PD Flüssigkeiten, Mikroskopie und Kultur",
        "entry_id": 317,
        "id": 661,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-37",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Peritonealflüssigkeit",
        "entry_id": 318,
        "id": 662,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-38",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Pernasaler Abstrich (für Pertussis)",
        "entry_id": 319,
        "id": 663,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-39",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Pernasale Abstriche",
        "entry_id": 320,
        "id": 664,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-40",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Pleuraerguss/Thoraxflüssigkeiten",
        "entry_id": 321,
        "id": 665,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-41",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Pleuraflüssigkeit",
        "entry_id": 322,
        "id": 666,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-42",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Pneumocystis jirovecii (DIF/PCR)",
        "entry_id": 323,
        "id": 667,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-43",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Eiterabstrich",
        "entry_id": 324,
        "id": 668,
        "lang": "de",
        "recommendation": "Drei Tage oder einmal pro Drainage-Episode",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-44",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Eiter/Exsudat",
        "entry_id": 325,
        "id": 669,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-45",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Samenflüssigkeit",
        "entry_id": 326,
        "id": 670,
        "lang": "de",
        "recommendation": "28 Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-46",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Haut, Nägel und Haare für Mykologie",
        "entry_id": 327,
        "id": 671,
        "lang": "de",
        "recommendation": "Drei Monate",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-47",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Sputum (dies schließt TB-Untersuchung aus, siehe M-56)",
        "entry_id": 328,
        "id": 672,
        "lang": "de",
        "recommendation": "Drei Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-48",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Syphilis",
        "entry_id": 329,
        "id": 673,
        "lang": "de",
        "recommendation": "14 Tage nach negativem Ergebnis bei gefährdeter Person\r Für Behandlungsansprache, RPR (Rapid Plasma Reagin) alle drei Monate testen",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-49",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Rachenabstrich",
        "entry_id": 330,
        "id": 674,
        "lang": "de",
        "recommendation": "Abhängig vom Ergebnis:\r Positiv: sieben Tage\r Negativ: drei Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-50",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Gewebe/Knochen Mikroskopie und Kultur",
        "entry_id": 331,
        "id": 675,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-51",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Gewebe und Biopsien",
        "entry_id": 332,
        "id": 676,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-52",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Toxoplasma IgG Screening negativ",
        "entry_id": 333,
        "id": 677,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-53",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Toxoplasma IgG Screening positiv",
        "entry_id": 334,
        "id": 678,
        "lang": "de",
        "recommendation": "Niemals",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-54",
        "source": "",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Tuberkulose",
        "entry_id": 335,
        "id": 679,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-55",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Urethralabstrich",
        "entry_id": 336,
        "id": 680,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-56",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Urin für Tuberkulose",
        "entry_id": 337,
        "id": 681,
        "lang": "de",
        "recommendation": "N/A",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-57",
        "source": "N/A",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Urin, Mikroskopie und Kultur",
        "entry_id": 338,
        "id": 682,
        "lang": "de",
        "recommendation": "Drei Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-58",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Wund- und Ulkusabstrich",
        "entry_id": 339,
        "id": 683,
        "lang": "de",
        "recommendation": "Sieben Tage",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-59",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "Aspergillus GM (Bio-Rad Platelia Aspergillus ELISA)",
        "entry_id": 340,
        "id": 684,
        "lang": "de",
        "recommendation": "Zweimal wöchentliches serielles Screening für Blut-GM bei Hochrisiko-Hämatologie-Patienten*:\r • einzelne negative Probe kann verwendet werden, um IA auszuschließen\r • zwei aufeinanderfolgende positive Proben bieten guten positiven Vorhersagewert\r • Reduktion des GM-Index während der ersten zwei Wochen der antimykotischen Therapie ist ein zuverlässiger Prädiktor für Behandlungsansprache\r Diagnostisches GM auf BAL ist der sensitivste Test\r *Neutropenische Patienten und allogene Stammzelltransplantations-Empfänger während der frühen Engraftment-Phase, die nicht unter schimmelpilzaktiver antimykotischer Prophylaxe oder Behandlung stehen",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-60",
        "source": "Maertens J et al. Blood 2001;97:1604– 1610.107 Furfaro E et al. Transpl Infect Dis 2012;14:E38– E39.108 Leeflang MM et al. Cochrane Database Syst Rev 2008;4: CD007394.109 Chai LY et al. J Clin Microbiol 2012;50:2330– 2336.110 Nouer SA et al. Clin Infect Dis 2011;53:671–676.111 Bergeron A et al. J Clin Microbiol 2012;50:823–830.112 Schelenz S et al. Lancet Infect Dis 2015;15:461–474.113 Lass-Florl C. Med Mycol 2019;57:S155– S160.114",
        "level_of_evidence": ""
    },
    {
        "chapter": "5.1 Allgemeine Mikrobiologie",
        "clinical_situation": "BDG",
        "entry_id": 341,
        "id": 685,
        "lang": "de",
        "recommendation": "Zweimal wöchentliches Screening für schwer kranke Intensivstations-Patienten und Patienten mit hämatologischen Malignomen und nach allogener hämatopoetischer Stammzelltransplantation:\r • einzelne negative Probe kann verwendet werden, um die Diagnose der meisten invasiven Pilzinfektionen auszuschließen (bemerkenswerte Ausnahmen sind mukorzähe Schimmelpilzinfektionen, Kryptokokkose, einige dimorphe Pilze und andere seltene Pilze)\r • Wiederholung positiver BDG-Ergebnisse ist klinisch nicht hilfreich, da es mehrere Wochen dauern kann, bis sie aus dem System verschwinden",
        "section": "Mikrobiologie",
        "subsection": null,
        "ref": "M-61",
        "source": "Eggimann P et al. Crit Care 2011;15:1017.115 Cuenca-Estrella M et al. Clin Microbiol Infect 2012;18:S9– S18.116 Hammarström H et al. Eur J Clin Microbiol Infect Dis 2015;34:917–925.117 Schelenz S et al. Lancet Infect Dis 2015;15:461–474.113 Rautemaa- Richardson R et al. J Antimicrob Chemother 2018;73:3488– <a href=\"/references#ref-118\" target=\"_blank\" class=\"reference-link\">3495.118<sup>ref</sup></a>",
        "level_of_evidence": ""
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Mütterliche HIV-Infektion",
        "entry_id": 342,
        "id": 686,
        "lang": "de",
        "recommendation": "Nicht gestillter Säugling\r Teste Säuglingsblut (EDTA) für HIV-Provirus-DNA-PCR:\r • in den ersten 48 Stunden\r • mit zwei Wochen (bei hohem Risiko*)\r • mit sechs Wochen (oder zwei Wochen nach Beendigung der Prophylaxe)\r • mit 12 Wochen (oder acht Wochen nach Beendigung der Prophylaxe)\r Bei anderen Gelegenheiten bei zusätzlichem Risiko:\r • teste HIV Ag/Ab für Seroreversion mit 18–24 Monaten\r Gestillter Säugling\r Teste Säuglingsblut (EDTA) für HIV-Provirus-DNA-PCR:\r • in den ersten 48 Stunden\r • mit zwei Wochen\r • monatlich für die Dauer des Stillens\r • mit vier und acht Wochen nach Beendigung des Stillens\r Bei anderen Gelegenheiten bei zusätzlichem Risiko:\r • teste HIV Ag/Ab für Seroreversion mit 18–24 Monaten\r *Hohes Risiko bedeutet nachweisbare mütterliche HIV-RNA-Virämie mit 36 Wochen und bei der Geburt",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-1",
        "source": "British HIV Association, <a href=\"/references#ref-119\" target=\"_blank\" class=\"reference-link\">2018.119<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Mütterliche Hepatitis-B-Infektion",
        "entry_id": 343,
        "id": 687,
        "lang": "de",
        "recommendation": "Teste Säuglingsblut (geronnenes Blut oder Trockenblutkarte) für HBsAg mit 12 Monaten",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-2",
        "source": "Public Health England, <a href=\"/references#ref-120\" target=\"_blank\" class=\"reference-link\">2021.120<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Bestätigte virämische HCV-Infektion in der Schwangerschaft",
        "entry_id": 344,
        "id": 688,
        "lang": "de",
        "recommendation": "Teste Säuglingsblut (EDTA) für HCV-RNA-PCR mit zwei bis drei Monaten. Falls nachgewiesen, wiederhole HCV-RNA-PCR mit sechs Monaten\r Zusätzlich teste Säuglingsblut (geronnenes Blut oder Trockenblutkarte) für Anti-HCV mit 12–18 Monaten\r Es gibt keine weitere Nachbeobachtung, falls Anti-HCV negativ und die HCV-RNA-PCR mit zwei bis drei Monaten ebenfalls negativ war\r Falls Anti-HCV positiv ist, führe weitere HCV-RNA-PCR durch und verweise auf PHE-Algorithmus",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-3",
        "source": "Public Health England, <a href=\"/references#ref-121\" target=\"_blank\" class=\"reference-link\">2018.121<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Nierenversagen – BBV-Status von Patienten, die HD im UK beginnen",
        "entry_id": 345,
        "id": 689,
        "lang": "de",
        "recommendation": "Teste HIV Ag/Ab, Anti-HCV und HBsAg vor Dialyse\r Schließe HCV-RNA-PCR ein, falls aktuelle Risikofaktoren für HCV-Erwerb vorliegen\r Anti-HBV sollte vor Immunisierung überprüft werden, besonders bei Patienten mit Risikofaktoren für frühere HBV-Exposition",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-4",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "A"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Laufende Überwachung für HIV in der prävalenten HD-Population",
        "entry_id": 346,
        "id": 690,
        "lang": "de",
        "recommendation": "Teste HIV Ag/Ab alle drei Monate (bei Risikofaktoren)",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-5",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Laufende Überwachung für HCV in der prävalenten HD-Population",
        "entry_id": 347,
        "id": 691,
        "lang": "de",
        "recommendation": "Teste Anti-HCV alle drei Monate (schließe HCV-RNA-PCR ein, falls aktuelle Risikofaktoren für HCV-Erwerb vorliegen)",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-6",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Laufende Überwachung für HBV in der prävalenten HD-Population",
        "entry_id": 348,
        "id": 692,
        "lang": "de",
        "recommendation": "Teste HBsAg alle drei Monate (falls Anti-HBs >100 IU/mL, dann kann sechsmonatliche Testung erwogen werden)",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-7",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "C"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Nierenversagen – verstärkte Überwachung für die mit mittlerem/hohem Risiko für neue BBV nach Dialyse im Ausland (alle BBV-Tests) oder falls eine neue BBV-Infektion in der HD-Einheit identifiziert wird (nur für die spezifische BBV-Infektion)\r Für HCV",
        "entry_id": 349,
        "id": 693,
        "lang": "de",
        "recommendation": "Teste HCV-RNA-PCR oder HCV-Antigen oder HCV-Antigen/Antikörper alle zwei Wochen für drei Monate",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-8",
        "source": "Department of Health, 2002.123 The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Nierenversagen – verstärkte Überwachung für die mit mittlerem/hohem Risiko für neue BBV nach Dialyse im Ausland (alle BBV-Tests) oder falls eine neue BBV-Infektion in der HD-Einheit identifiziert wird (nur für die spezifische BBV-Infektion)\r Für HBV",
        "entry_id": 350,
        "id": 694,
        "lang": "de",
        "recommendation": "Teste HBsAg oder HBV-PCR alle zwei Wochen für drei Monate (unabhängig vom Anti-HBs-Level)",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-9",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Nierenversagen – verstärkte Überwachung für die mit mittlerem/hohem Risiko für neue BBV nach Dialyse im Ausland (alle BBV-Tests) oder falls eine neue BBV-Infektion in der HD-Einheit identifiziert wird (nur für die spezifische BBV-Infektion)\r Für HIV",
        "entry_id": 351,
        "id": 695,
        "lang": "de",
        "recommendation": "Teste HIV Ag/Ab oder HIV-RNA-PCR alle zwei Wochen für drei Monate (nur bei Risiko nach Dialyse außerhalb der Basis)",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-10",
        "source": "The Renal Association, <a href=\"/references#ref-122\" target=\"_blank\" class=\"reference-link\">2019.122<sup>ref</sup></a>",
        "level_of_evidence": "B"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Potenzielle signifikante Exposition gegenüber HBsAg-positivem Material, Hepatitis-B-empfänglich",
        "entry_id": 352,
        "id": 696,
        "lang": "de",
        "recommendation": "Bewerte Risiko und HBV-Immunität des Empfängers\r Sammle Baseline-Blut zur Lagerung vom Empfänger\r Interveniere mit HBV-Impfstoff ± HBIG entsprechend dem Szenario\r Teste HBsAg nach drei Monaten\r Teste HBsAg, Anti-HBc nach sechs Monaten\r Teste Anti-HBs ein bis zwei Monate nach Impfkurs",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-11",
        "source": "",
        "level_of_evidence": "GPP"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Potenzielle signifikante Exposition gegenüber HIV-positivem Material, aber keine Post-Expositions-Prophylaxe gegeben\r (Hinweis: Falls der Empfänger PrEP nimmt, beachte, dass dies die HIV Ag/Ab-Antworten verändern kann und der Fall mit einem Virologen besprochen werden sollte)",
        "entry_id": 353,
        "id": 697,
        "lang": "de",
        "recommendation": "Sammle Baseline-Blut zur Lagerung\r Falls dem Arbeitsschutz (OH) ausgesetzt, besagt die Leitlinie, dass minimale Testung ein HIV Ag/Ab-Test 12 Wochen nach Exposition sein sollte. Jedoch kann auch frühere Testung zusätzlich dazu erfolgen, falls erforderlich (vier Wochen nach Exposition)\r In einem nicht-arbeitsmedizinischen Setting sollte die BASHH-Leitlinie befolgt werden, die besagt, dass ein negativer HIV Ag/Ab-Test mit einem Test der vierten Generation, durchgeführt vier Wochen nach Exposition, wahrscheinlich HIV-Infektion ausschließt. Ein weiterer Test acht Wochen nach Exposition muss nur nach einem Ereignis erwogen werden, das als hohes Infektionsrisiko bewertet wird",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-12",
        "source": "Department of Health and Social Care, 2008.124 BASHH guidelines, <a href=\"/references#ref-125\" target=\"_blank\" class=\"reference-link\">2019.125<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Potenzielle signifikante Exposition gegenüber HIV-positivem Material und Post-Expositions-Prophylaxe gegeben",
        "entry_id": 354,
        "id": 698,
        "lang": "de",
        "recommendation": "Sammle Baseline-Blut zur Lagerung\r Die DOH OH-Leitlinie besagt, dass minimale Testung ein HIV Ag/Ab-Test 12 Wochen nach Beendigung der PEP sein sollte\r Zusätzlich kann ein früherer Test ebenfalls durchgeführt werden (vier bis sechs Wochen nach Beendigung der PEP)",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-13",
        "source": "Department of Health and Social Care, 2008.124 BASHH guidelines, <a href=\"/references#ref-125\" target=\"_blank\" class=\"reference-link\">2019.125<sup>ref</sup></a>",
        "level_of_evidence": "D"
    },
    {
        "chapter": "6.1 Angeborene/perinatale blutübertragene Virusinfektionen – Testung bei asymptomatischen Säuglingen",
        "clinical_situation": "Potenzielle signifikante Exposition gegenüber HCV-positivem Material",
        "entry_id": 355,
        "id": 699,
        "lang": "de",
        "recommendation": "Teste nach sechs Wochen mittels HCV-RNA-PCR und nach 12 Wochen sowohl mittels HCV-RNA-PCR als auch Anti-HCV\r Falls negativ, teste nach 24 Wochen nur mit Anti-HCV",
        "section": "Virologie",
        "subsection": null,
        "ref": "V-14",
        "source": "Ramsay ME. Commun Dis Public Health 1999;2:258– 262.126",
        "level_of_evidence": "D"
    }
]